Document:

exv10w27

 

Exhibit 10.27

Certain information in this document, marked by brackets, has been omitted and filed
separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.

CROSS LICENSE AGREEMENT

     This Cross License Agreement (the “Agreement”) dated as of July 16, 2003 (the “Effective
Date”) is entered into by and between Avidia Research Institute, a Delaware corporation, having a
place of business at 515 Galveston Drive, Redwood City, California 94063 (“Avidia”) and Maxygen,
Inc., a Delaware corporation, having a place of business at 515 Galveston Drive, Redwood City,
California 94063 (“Maxygen”).

BACKGROUND

     A. In connection with the establishment of Avidia, Maxygen has assigned to Avidia certain
patent applications relating to methods for preparing novel monomeric or multimeric proteins
pursuant to an Assignment Agreement of even date herewith;

     B. Maxygen desires to obtain from Avidia an exclusive worldwide license under the Assigned
Patent Rights (as defined below) for the Maxygen Field (as defined below); and Avidia is willing to
grant such a license to Maxygen, on the terms and conditions herein;

     C. Maxygen owns or Controls certain intellectual property that is necessary for the practice
of the Assigned Patent Rights, as well as intellectual property that may be useful for such
practice, in each case, outside the Maxygen Field, and Avidia desires to obtain from Maxygen
non-exclusive licenses to use such intellectual property outside the Maxygen Field; and Maxygen is
willing to grant to Avidia such licenses, on the terms and conditions herein;

     D. Maxygen owns certain software and tangible property useful for the practice of the Assigned
Patent Rights outside the Maxygen Field, and Avidia desires to obtain from Maxygen non-exclusive
licenses to use such software and tangible property outside the Maxygen Field; and Maxygen is
willing to grant to Avidia such licenses, on the terms and conditions herein; and

     E. Maxygen wishes to obtain options to acquire exclusive licenses to Products for certain
Avidia Targets (as defined below); and Avidia is willing to grant such a license to Maxygen, on the
terms and conditions herein

     NOW THEREFORE, in consideration of the foregoing and of the mutual covenants hereinafter set
forth and other good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Parties hereby agree as follows:

     1. DEFINITIONS. The following capitalized terms defined in this Article 1 shall have the
meanings set forth below for purposes of this Agreement:

          1.1 “Affiliate” means any corporation, firm, limited liability company, trust,
partnership or other entity that directly or indirectly controls or is controlled by or is under common control with a Party to this Agreement. As used in this definition, “controls”,
“controlled by” and “under common control with” means the possession, directly or indirectly, of
the power to direct or cause the direction of the management and policies of an entity, whether
through the ownership of voting securities or partnership interest, by contract or otherwise. In

 

 

the case of a corporation, the direct or indirect ownership of fifty percent (50%) or more of
its outstanding voting shares, or in the case of a partnership, status as a general partner, or in
the case of any other type of legal entity, fifty percent (50%) or more of the ownership interests,
shall in any event be deemed to confer control, it being understood that the direct or indirect
ownership of a lesser percentage of such shares or ownership interest shall not necessarily
preclude the existence of control.

          1.2 “Agriculture Subfield” shall have the meaning set forth in Exhibit A hereto.

          1.3 “Approved DBP Therapeutic Conjugate” means a particular DBP Therapeutic Conjugate
that Maxygen has agreed that Avidia may develop and commercialize pursuant to Section 2.5. The
Approved DBP Therapeutic Conjugates as of the Effective Date are listed on Exhibit B hereto.

          1.4 “Assigned Patent Rights” means, collectively: (a) the patent applications listed
on Exhibit C hereto; (b) all patent applications filed on an invention described in an Invention
Disclosure; (c) all divisions, continuations (other than continuations-in-part), substitutions and
patents of addition of any of the preceding; (d) all foreign counterparts of any of the foregoing;
and (e) all patents and/or registrations that issue from any of the foregoing patent applications
(including, without limitation, all reissues, renewals, extensions, substitutions, confirmations,
re-registrations, re-examinations, re-validations, supplementary protection certificates and/or
other governmental actions that extend the term of any such letters patent).

          1.5 “Authorized Method” means the practice of the Assigned Patent Rights and/or the
Subject Improvements to generate one or more libraries of nucleic acids encoding Domain-Based
Proteins by the process of: (a) [****]; and (b) [****].

          1.6 “Avidia Know-How” means all Know-How that is owned or Controlled by Avidia prior
to the Trigger Date that is necessary or useful for the practice of the Assigned Patent Rights
and/or the Subject Improvements and/or Avidia Necessary Claims in the Maxygen Field.

          1.7 “Avidia Necessary Claim” means a claim of any issued patent (other than those
within the Assigned Patent Rights) owned or Controlled by Avidia that is necessary for the practice
of the Authorized Method in the Maxygen Field. As used in this definition, “necessary” means that
the [****]. The Avidia Necessary Claims shall be listed on Exhibit D hereto, which shall be
updated in accordance with Section 3.3.

          1.8 “Avidia Target” means any Ligand (other than an Excluded Target) for which
research is conducted by Avidia (or its subcontractor) to develop a Product for [****] or [****]
therapeutic and/or prophylactic use that [****].

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

2

 

          1.9 “Avidia Team” means the following individuals: [****] and [****].

          1.10 “Avidia Useful Claim” means a claim of any Patent Right owned or Controlled by
Avidia (other than the Avidia Necessary Claims or any claims within the Assigned Patent Rights)
that: (a) is useful, but not necessary, for the practice of the Assigned Patent Rights and/or the
Subject Improvements in the Maxygen Field, or (b) becomes a “Avidia Useful Claim” pursuant to
Section 3.6 below.

          1.11 “Cap” shall have the meaning set forth in Section 5.1.2 below.

          1.12 “Change of Control” means: (a) a dissolution or liquidation of Avidia; (b) a
sale of all or substantially all the assets of Avidia; or (c) any consolidation or merger of Avidia
with or into any other corporation or other entity or person, or any other corporate
reorganization, in which those persons or entities that are Avidia stockholders immediately prior
to such consolidation, merger or reorganization, own less than fifty percent (50%) of the surviving
entity’s voting power immediately after such consolidation, merger or reorganization; in each case,
in which those persons or entities that are Avidia stockholders immediately prior to the relevant
event described in clauses (a), (b) or (c) above receive cash or publicly-traded securities or some
combination thereof having an aggregate value of at least [****] U.S. dollars (U.S.$ [****]).

          1.13 “Chemicals Subfield” shall have the meaning set forth in Exhibit E hereto.

          1.14 “Confidential Information” means any and all information, whatever its form or
medium (whether written, oral, electronic, graphic or otherwise), including technical information,
results, data and/or design of experiments, that is disclosed by any Party to the other Party that
(a) if disclosed in written or other tangible form, is marked or labeled as “confidential” or
“proprietary” or with a similar marking or legend sufficient to notify the receiving Party that
such information is subject to the terms of this Agreement, or (b) if disclosed orally or in other
intangible form, is identified as confidential or proprietary by the disclosing Party at the time
of disclosure.

          1.15 “Control” or “Controlled” means possession of the ability to grant
licenses or sublicenses, as the case may be, to intellectual property or Know-How or to transfer
Materials, in each case, without violating the terms of any agreement or other arrangement with any
Third Party. Control shall include the right to grant sublicenses or transfer Materials where the
grant or practice of such sublicense or transfer may incur a contractual payment obligation to a
Third Party, but only to the extent the Party receiving the sublicense or transfer hereunder agrees
to fully reimburse the granting Party for any such payments due to such Third Party, unless
otherwise expressly agreed in writing by the Parties.

          1.16 “CPI” means the Consumer Price Index, All Urban Customers, as published in the
U.S. Bureau of Labor Statistics.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

3

 

          1.17 “DBP Research Conjugate” means a non-naturally occurring fusion protein(s) that
contains a protein described in Section 1.20(a) and (b) (and (c) and/or (e), as applicable) that
has fused at [****] of such protein [****] other specific protein(s) [****], wherein (i) such other
specific protein(s) [****] is/are [****], or (ii) such fusion protein is [****].

          1.18 “DBP Therapeutic Conjugate” means a non-naturally occurring fusion protein (i)
that contains a protein described in Section 1.20(a) and (b) (and (c) and/or (e), as applicable)
that has fused at [****] of such protein [****] other specific protein(s) [****] that is [****],
and (ii) is [****].

          1.19 “Domain” means a protein subsequence of between [****] and [****] contiguous
amino acids, that is (a) a [****], or (b) a [****] that (i) is [****], and (ii) has a [****].

          1.20 “Domain-Based Protein” means a non-naturally occurring protein expressed from a
[****] that:

               (a) is capable of binding specifically to one or more Ligands; and

               (b) consists solely of between one (1) and [****] Domain(s) (from up to three (3) different
Families), that are covalently bound (either directly to each other or, optionally, via linkers
each of which is less than [****] amino acids), and consists of no other amino acid residues,
except as expressly permitted in (c), (d) or (e) below; and

               (c) optionally, has fused at [****] of the protein described in (a) and (b) above an amino
acid sequence of less than [****] amino acids; and

               (d) optionally, has fused at [****] of the protein described in (a) and (b) above (and (c)
and/or (e), as applicable) one or more other [****] proteins [****], if, and only if:

                    (i) [****], or

                    (ii) [****], or

                    (iii) such fusion protein is an Approved DBP Therapeutic Conjugate approved by Maxygen
pursuant to Section 2.5 below; and

               (e) optionally, at [****] of a protein described above (i.e., a protein described in any
permitted combination of (a), (b), (c) and (d) above), a linker of less than [****] amino acids
that allows more rapid purification of such protein or detection of such protein in an assay (e.g.,
ELISA).

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

4

 

It is understood and agreed by the Parties that, as used herein, “Domain-Based Protein” shall not
include, except as expressly permitted in (c), (d) or (e) above, any composition of matter
containing (however attached or bound): (x) any [****], or (y) any [****].

As used herein, “Domain-Based Protein” shall include any composition of matter that consists solely
of (1) non-covalently bound multimers of similar or different Domain-Based Proteins or (2)
Domain-Based Proteins that are bound, covalently or non-covalently, to molecules that [****].

          1.21 “Excluded Target” means a Ligand (a) that is proprietary to any Third Party
(i.e., [****]); or (b) that was an Avidia Target but ceased to be an Avidia Target pursuant to
Section 5.3.2 or 5.3.4; or (c) for which Avidia did not commence any research for its own benefit
to develop any Product [****], but with regard to which a Third Party has entered into a written
agreement with Avidia pursuant to which such Third Party will collaborate with and sponsor research
at Avidia to develop Products [****].

          1.22 “Family” means a group of [****] sequences, in which the members of such group
(a) are [****], and (b) have a [****] and remain the same whether such a member is isolated or
covalently joined to other peptides in a larger protein.

          1.23 “Invention Disclosure” means an invention disclosure listed on Exhibit F hereto.

          1.24 “Know-How” means proprietary data, instructions, processes, formulae, materials,
expert opinions and information, including, without limitation, biological, chemical,
pharmacological, toxicological, pharmaceutical, physical, analytical, pre-clinical, clinical,
safety, manufacturing and quality control data and information, in each case, that is not generally
known. Know-How does not include any inventions included in the Patent Rights.

          1.25 “Known” means (i) known or believed by Avidia or by Avidia’s Affiliates or
Licensees who are working on the relevant Domain-Based Protein or DBP Therapeutic Conjugate, or
(ii) disclosed by information in the public domain, in the form of a peer-reviewed scientific
publication or abstract or other credible scientific publication.

          1.26 “Licensed Product” means a Product for the treatment or prophylaxis of [****] or
[****] disease that [****], for which Maxygen has exercised a Target Option with respect to such
Avidia Target and entered into a Product License Agreement.

          1.27 “Licensee” means any Third Party that Avidia or Maxygen has granted a license or
sublicense, as the case may be, to any of the Assigned Patent Rights.

          1.28 “Ligand” means a naturally occurring biomolecule.

          1.29 “Major Market Country” means [****].

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

5

 

          1.30 “Materials” means the biological materials listed on Exhibit G hereto.

          1.31 “Maxygen Field” means the development, manufacture, use and/or commercialization
of Maxygen Products.

          1.32 “Maxygen Information” means any non-public information that was (i) disclosed,
prior to the Effective Date, by or on behalf of Maxygen or its Affiliates to a member of the Avidia
Team, or (ii) developed by any member of the Avidia Team during their employment by or consulting
with Maxygen, or (iii) learned by any member of the Avidia Team during their employment by or
consulting with Maxygen from Maxygen or a Third Party under confidentiality with Maxygen.

          1.33 “Maxygen Necessary Claim” means a claim of any issued patent owned or Controlled
by Maxygen that is necessary for the practice of the Authorized Method outside the Maxygen Field.
As used in this definition, “necessary” means that the [****]. The Maxygen Necessary Claims
licensed to Avidia as of the Effective Date are listed on Exhibit H hereto, which shall be updated
in accordance with Section 2.3.

          1.34 “Maxygen Necessary Know-How” means all Know-How owned or Controlled by Maxygen
prior to the Trigger Date that is necessary to practice of the Authorized Method outside the
Maxygen Field.

          1.35 “Maxygen Other Know-How” means all Know-How owned or Controlled by Maxygen prior
to the Trigger Date that was developed (a) by any member of the Avidia Team in the period from June
1, 2001 until the Effective Date or (b) prior to the Effective Date pursuant to (i) the
Consulting Agreement, entered by [****] and Maxygen, Inc., effective January 21,
2003, or (ii) the Laboratory Services Agreement, entered by [****] and Maxygen, Inc.,
effective February 14, 2003; provided, Maxygen Other Know-How shall not include any Maxygen
Necessary Know-How or any Shuffling Technology.

          1.36 “Maxygen Product” means (a) any Product in the Chemicals Subfield; (b) any
Product in the Agriculture Subfield; and/or (c) any Reserved Therapeutic Product.

          1.37 “Maxygen Useful Claim” means a claim of a Patent Right owned or Controlled by
Maxygen (other than the Maxygen Necessary Claims) that: (a) is useful, but not necessary, for the
practice of the Assigned Patent Rights and/or the Subject Improvements outside the Maxygen Field,
or (b) becomes a “Maxygen Useful Claim” pursuant to Section 2.4 below. The Maxygen Useful Claims existing as of the Effective Date are listed on Exhibit I
hereto.

          1.38 “Maxygen Useful Know-How” means all Know-How owned or Controlled by Maxygen prior
to the Trigger Date that is necessary or useful for the practice of the Assigned Patent Rights
and/or the Subject Improvements outside the Maxygen Field;

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

6

 

provided, Maxygen Useful Know-How shall not include any Maxygen Necessary Know-How, Maxygen Other Know-How or Shuffling Technology.

          1.39 “Party” means Maxygen or Avidia, and the “Parties” means Maxygen and
Avidia.

          1.40 “Patent Rights” means any and all United States or foreign provisional and/or
utility patent applications (including, without limitation, all divisions, continuations in whole
or in part, substitutions and patents of addition), and any and all United States or foreign
letters patent and/or registrations (including, without limitation, all reissues, renewals,
extensions, confirmations, re-registrations, re-examinations, re-validations, supplementary
protection certificates and/or other governmental actions that extend the term of any such letters
patent).

          1.41 “Product” means any product that contains a Domain-Based Protein that is (a)
claimed in one or more of the Assigned Patent Rights or (b) made, or developed with [****].

          1.42 “Product License Agreement” means that certain form of Product License Agreement
attached hereto as Exhibit J.

          1.43 “Qualified IPO” means a firmly underwritten public offering of shares of common
stock of Avidia for a total offering of not less than twenty million U.S. dollars ($20,000,000),
before deduction of underwriter’s commissions and expenses.

          1.44 “Reserved Therapeutic Product” means any Product for [****] therapeutic or
prophylactic use, that is:

               (a) a TPO [****];

               (b) a TPO/IL3 [****];

               (c) a TNF/IL-1 [****];

               (d) [****] any interferon receptor;

               (e) [****] any interferon or any interferon receptor;

               (f) a p40 (subunit of IL-12 and IL-23) [****];

               (g) [****] CD40;

               (h) [****] CD40 ligand;

               (i) [****] B.7.1 (CD80);

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

7

 

               (j) [****] B.7.2 (CD86);

               (k) [****] CD28; or

               (l) [****] CTLA4.

For purposes of this definition, “agonist” means a [****] agonist of the applicable Ligand and/or
cognate receptor, and “antagonist” means a [****] antagonist of the applicable Ligand and/or
cognate receptor. The criteria for agonists and antagonists for the above targets are set forth on
Exhibit K hereto. It is understood and agreed that an agonist and/or an antagonist functions by
binding to the applicable Ligand and/or the cognate receptor.

          1.45 “Restriction Enzyme Processes” means processes involving the use of restriction
enzymes to cut nucleic acids at predetermined positions and then recombining such nucleic acids by
ligation.

          1.46 “Shuffle”, “Shuffled” and “Shuffling” means the recombination
and/or rearrangement and/or mutation of genetic material for the creation of genetic diversity.

          1.47 “Shuffling Technology” means (a) all Patent Rights owned or Controlled by Maxygen
that are necessary or useful for Shuffling and (b) all Know-How owned or Controlled by Maxygen that
is necessary or useful for Shuffling and (i) exists as of the Effective Date or (ii) is disclosed
to Avidia by Maxygen during the term of this Agreement.

          1.48 “Software” means each, and collectively all, of the software programs owned by
Maxygen that are listed on Exhibit L hereto, in source and object code format, and associated
documentation necessary for the operation of such software, but only to the extent and in the form
such documentation exists as of the Effective Date, unless otherwise agreed in writing by the
Parties.

          1.49 “Software Improvement” means any modification, derivative work of or improvement
made by Avidia to any aspect of the Software.

          1.50 “Splicing By Overlap Extension” means a PCR-based extension process for joining
two or more nucleic acid molecules at defined sites at the ends of the molecules by the use of
specially designed Bipartite Primers. By way of illustration, an example of such a process is
described in Horten et al., Gene, 77:61-68 (1989). As used in this definition, “Bipartite Primer”
means an oligonucleotide primer containing solely subsequences from the ends of two different nucleic acids such that the two nucleic acids can be joined together by
PCR extension.

          1.51 “Subject Improvement” means any improvement of or to any invention claimed in the
Assigned Patent Rights, (a) that is conceived and reduced to practice or otherwise developed, in
the period from the Effective Date until and including the Trigger Date, by (i)

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

8

 

Maxygen, (ii) Avidia, or (iii) any Licensee of either Party, provided that neither Party shall be obliged to
incur additional contractual payment obligations or to engage in undue additional negotiation with
such Licensee to obtain such rights necessary to perform its obligations under Sections 2.1(a) or
3.1(a), and (b) the practice of which falls within the scope of a claim of a patent application or
patent within the Assigned Patent Rights in any country or multinational jurisdiction, which claim
is entitled to filing priority based on a patent application or patent within the Assigned Patent
Rights that was filed on or before the Trigger Date; provided, a Subject Improvement shall (x)
include any claims of Patent Rights claiming the applicable improvement and any related Know-How
for practicing such Subject Improvement and (y) exclude the Assigned Patent Rights.

          1.52 “Suspension Date” shall have the meaning set forth in Section 5.2.1(c).

          1.53 “Target Option” shall have the meaning set forth in Section 5.1.1(a) below.

          1.54 “Territory” means worldwide.

          1.55 “Third Party” means any person or entity other than Maxygen or Avidia or an
Affiliate of Maxygen or Avidia.

          1.56 “Trigger Date” means the earliest of (a) the fourth anniversary of the Effective
Date, (b) the closing date of a Qualified IPO, or (c) a Change of Control; provided, if Maxygen
exercises its Target Option with respect to [****] or more Avidia Targets and the Parties enter
into the corresponding Product License Agreements, prior to the earliest to occur of (a), (b) or
(c) above, then the Trigger Date shall automatically be extended until the earliest to occur of (x)
the sixth anniversary of the Effective Date, (y) the closing date of a Qualified IPO, or (z) a
Change of Control.

          1.57 “Veterinary Product” means any Product for veterinary therapeutic or prophylactic
use, that is:

               (a) [****];

               (b) [****];

               (c) [****];

               (d) [****];

               (e) [****];

               (f) [****];

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

9

 

               (g) [****];

               (h) [****];

               (i) [****]; or

               (j) [****].

For purposes of this definition, “agonist” means a [****] agonist of the applicable Ligand and/or
cognate receptor, and “antagonist” means a [****] antagonist of the applicable Ligand and/or
cognate receptor. The criteria for agonists and antagonists for the above targets are set forth on
Exhibit K hereto. It is understood and agreed that an agonist and/or an antagonist functions by
binding to the applicable Ligand and/or the cognate receptor.

     2. LICENSE TO AVIDIA

          2.1 License Grant. In partial consideration for the Avidia stock granted to Maxygen
pursuant to [****] and subject to the terms and conditions of this Agreement, Maxygen hereby grants
to Avidia the following licenses:

               (a) a non-exclusive, [****], perpetual, irrevocable, [****] license, under the Maxygen
Necessary Claims and the Maxygen Necessary Know-How to practice the Authorized Method, solely to
develop, make, have made, use, import, have imported, offer to sell and sell Products outside the
Maxygen Field in the Territory;

               (b) a non-exclusive, [****], perpetual, irrevocable, [****] license, under the Maxygen Useful
Claims and the Maxygen Useful Know-How, solely to develop, make, have made, use, import, have
imported, offer to sell and sell Products outside the Maxygen Field in the Territory;

               (c) a non-exclusive, [****], perpetual, irrevocable, [****] license to practice the Maxygen
Other Know-How in the Territory to (i) develop, make, have made, use, import, have imported, offer
to sell and sell Products outside the Maxygen Field, and (ii) for any other purpose, except to
develop, make, have made, use, import, have imported, offer to sell and sell any protein-based
product for [****] other than [****];

               (d) a non-exclusive, [****], perpetual, irrevocable, [****] license, under Maxygen’s interest
in the Subject Improvements (including any corresponding Patent Rights and/or Know-How), solely to develop, make, have made, use, import, have imported, offer
to sell and sell Products outside the Maxygen Field in the Territory;

               (e) a non-exclusive, [****], perpetual, irrevocable license, to make, have made and use the
Materials and/or their derivatives, to develop, make, have made, use,

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

10

 

import, have imported, offer to sell and sell Products outside the Maxygen Field in the Territory; and

               (f) a non-exclusive, [****], perpetual, irrevocable, non-transferable (except pursuant to
Section 14.2.1) license to the Software to (i) use such Software internally within Avidia, (ii)
display such Software internally within Avidia, (iii) reproduce such Software, to the extent
necessary to prepare backup copies for Avidia’s internal use, and (iv) make derivative works of
such Software for internal use within Avidia, in each case, solely in conjunction with Avidia’s
efforts to develop, make, have made, use, import, have imported, offer to sell and sell Products
outside the Maxygen Field in the Territory.

          2.2 Sublicenses. Avidia may grant and authorize sublicenses to any of the rights
granted it in Section 2.1(a)-(e); provided, however, Avidia may only grant sublicenses under
Sections 2.1(a), (b), (d) and (e) in conjunction with a grant of a license of the Assigned Patent
Rights and solely for the purpose of allowing the practice of the Assigned Patent Rights to
develop, make, have made, use, import, have imported, offer to sell and sale of Products outside
the Maxygen Field in the Territory. Promptly after the grant of any such sublicense, Avidia shall
notify Maxygen in writing of the identity of each such Licensee and the specific rights (by field
and geographic region) granted to each such Licensee, provided that Avidia shall have no obligation
to reveal any information that is confidential information of such Licensee.

          2.3 Other Necessary Claims.

               2.3.1 Notice; Decision. If during the term of this Agreement Avidia becomes aware of
any claims of any patents owned or Controlled by Maxygen that Avidia believes are necessary for the
practice of the Authorized Method, then Avidia may contact Maxygen identifying the relevant claims
of the relevant patents and requesting a license from Maxygen. In any such event, Maxygen agrees
to discuss in good faith with Avidia whether Avidia requires a license to any such claims of any
such patent for such purpose. Maxygen further agrees that, if the Parties agree that Avidia
requires a license to such claims of any patents to practice the Authorized Method, such request
will be considered favorably by Maxygen, unless the grant of such license by Maxygen would have a
material adverse impact on Maxygen or its Affiliates, as determined in Maxygen’s sole discretion.
If Maxygen’s decision is favorable, such claims of any patents shall be added to Exhibit H (which
addition shall be reflected in a writing signed by both Parties), and such claims shall be Maxygen
Necessary Claims unless any payments would be owed to any Third Party for the granting or practice
of any such license, in which case the procedures set forth in Section 2.3.3 below shall apply.

               2.3.2 Neutral Determination.

                    (a) If the Parties are unable to agree on whether a license to any claims of any patents owned
or Controlled by Maxygen is necessary for Avidia to practice the Authorized Method, either Party
shall submit the matter to a mutually agreed independent

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

11

 

patent attorney (the “Neutral”) who shall have the authority to determine whether a license to claims of any such patent is necessary for
Avidia to practice the Authorized Method. As used in this Section 2.3.2, “necessary” means that
the methods claimed in the Assigned Patent Rights and/or Subject Improvements cannot practically be
practiced to perform the Authorized Method without infringing the applicable claims of any patent
owned or Controlled by Maxygen.

                    (b) The Parties shall equally share the costs associated with any such evaluation. If the
Neutral determines that such a license is necessary for the practice of the Authorized Method, then
subject to Section 2.3.4, so long as the grant of such license by Maxygen would not have a material
adverse impact on Maxygen, the applicable claims of such patent shall be added to Exhibit H and be
“Maxygen Necessary Claims” unless any payments would be owed to Third Parties for the granting or
practice of any such license, in which case the procedures set forth in Section 2.3.3 below shall
apply.

                    (c) The Parties shall direct the Neutral that any evaluation subject to this Section 2.3.2 be
completed within ninety (90) days and each shall reasonably cooperate to allow such evaluation to
be completed within such time period.

               2.3.3 License Terms. If (a) the Parties agree or the Neutral decides that any claims
of a particular patent owned or Controlled by Maxygen are necessary for the practice of the
Authorized Method, and (b) payments would be owed to Third Parties for the granting or practice of
any such license, then Maxygen shall disclose all such payments to Avidia in writing. If Avidia is
still interested in obtaining a license to such patent, then it shall notify Maxygen in writing and
the Parties shall negotiate in good faith the scope and terms of such a license to Avidia. Any
license granted by Maxygen to Avidia pursuant to this Section 2.3.3 must be embodied in a written
document signed by both Parties. In any such agreement, Avidia will agree (x) to be responsible
for paying any amounts due to Third Parties for the practice of any such license by Avidia and its
Licensees, and (y) indemnify and hold harmless Maxygen and its Affiliates and their respective
directors, officers, employees and agents from and against any and all losses, injuries, damages
and/or liabilities resulting from or arising out of or in connection with the practice of such
license by Avidia or its Licensees.

               2.3.4 Acknowledgement. It is understood and agreed by the Parties that Shuffling
Technology is one of Maxygen’s most valuable proprietary assets and that protection of Shuffling
Technology is of paramount importance to Maxygen, and notwithstanding Section 2.3.2 above, that the
Parties do not intend that Avidia will receive from Maxygen the grant of any license to any
Shuffling Technology without Maxygen’s express written consent under this Section 2.3, which
Maxygen may provide at its sole discretion on a case-by-case basis.

          2.4 Maxygen Useful Claims. If after the Effective Date Avidia becomes aware of any
claims in Patent Rights owned or Controlled by Maxygen that Avidia believes would be useful for the
practice of the Assigned Patent Rights and/or the Subject Improvements outside the Maxygen Field,
then Avidia may request a license from Maxygen thereto identifying the relevant claims and Patent
Rights. In any such event, Maxygen agrees to discuss in good faith with Avidia the terms of such a proposed license to Avidia; provided, Maxygen shall have
no obligation to grant to Avidia any license to such claims. If the Parties agree on the terms for
such a license that are the same as those set forth in this Agreement, then such claims in such

12

 

Patent Rights shall be “Maxygen Useful Claims.” If the Parties agree on the terms for such a
license that are different than those set forth in this Agreement, then the Parties will enter into
a written agreement reflecting such terms. In any such agreement, Avidia will agree (a) to be
responsible for paying any amounts due to Third Parties for the practice of any such license by
Avidia and its Licensees, and (b) indemnify and hold harmless Maxygen and its Affiliates and their
respective directors, officers, employees and agents from and against any and all losses, injuries,
damages and/or liabilities resulting from or arising out of or in connection with the practice of
such license by Avidia or its Licensees.

          2.5 DBP Therapeutic Conjugates.

               2.5.1 Acknowledgement. Avidia acknowledges that it shall not have any right, without
Maxygen’s express written consent, to directly or indirectly (a) intentionally develop any DBP
Therapeutic Conjugate for [****], or (b) make, use, import, sell or otherwise commercialize any DBP
Therapeutic Conjugate for [****].

               2.5.2 Notice; Discussion. If during the term of this Agreement Avidia wishes to
develop or commercialize any DBP Therapeutic Conjugate, then Avidia shall notify Maxygen and
request approval from Maxygen to develop or commercialize such DBP Therapeutic Conjugate,
identifying in writing (a) [****], and (b) [****]. In any such event, Maxygen agrees to discuss
with Avidia in good faith Avidia’s interest in developing or commercializing such DBP Therapeutic
Conjugate. Maxygen further agrees that such requests by Avidia for Maxygen’s approval will be
considered favorably by Maxygen, unless Maxygen determines, in its sole discretion, that such an
approval may have a material adverse impact on Maxygen or its Affiliates or Licensees.

               2.5.3 [****]; Approval. If Maxygen is willing to provide Avidia its approval that
Avidia may develop and/or commercialize a particular DBP Therapeutic Conjugate, then the Parties
shall [****] and any such DBP Therapeutic Conjugate thereafter shall be an Approved DBP Therapeutic
Conjugate for purposes of this Agreement.

               2.5.4 Expectation. It is understood and agreed that it is the expectation of the
Parties that no payments shall be required to be paid by Avidia to Maxygen for any such approval by
Maxygen of any DBP Therapeutic Conjugate.

          2.6 Effect of Trigger Date. Upon the occurrence of the Trigger Date:

               (a) all licenses granted to Avidia (and sublicenses granted by Avidia to its Licensees) under
this Agreement in effect as of the Trigger Date shall remain in effect, subject to the terms and
conditions of this Agreement; and

               (b) Avidia shall not receive additional license rights to Subject Improvements conceived and
reduced to practice or otherwise developed by Maxygen, except with respect to (i) patents or patent
applications filed after the Trigger Date that claim such

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

13

 

Subject Improvements or (ii) such Subject Improvements that fall within the scope of claims of patent applications or patents within the
Assigned Patent Rights which were filed after the Trigger Date but are entitled to claim filing
priority based on another patent application or patent within the Assigned Patent Rights filed on
or before the Trigger Date. By way of illustration and without limitation, [****].

          2.7 No License Rights. Notwithstanding Section 2.1, it is understood and agreed that
no license or right is granted to Avidia by Maxygen and no covenant is made by Maxygen to Avidia
with regard to any Patent Rights or Know-How or Software owned or Controlled by Maxygen:

               (a) that pertain to the practice of the Shuffling Technology, except as expressly set forth in
Section 2.1(a) with regard to Maxygen Necessary Claims and Maxygen Necessary Know-How, or as may be
expressly agreed by Maxygen in a further written agreement; and/or

               (b) to develop, make, have made, use, import, have imported, offer for sale, sell or have sold
(i) any instrument intended to perform DNA synthesis or produce DNA variants, or (ii) any kit, or
set of materials or reagents, that is intended to enable a Third Party to conduct DNA synthesis or
produce DNA variants; and/or

               (c) to develop, make, have made, use, import, have imported, offer for sale, sell or have sold
any DBP Therapeutic Conjugate for [****] except an Approved DBP Therapeutic Conjugate.

          2.8 Third Party Obligations. Avidia shall be solely responsible for the payment of
any amounts due to Third Parties to obtain any rights necessary for Avidia to develop or
commercialize the inventions claimed in the Assigned Patent Rights and/or in connection with the
development, manufacture, use, importation or sale of Products outside the Maxygen Field.

          2.9 No Implied Rights. No licenses or other rights, other than those expressly set
forth in this Agreement, are granted by Maxygen to Avidia hereunder, and no additional license or
other rights shall be deemed granted by Maxygen to Avidia by implication, estoppel or otherwise.

     3. LICENSE TO MAXYGEN

          3.1 License Grant. Subject to the terms and conditions of this Agreement (including
without limitation Section 3.8), Avidia hereby grants to Maxygen, and Maxygen hereby accepts, the
following licenses:

               (a) an exclusive, irrevocable, perpetual, [****] license under the Assigned Patent Rights and
the Avidia Necessary Claims to practice the Authorized Method,

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

14

 

solely to develop, make, have made, use, import, have imported, offer to sell and sell Maxygen Products for the Maxygen Field in the
Territory;

               (b) an exclusive, irrevocable, perpetual, [****] license under the Avidia Useful Claims and
Avidia Know-How, solely to develop, make, have made, use, import, have imported, offer to sell and
sell Maxygen Products for the Maxygen Field in the Territory;

               (c) a non-exclusive, irrevocable, perpetual, [****] license under Avidia’s interest in the
Subject Improvements (including any corresponding Patent Rights and/or Know-How), solely to
develop, make, have made, use, import, have imported, offer to sell and sell Maxygen Products for
the Maxygen Field in the Territory;

               (d) an exclusive, irrevocable, perpetual, [****] license under Avidia’s interest in any Patent
Rights or Know-How owned or Controlled by Avidia necessary or used to develop, make, have made, use
therapeutically or prophylactically, import, have imported, offer to sell and sell, Veterinary
Products, solely to develop, make, have made, use, import, have imported, offer to sell and sell
Reserved Therapeutic Products in the Territory;

               (e) an exclusive, irrevocable, perpetual, [****] license, under Avidia’s interest in any
Patent Rights or Know-How owned or Controlled by Avidia necessary or used to develop, make, have
made, use therapeutically or prophylactically, import, have imported, offer to sell and sell any
Product which is a DBP Research Conjugate, solely to develop, make, have made, use therapeutically
or prophylactically, import, have imported, offer to sell and sell Maxygen Products in the Maxygen
Field in the Territory; and

               (f) a non-exclusive, irrevocable, perpetual, [****] license under Avidia’s interest in any
Patent Rights owned or Controlled by Avidia (i) that claim inventions conceived or reduced to
practice in the period from the Effective Date until and including the Trigger Date and (ii) that
would be infringed, but for such license, by the practice by Maxygen and/or its Affiliates of the
Shuffling Technology as it exists up to and including the Trigger Date, solely to make, use,
import, offer to sell and sell Maxygen Products in the Maxygen Field and products other than
Products in the Territory.

          3.2 Right to Sublicense.

               (a) Maxygen may grant and authorize sublicenses to any of the rights granted it in Section
3.1(a)-(c); provided, however, Maxygen may only grant such sublicenses in conjunction with a grant
of a sublicense of the Assigned Patent Rights and solely for the purpose of allowing the practice
of the Assigned Patent Rights to develop, make, have made, use, import, have imported, offer to
sell, and sell Maxygen Products in the Maxygen Field. Promptly after the grant of any such
sublicense, Maxygen shall notify Avidia in writing of the identity of any such Licensees and the
specific rights (by field and geographic region) granted to any such Licensee, provided that
Maxygen shall have no obligation to reveal any information that is confidential information of such
Licensee.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

15

 

               (b) Maxygen may grant and authorize sublicenses to any of the rights granted it in
Section 3.1(d)-(f). Promptly after the grant of any such sublicense, Maxygen shall notify Avidia
in writing of the identity of any such Licensees and the specific rights (by field and geographic
region) granted to any such Licensee, provided that Maxygen shall have no obligation to reveal any
information that is confidential information of such Licensee.

          3.3 Other Necessary Claims.

               3.3.1 Notice; Decision. If during the term of this Agreement, Maxygen becomes aware
of any claims of any patents owned or Controlled by Avidia that Maxygen believes are necessary for
the practice of the Authorized Method, then Maxygen may contact Avidia identifying the relevant
claims of the relevant patents and requesting a license from Avidia with respect thereto. In any
such event, Avidia agrees to discuss in good faith with Maxygen whether Maxygen requires a license
to any such claims of any such patent for such purpose. Avidia further agrees that, if the Parties
agree that Maxygen requires a license to such claims of any patents to practice the Authorized
Method, such request will be considered favorably by Avidia, unless the grant of such license by
Avidia would have a material adverse impact on Avidia or its Affiliates, as determined in Avidia’s
sole discretion. If Avidia’s decision is favorable, such claims of any patents shall be added to
Exhibit D (which addition shall be reflected in a writing signed by both Parties), and such patent
shall be an Avidia Necessary Claim, unless any payments would be owed to any Third Party for the
granting or practice of any such license, in which case the procedures set forth in Section 3.3.3
below shall apply.

               3.3.2 Neutral Determination.

                    (a) If the Parties are unable to agree on whether a license to any claims of any patents owned
or Controlled by Avidia is necessary for Maxygen to practice the Authorized Method, either Party
shall submit the matter to a mutually agreed independent patent attorney (the “Neutral”) who shall
have the authority to determine whether a license to claims of any such patent is necessary for
Maxygen to practice the Authorized Method. As used in this Section 3.3.2, “necessary” means that
the methods claimed in the Assigned Patent Rights and/or Subject Improvements cannot practically be
practiced to perform the Authorized Method without infringing the applicable claims of any patent
owned or Controlled by Avidia.

                    (b) The Parties shall equally share the costs associated with any such evaluation. If the
Neutral determines that such a license is necessary for the practice of the Authorized Method, then
subject to Section 3.3.3, so long as the grant of such license by Avidia would not have a material
adverse impact on Avidia, the applicable claims of such patent shall be added to Exhibit D and be
an “Avidia Necessary Claim” unless any payments would be owed to Third Parties for the granting or
practice of any such license, in which case the procedures set forth in Section 3.3.3 below shall
apply.

                    (c) The Parties shall direct the Neutral that any evaluation subject to this Section 3.3.2 be
completed within ninety (90) days and each shall reasonably cooperate to allow such evaluation to
be completed within such time period.

               3.3.3 License Terms. If (a) the Parties agree or the Neutral decides that any claims
of a particular patent owned or Controlled by Avidia are necessary for the practice of

16

 

the Authorized Method, and (b) payments would be owed to Third Parties for the granting or practice of any such license, then Avidia shall disclose all such payments to Maxygen in writing.
If Maxygen is still interested in obtaining a license to such patent, then it shall notify Avidia
in writing and the Parties shall negotiate in good faith the scope and terms of such a license to
Maxygen. Any license granted by Avidia to Maxygen pursuant to this Section 3.3.3 must be embodied
in a written document signed by both Parties. In any such agreement, Maxygen will agree (x) to be
responsible for paying any amounts due to Third Parties for the practice of any such license by
Maxygen and its Licensees, and (y) indemnify and hold harmless Avidia and its Affiliates and their
respective directors, officers, employees and agents from and against any and all losses, injuries,
damages and/or liabilities resulting from or arising out of or in connection with the practice of
such license by Maxygen or its Licensees.

          3.4 Effect of Trigger Date. Upon the occurrence of the Trigger Date:

               (a) all licenses granted to Maxygen (and sublicenses granted by Maxygen to its Licensees)
under this Agreement in effect as of the Trigger Date shall remain in effect, subject to the terms
and conditions of this Agreement; and

               (b) Maxygen shall not receive additional license rights to Subject Improvements conceived and
reduced to practice or otherwise developed by Avidia, except with respect to (i) patents or patent
applications filed after the Trigger Date that claim such Subject Improvements or (ii) such Subject
Improvements that fall within the scope of claims of patent applications or patents within the
Assigned Patent Rights for which Avidia is entitled to claim filing priority based on another
patent application or patent within the Assigned Patent Rights filed on or before the Trigger Date.
By way of illustration and without limitation, [****].

          3.5 Reserved Rights. Notwithstanding the exclusive licenses granted to Maxygen in the
Maxygen Field:

               (a) Avidia shall retain the right under the Assigned Patent Rights and all other intellectual
property licensed by Avidia to Maxygen (i) to develop evidence demonstrating proof of principle for
the inventions claimed in the Assigned Patent Rights (subject to the limitations in Section 10.1.3
and the further limitation that Avidia will not conduct any research or development with regard to
any Reserved Therapeutic Product subject to Section 1.44(d) or (e)), and (ii) to develop, make,
have made, use, import, have imported, offer to sell and sell Veterinary Products.

               (b) Avidia shall have the right to (i) disclose to potential investors (or their agents) or
corporate partners, pursuant to nondisclosure agreements containing terms at least as restrictive
as those in Article 6, the results of work done by the Avidia Team in the period from June 1, 2001
until the Effective Date relating to the practice of the Assigned Patent Rights, and (ii) subject
to Section 6.4, Avidia shall have the right to publish in scientific journals

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

17

 

or present at scientific meetings the results of work done by the Avidia Team from June 1,
2001 relating to the practice of the Assigned Patent Rights until the Effective Date.

               (c) Avidia shall have the right to file, prosecute and maintain any patent applications or
patents arising from the results of the activities performed pursuant to Section 3.5(a) above. If
Avidia determines that it will not seek patent protection for particular inventions conceived or
reduced to practice in the course of such activities, then Avidia shall notify Maxygen of such
decision in writing, and Maxygen shall have the right, for a period not to exceed sixty (60) days),
to request that Avidia file, prosecute and maintain patent applications and patents on such
invention(s), provided such invention pertains to the Maxygen Field. In the event Maxygen does not
so request in such sixty (60) day period, it shall be deemed to have decided not to file a patent
application for such particular invention. Where so requested under this Section 3.5(c), and
pursuant to Section 7.1, Avidia (i) shall file, prosecute and maintain any such patent applications
and patents as may reasonably be requested by Maxygen to protect Maxygen’s rights thereto in the
Maxygen Field or (ii) shall provide Maxygen the opportunity to take responsibility for such filing,
prosecution or maintenance.

               (d) Upon the earlier of (i) Avidia’s or Maxygen’s filing of the applicable patent
application(s) described in Section 3.5(c) above, or (ii) a decision of Maxygen not to have Avidia
file patent application(s) with regard to a particular invention, Avidia shall have the right to
(x) disclose to potential partners or investors, and/or (y) pursuant to the procedure set forth in
Section 6.4 (which shall in no event be construed as delaying publication beyond the time limits
set forth in this Section 3.5(d)), publish in scientific journals or present at scientific
meetings, the applicable results of work done pursuant to Section 3.5(a) above.

               (e) At least semiannually, Avidia shall provide to Maxygen a written report [****] regarding
any activities performed pursuant to Section 3.5(a) above and [****].

          3.6 Avidia Useful Claims. If after the Effective Date Maxygen becomes aware of any
claims in Patent Rights owned or Controlled by Avidia that Maxygen believes would be useful for the
practice of the Assigned Patent Rights and/or the Subject Improvements in the Maxygen Field, then
Maxygen may request a license from Avidia thereto identifying the relevant claims and Patent
Rights. In any such event, Avidia agrees to discuss in good faith with Maxygen the terms of such a
proposed license to Maxygen; provided, Avidia shall have no obligation to grant to Maxygen any
license to such claims. If the Parties agree on the terms for such a license that are the same as
those set forth in this Agreement, then such claims in such Patent Rights shall be “Avidia Useful
Claims.” If the Parties agree on the terms for such a license that are different than those set
forth in this Agreement, then the Parties will enter into a written agreement reflecting such
terms. In any such agreement, Maxygen will agree to (a) be responsible for paying any amounts due
to Third Parties for the practice of any such license by Maxygen and its Licensees, and (b)
indemnify and hold harmless Avidia and its Affiliates and their respective directors, officers,
employees and agents from and against any and all losses,

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

18

 

injuries, damages and/or liabilities resulting from or arising out of or in connection with
the practice of such license by Maxygen or its Licensees.

          3.7 Third Party Obligations. Maxygen shall be solely responsible for the payment of
any amounts due to Third Parties to obtain any rights necessary for Maxygen to develop,
manufacture, use, import, offer for sale or sell Maxygen Products in the Maxygen Field.

          3.8 Reserved Therapeutic Products.

               3.8.1 Waiver of License Rights. Maxygen may, at its sole discretion, waive its
exclusive license rights to any of the Reserved Therapeutic Products, with express written notice
to Avidia identifying the specific Reserved Therapeutic Products to which the waiver applies. Such
waived exclusive license rights shall revert to Avidia upon receipt of such notice.

               3.8.2 Other Assays for Reserved Therapeutic Products. The principles and agreed
criteria for determining whether a particular Domain-Based Protein is a Therapeutic Reserved
Product are set forth on Exhibit K hereto. If either Party believes that an assay not listed on
Exhibit K is suitable for evaluating the [****] of a particular Domain-Based Protein to determine
whether it is a Therapeutic Reserved Product, it may notify the other Party and provide a written
description of the assay and an explanation of why such assay is appropriate to evaluate the [****]
of a particular Domain-Based Protein. In any such event, the Parties shall discuss in good faith
whether such assay is appropriate for the proposed purpose with regard to the applicable
Domain-Based Protein. If the Parties agree that such an assay is appropriate to evaluate [****] of
a Domain-Based Protein to determine if it is a Therapeutic Reserved Product, then such assay shall
be added to Exhibit K via written amendment. If the Parties fail to agree that such assay is
appropriate for such purpose, the proposed assay shall not be added to Exhibit K. If the Parties
are unable to reach agreement on at least one assay for assessing the [****] of a Domain-Based
Protein with regard to the applicable Ligand or its cognate receptor, such an assay and the results
in such assay that evidence [****] will be selected by an agreed Neutral Third Party; provided,
such assay [****] must be consistent with the general principles and specific criteria set forth in
Exhibit K.

               3.8.3 Waiver of Assay Criteria. If Avidia generates assay results showing that a
particular Domain-Based Protein meets the criteria for a Reserved Therapeutic Product set forth in
Exhibit K, but Avidia believes that such Domain-Based Protein should not be considered a Reserved
Therapeutic Protein, then, at Avidia’s written request, Maxygen may, at its sole discretion,
determine whether such assay results are sufficient (or insufficient) to demonstrate that such
Domain-Based Protein is not a Reserved Therapeutic Product. If Maxygen makes a determination that
such results are sufficient to demonstrate that such Domain-Based Protein is not a Reserved
Therapeutic Product, it shall provide Avidia with express written notice of its decision,
identifying the specific (a) assay(s), (b) Domain-Based Protein(s), and (c) Reserved Therapeutic
Product criteria to which such determination applies. If

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

19

 

Maxygen decides that the assay results are insufficient to demonstrate that such Domain-Based
Protein is not a Reserved Therapeutic Product, but Avidia believes that it has conclusive
scientific evidence that demonstrates that such Domain-Based Protein is not a Reserved Therapeutic
Product, then Avidia may submit the matter to a mutually agreed independent molecular biologist
(the “Neutral”) who shall have the authority to determine whether such assay results are sufficient
to demonstrate that such Domain-Based Protein is not a Reserved Therapeutic Product. The Party
against whom the Neutral rules shall bear the costs associated with such determination.

               3.8.4 Assays. At Avidia’s request, Maxygen shall cooperate with and provide
reasonable assistance to Avidia to facilitate the performance by Avidia of assays listed on Exhibit
K. At Maxygen’s discretion, such assistance may include: (i) performing one or more of such
assays on behalf of Avidia, if such assays are then being performed at Maxygen; or (ii) providing
to Avidia one or more of such assays and/or reagents for conducting such assays. Notwithstanding
the foregoing, Maxygen shall have no obligation to (a) incur any additional expense in providing
any such assistance or materials (unless Maxygen agrees in its sole discretion to provide such
assistance or materials in exchange for reimbursement from Avidia of all associated additional
expenses thereby incurred by Maxygen), (b) acquire, make or develop any materials or assays not
then in Maxygen’s possession, or (c) violate any agreement entered by Maxygen with any Third Party.

               3.8.5 Reports. At least semiannually until and including the Trigger Date, Maxygen
shall provide to Avidia a written report [****] performing research or development upon Reserved
Therapeutic Products and [****].

          3.9 No Implied Rights. No licenses or other rights, other than those expressly set
forth in this Agreement, are granted by Avidia to Maxygen hereunder, and no additional license or
other rights shall be deemed granted by Avidia to Maxygen by implication, estoppel or otherwise.

     4. TECHNOLOGY TRANSFER; OTHER COLLABORATIVE ACTIVITIES

          4.1 Delivery. Promptly following the Effective Date, at Avidia’s written request,
Maxygen shall, to the extent that they are in Maxygen’s possession and Control, deliver to Avidia
(a) documents embodying Maxygen Necessary Know-How, Maxygen Team Know-How or Maxygen Useful
Know-How, as agreed by the Parties, (b) the Software (in electronic format), and (c) samples of the
Materials sufficient to allow Avidia to establish initial stocks of the same; provided, in each
case, Maxygen shall have no further obligation to deliver further Software, Know-How or Materials,
unless otherwise agreed in writing by the Parties. All Know-How and Software provided to Avidia
pursuant to this Article 4, shall be treated as Confidential Information of Maxygen that is subject
to Article 6. All Know-How provided to Maxygen pursuant to this Article 4 shall be treated as
Confidential Information of Avidia that is subject to Article 6.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

20

 

          4.2 Assistance. Each Party shall, at the request of the other Party [****], provide
technical assistance to the requesting Party to instruct and assist the requesting Party in the
practice of the Know-How and Patent Rights licensed it herein; provided, however, neither Party
shall be obligated to provide more than [****] per year of such assistance to the other Party,
unless otherwise agreed in writing by the Parties.

          4.3 Subject Improvements. Until the Trigger Date, Avidia and Maxygen shall each
annually notify the other of any patent applications or patents filed in the previous year by or on
behalf of such Party claiming any Subject Improvement(s) that such Party or its Licensee(s) owns or
Controls, and provide to the other Party copies of any of the foregoing that have not been
previously provided to such other Party.

          4.4 Materials.

               4.4.1 Use. Avidia acknowledges that the Materials are experimental in nature and may
have unknown characteristics and properties. Avidia agrees to use prudence and all reasonable care
in the use, handling, storage, transportation, disposition and containment of any and all the
Materials, and to maintain and use the Materials under suitable containment conditions in
compliance with all applicable national, state and local laws, regulations, rules, ordinances,
codes of practice and current good laboratory practices.

               4.4.2 Bailment. All right, title and interest in and to the tangible materials
comprising the Materials is/are and shall continue to be solely owned by Maxygen. Maxygen hereby
grants to Avidia, and Avidia hereby accepts, a bailment to non-exclusively use the Materials
provided by Maxygen to Avidia to practice the license granted in Section 2.1(e).

               4.4.3 Assumption of Risk. AVIDIA EXPRESSLY ACKNOWLEDGES THAT IT HEREBY ASSUMES ANY
AND ALL RISKS ASSOCIATED WITH THE USE OF THE MATERIALS, AND THAT MAXYGEN SHALL HAVE NO LIABILITY TO
AVIDIA OR ANY THIRD PARTY FOR ANY LIABILITY, PROBLEM, LOSS OR DAMAGE RESULTING FROM AVIDIA’S OR
AVIDIA’S LICENSEES USE OF THE MATERIALS.

          4.5 Software.

               4.5.1 No Obligation to Correct or Update. The Parties agree that the Software
licensed to Avidia in Section 2.1(f) was developed by Maxygen for its internal use and not for use
by Avidia or any Third Party and may have bugs, errors or other defects that may result in
unreliable or incorrect results or may render it inoperative. Avidia agrees that, unless the
Parties otherwise agree in writing, Maxygen has (a) no obligation or duty to provide Avidia any
support with regard to the installation, maintenance or use of the Software, unless otherwise
agreed in writing by the Parties, and (b) no obligation or duty to correct, or attempt to correct,
any bugs, errors or other defects in the Software or any Software Improvement. If Maxygen in its
sole discretion provides Avidia with (i) corrections for any bugs, errors or other defects in the

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

21

 

Software or (ii) any updates for the Software not in existence on the Effective Date, then
such corrections and updates shall be deemed “Software” and Avidia shall have the license set forth
in Section 2.1(f) with respect thereto.

               4.5.2 No Patent Filings. Avidia agrees that the Software, including all intellectual
property rights therein, is owned solely by Maxygen, and agrees not to file any patent application
on any aspect of the Software, any Software Improvement and/or any derivative work based on the
Software, without Maxygen’s prior written consent, which Maxygen may provide or withhold in its
sole discretion.

               4.5.3 No Transfer. Avidia covenants that Avidia will not, without Maxygen’s written
consent, which Maxygen may grant or withhold in its sole discretion, transfer to any Third Party
any of the Software or any Software Improvements, or any object code or source code for any
Software or Software Improvement.

               4.5.4 Assumption of Risk. AVIDIA EXPRESSLY ACKNOWLEDGES THAT IT HEREBY ASSUMES ANY
AND ALL RISKS ASSOCIATED WITH THE USE OF THE SOFTWARE, AND THAT MAXYGEN SHALL HAVE NO LIABILITY TO
AVIDIA OR ANY THIRD PARTY FOR ANY LIABILITY, PROBLEM, LOSS OR DAMAGE RESULTING FROM AVIDIA’S USE OF
THE SOFTWARE.

          4.6 Collaborative Research. At any time, Maxygen and Avidia may agree to conduct
collaborative research pursuant to a written agreement with regard to any Reserved Therapeutic
Product and/or Licensed Product licensed by Maxygen. Unless otherwise agreed by the Parties,
Maxygen shall pay for any research conducted by Avidia pursuant to such research collaboration at
an FTE rate of $[****]/FTE/year, such FTE rate to be revised annually to account for any change in
the CPI, using 2003 as the comparison year. If Maxygen and Avidia enter into such a research
collaboration with respect to a Reserved Therapeutic Product: (a) such shall be deemed an exercise
of one of Maxygen’s [****] Target Options, and shall count toward the Cap, as defined in Section
5.1.2; and (b) any Reserved Therapeutic Product developed or commercialized by Maxygen which is
derived from the work done by Avidia pursuant to such collaboration shall be subject to such
financial terms, if any, set forth in such written agreement. For clarification, Maxygen shall be
free to develop or commercialize any Reserved Therapeutic Product without collaborating with
Avidia, and in such event Maxygen shall not have any financial obligation to Avidia with respect to
such Reserved Therapeutic Product.

          4.7 Subject Improvements. Each Party shall own any Subject Improvements made by it,
and any related Patent Rights and/or Know-How.

     5. MAXYGEN OPTIONS

          5.1 Target Options.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

22

 

               5.1.1 Option Grant. Avidia hereby grants to Maxygen, and Maxygen hereby accepts,
[****] options (each a “Target Option”), exercisable until the Trigger Date, to obtain, with
respect to a given Avidia Target, an exclusive worldwide, royalty-bearing license, with the right
to sublicense, to develop, make, have made, use, import, have imported, offer for sale and sell
Licensed Products directed against the applicable Avidia Target, as set forth in the form of
Product License Agreement attached hereto as Exhibit I.

               5.1.2 Maximum. Maxygen may obtain such licenses with respect to the first [****]
Avidia Targets as to which Maxygen exercises its Target Options. In no event shall the total number
of Target Options exercised by Maxygen exceed [****] (the “Cap”). The obligations of Avidia
pursuant to this Article 5 shall expire upon the Parties’ entry into the corresponding Product
License Agreement pursuant to Maxygen’s exercise of its [****] Target Option.

          5.2 Avidia Target Reports.

               5.2.1 Reports.

                    (a) Semiannual Reports. Until the earlier of the Trigger Date or when the Cap is
reached, at least semiannually, Avidia shall notify Maxygen of all Avidia Targets outside the
Maxygen Field upon which Avidia is working (directly or through a subcontractor), identifying each
such Avidia Target, and shall provide to Maxygen a written report [****] regarding such Avidia
Target(s) and potential Licensed Products relating thereto. Avidia may, at its discretion, include
in such semiannual reports other human therapeutic targets (e.g., receptors) outside the Maxygen
Field that Avidia has identified as suitable for the development of agonist or antagonist Products
but upon which it has not commenced any work; provided, such targets shall not be considered Avidia
Targets.

                    (b) Other Reports. If during the period between the semiannual reports described
above, Avidia wishes to notify Maxygen of any Avidia Targets, it may so notify Maxygen, providing a
written report [****]. In addition, at such time as Avidia has expended [****] dollars ($[****])
on research relating to a particular Avidia Target not previously included in a semiannual report
pursuant to Section 5.2.1(a) above or any other reports pursuant to this Section 5.2.1(b),
(provided that such time is before the earlier of the Trigger Date or when the Cap is reached), it
shall notify Maxygen and provide to Maxygen a written report relating to such Avidia Target [****],
so that Maxygen will have an opportunity to determine whether it wishes to exercise its Target
Option thereto before such Avidia Target becomes an Excluded Target.

                    (c) Further Information. With respect to any Avidia Target subject to a semiannual
report set forth in Section 5.2.1(a) or other report under Section 5.2.1(b) (the “Target Reports”),
during the [****] day period referred to in Section 5.3.1 during which Maxygen is determining
whether to exercise its Target Option with respect to such Avidia

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

23

 

Target, Avidia shall (i) update any information or data provided in such Target Reports [****],
up and until the earlier of Maxygen’s exercise of the Target Option, or [****] days from
Maxygen’s receipt of the applicable Avidia report; and (ii) use reasonable efforts to promptly
respond to any reasonable questions raised by Maxygen with regard to the data relating to any
Avidia Target and potential Licensed Products relating thereto to allow Maxygen to determine
whether it wishes to exercise its Target Option thereto; provided however that Avidia shall not be
obliged to perform any research to answer any questions raised by Maxygen.

                    (d) Excluded Targets. If Avidia concludes that a Ligand should be deemed as an
Excluded Target under Section 1.21(a) (except any that also qualifies as an Excluded Target
pursuant to Section 1.21(b) or (c)), prior to conducting any research on such Ligand, Avidia shall
notify Maxygen of the identity of any such Ligand and of any basis for its conclusion that such a
Ligand should be deemed an Excluded Target. If Maxygen disagrees, then the Parties shall submit
such issue to a mutually agreed independent patent attorney (the “Neutral”) who shall have the
authority to determine whether [****] and whether such Ligand is in fact an Excluded Target.
Maxygen shall bear the costs associated with any such evaluation, unless the Neutral determines
that such Ligand is not an Excluded Target, in which case Avidia shall bear such costs. If the
Neutral determines that such a Ligand is not an Excluded Target, then it shall be an Avidia Target
for all purposes of this Agreement. Notwithstanding the foregoing, a Ligand shall be presumed to
be an Excluded Target for the purpose of this Agreement if [****], and Maxygen shall not have the
right to submit the issue of whether such Ligand is an Excluded Target to a Neutral for evaluation
in such instances; provided Maxygen shall be entitled to have the Neutral verify that Avidia has
[****]. Avidia shall not have any obligation hereunder to disclose to Maxygen or the Neutral any
[****].

               5.2.2 Other Disclosures. In addition to the reports described in Section 5.2.1 above,
concurrently with each such report Avidia shall also disclose to Maxygen in writing, subject to
Section 7.3, all issued patents and published patent applications owned by Third Parties of which
Avidia is aware that [****], in each case, that Avidia has not previously disclosed to Maxygen.
The Parties acknowledge and agree that the foregoing shall not be interpreted as obligating Avidia
to search for or inquire as to the existence of, such Third Party patents and patent applications.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

24

 

          5.3 Target Option Exercise.

               5.3.1 Notice. Within [****] days of its receipt from Avidia of any report described
in Section 5.2, provided that the Cap has not been reached, Maxygen shall have the right to
exercise its Target Option to obtain an exclusive license with respect to Products directed toward
such Avidia Target(s). If Maxygen wishes to exercise its Target Option for a particular Avidia
Target, it shall send to Avidia a completed and signed Product License Agreement for such Avidia
Target and its corresponding Licensed Product. Maxygen shall be deemed to have exercised a Target
Option when Avidia countersigns such Product License Agreement and returns it to Maxygen.

               5.3.2 Maxygen Rejection. After Avidia provides Maxygen with any report pursuant to
Section 5.2, in the event that Maxygen notifies Avidia that it will not exercise its Target Option
with respect to a particular Avidia Target, or fails to timely provide Avidia within the applicable
[****] day period the completed and signed Product License Agreement for a particular Avidia Target
and the corresponding Licensed Products, then subject to the further notice and disclosure
obligations described in Sections 5.4.1, Avidia shall be free to seek a Third Party sponsor of a
project for such Avidia Target, or any other license or collaborative arrangement with a Third
Party with respect to such Avidia Target and/or a Product directed thereto. If Avidia enters into
such a Third Party collaboration for a particular Avidia Target and/or Product(s) directed thereto
within [****] months of Maxygen’s declining or failing to exercise its Target Option for such
Avidia Target, then such target shall become an Excluded Target. However, if Avidia has not
entered into such a Third Party collaboration for a particular Avidia Target and/or Product(s)
directed thereto within [****] months of Maxygen’s declining or failing to exercise its Target
Option for such Avidia Target, then Avidia shall be obligated to present any such Avidia Target to
Maxygen again in the next semiannual report or earlier, at Avidia’s option, prior to entering into
a Third Party collaboration for such Avidia Target. In any such case, Maxygen shall again have the
opportunity to exercise its Target Option with respect thereto, in accordance with Section 5.3.1
and on the terms set forth in the Product License Agreement.

               5.3.3 Maxygen Waiver. If Avidia notifies Maxygen of any potential target upon which
Avidia has not commenced research and development using the Assigned Patent Rights, then Maxygen
may, at its sole discretion, notify Avidia in writing that Maxygen is not interested in such target
and thereby waive its right to evaluate data that may be created by Avidia relating to such target.
In such case, such specific target shall never become an Avidia Target for purposes of this
Agreement.

               5.3.4 Excluded Target. In the event that, with respect to a given Avidia Target,
Avidia has expended greater than [****] U.S. Dollars (U.S.$ [****]) in a period of [****] or fewer
continuous months (the “Trigger Amount”) directly on the research and development of one or more
Products directed against such Avidia Target, then such Avidia Target shall cease being an Avidia
Target for purposes of this Article 5, and shall be deemed to

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

25

 

be an Excluded Target. In such event Avidia shall notify Maxygen of the identity of such
Excluded Target, and at Maxygen’s request, provide a written accounting of the expenditures meeting
such Trigger Amount. For clarification, the Trigger Amount shall include [****], in each case, as
determined and allocated in accordance with U.S. generally accepted accounting principles,
consistently applied.

          5.4 Suspension Date.

               5.4.1 Notification to Maxygen.

                    (a) Notification. If Avidia has received [****] a Change of Control, and the Cap has
not been reached by such date, then within [****] days after Avidia’s notification to Maxygen that
it has received [****], Avidia shall notify Maxygen of (i) all new Avidia Targets (i.e., Avidia
Targets not disclosed in the previous notifications) and [****] relating thereto, and (ii) [****]
any Avidia Target previously disclosed which has not become an Excluded Target pursuant to Section
5.3.2 or 5.3.4, if any, [****] the last notification of such Avidia Target to Maxygen.

                    (b) Further Information. With respect to [****] a report provided by Avidia pursuant
to Section 5.4.1(a), Avidia shall use reasonable efforts to promptly respond to any reasonable
questions raised by Maxygen [****] relating to any Avidia Target and potential Licensed Products
relating thereto to allow Maxygen to determine whether it wishes to exercise its Target Option
thereto; provided however that Avidia shall not be obliged to perform any research to answer any
questions raised by Maxygen.

                    (c) Other Disclosures. In addition to the notification described in Section 5.4.1(a)
above, concurrently with each such report Avidia shall also disclose to Maxygen in writing, subject
to Section 7.3, all issued patents and published patent applications [****], in each case, that
Avidia has not previously disclosed to Maxygen. The Parties acknowledge and agree that the
foregoing shall not be interpreted as obligating Avidia [****].

               5.4.2 Notification to Avidia. Within [****] days of its receipt from Avidia of any
report described in Section 5.4.1(a) above, Maxygen shall have the right to exercise its remaining
Target Option(s) with respect to Products directed toward such Avidia Target(s), provided that the
Cap is not exceeded. If Maxygen wishes to exercise a Target Option for a particular Avidia Target,
it shall send to Avidia [****]. Maxygen shall be deemed to have exercised a Target Option when
[****]. Avidia may not [****] with respect to any Avidia Target or Licensed Product that is the
subject to a Product License Agreement, [****].

               5.4.3 Suspension Date. The [****] day after Maxygen’s receipt from Avidia of any
report described in Section 5.4.1(a) above shall be deemed a “Suspension Date.” After such
Suspension Date, Maxygen may not exercise any further Target Options; provided, if (i) such [****]
Change of Control does not occur within [****] days of Avidia’s notice to Maxygen [****], or within
[****] thereof [****], if any regulatory ruling or government consent

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

26

 

is required for such Change of Control, or (ii) Avidia has abandoned its discussions
pertaining to such [****] Change of Control, then upon the earlier to occur of such events, Avidia
shall promptly notify Maxygen and such Suspension Date shall no longer be in effect, and Maxygen’s
rights shall be reinstated as they were prior to such Suspension Date.

          5.5 Product License Agreement.

               5.5.1 Avidia acknowledges that it may not [****] with respect to any Licensed Product that is
the subject of a Product License Agreement, [****].

               5.5.2 Within [****] days, or such longer period as the Parties may agree in writing (the
“Interim Period”), after [****] a Product License Agreement, Avidia shall cease all work directly
related to the Licensed Product to which such Product License Agreement pertains. During such
Interim Period, Avidia may [****].

               5.5.3 Avidia shall have the right to (a) disclose to potential investors (or their agents),
under terms of confidentiality at least as restrictive as those in Article 6, the results of work
done by it with respect to the applicable Avidia Target or Licensed Product to which such Product
License Agreement pertains, [****], and/or (b) subject to the procedures set forth in Section 6.4,
publish in scientific journals or present at scientific meetings, the applicable results of work
done by it with respect to the applicable Avidia Target or Licensed Product, [****]; provided in
each case that Avidia has filed, pursuant to Section 7.1, patent application(s) with respect to any
patentable inventions related thereto prior to any such disclosure or publication.

               5.5.4 Avidia shall have the right to disclose to potential corporate partners under terms of
confidentiality at least as restrictive as those in Article 6, general results of work done by it
with respect to the applicable Avidia Target or Licensed Product (e.g., [****]) to which such
Product License Agreement pertains, but shall not disclose (a) [****] of any Licensed Product
subject to the applicable Product License Agreement or (b) that Maxygen has entered into a Product
License Agreement with Avidia with respect to such Avidia Target.

               5.5.5 In event of that one or more terms of this Agreement relating to licenses and related
intellectual property rights set forth in this Agreement conflict with or are not entirely
consistent with one or more terms of a particular Product License Agreement, the terms set forth in
such Product License Agreement shall prevail with regard to the Products subject to such Product
License Agreement. By way of example, but without limitation, [****].By way of further example,
[****].

     6. CONFIDENTIALITY

          6.1 Confidential Information. Except as expressly provided herein, the Parties agree
that, for the term of this Agreement, the receiving Party shall keep completely confidential and
shall not publish or otherwise disclose and shall not use for any purpose except for the

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

27

 

purposes contemplated by this Agreement any Confidential Information furnished to it by the
disclosing Party hereto pursuant to this Agreement, except to the extent that it can be established
by the receiving Party by competent proof that such Confidential Information:

               6.1.1 was already known to the receiving Party, other than under an obligation of
confidentiality, at the time of disclosure;

               6.1.2 was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the receiving Party;

               6.1.3 became generally available to the public or otherwise part of the public domain after
its disclosure to the receiving Party, other than through any act or omission of the receiving
Party in breach of this Agreement or any other agreement between the Parties or in contravention of
the disclosing Party’s rights under applicable law;

               6.1.4 was independently developed by the receiving Party without reference to or use of any
Confidential Information disclosed by the disclosing Party; or

               6.1.5 was subsequently disclosed to the receiving Party free of obligations of confidentiality
by a Third Party without legal obligation to the disclosing Party or its Affiliates with regard
thereto.

          6.2 Permitted Use and Disclosures. Each Party may use and disclose Confidential
Information disclosed to it by the other Party as necessary, for the purposes of: prosecuting or
defending litigation, complying with applicable governmental laws, rules or regulations or court
order issued by a court of competent jurisdiction or otherwise submitting required information to
tax or other governmental authorities, or negotiating and/or entering into a permitted sublicense
or otherwise exercising license rights expressly granted to it by the other Party pursuant to the
terms of this Agreement, provided that if a Party is required to make any such disclosure, other
than pursuant to a confidentiality agreement, it will give reasonable advance notice to the other
Party of such disclosure and will use its reasonable efforts to secure confidential treatment of
such information in consultation with the other Party prior to its disclosure (whether through
protective orders or otherwise) and disclose only the minimum necessary to comply with such
requirements.

          6.3 Publicity. Except as expressly permitted in this Article 6, or as required by law
or regulation, each Party agrees not to disclose the terms of this Agreement to any Third Party
without the prior written consent of the other Party, which consent shall not be unreasonably
withheld; provided, however, each Party may disclose this Agreement or its terms without such
consent (a) to its attorneys, advisors, investors and others on a need-to-know basis, under
circumstances that reasonably ensure the confidentiality thereof, (b) in any prospectus, offering
memorandum, or other document, filing or public announcement required by applicable securities laws
or other applicable law or regulation, and/or (c) in confidence, to actual or prospective financing
sources in connection with a financing, sublicenses, actual or prospective corporate partners, or
Third Parties with whom such Party may enter a strategic combination, on a need-to-know basis.

28

 

          6.4 Public Disclosures

               6.4.1 Limits on Public Disclosures. Any public disclosure (electronic or paper) by
Avidia describing any method for making, using or manufacturing any Maxygen Product in the Maxygen
Field and/or any Maxygen Product composition in the Maxygen Field shall require Maxygen’s written
consent, which consent shall not be unreasonably withheld. Any public disclosure (electronic or
paper) by Maxygen describing any method for making, using or manufacturing any Product outside the
Maxygen Field and/or any Product composition outside the Maxygen Field shall require Avidia’s
written consent, which consent shall not be unreasonably withheld.

               6.4.2 Pre-Publication Review. To avoid loss of patent rights as a result of premature
public disclosure of patentable information, each Party shall submit to the other Party all
manuscripts describing scientific results obtained from the practice of the Assigned Patent Rights
that have applicability to the receiving Party’s field, and the receiving Party shall notify the
disclosing Party in writing within thirty (30) days after receipt of any disclosure whether the
receiving Party desires to file or have filed a patent application on any invention disclosed in
such scientific results with respect to its permitted field of use. In the event that the
receiving Party desires to file such a patent application, the disclosing Party shall withhold
publication or disclosure of such scientific results until the earlier of the date upon which (i) a
patent application is filed thereon, or (ii) the Parties determine after consultation that no
patentable invention exists or, alternatively, that patent protection should not be sought for such
invention, or (iii) sixty (60) days after receipt by the disclosing Party of the receiving Party’s
written notice of the receiving Party’s desire to file such patent application. Further, if such
scientific results contain the information of the receiving Party that is subject to use and/or
nondisclosure restrictions under this Article 6, the disclosing Party agrees to remove such
information from the proposed publication or disclosure, upon request by the receiving Party. Any
publication subject to this Section 6.4 shall include an acknowledgment of the contributions of
each Party, in accordance with customary scientific norms.

          6.5 Injunctive Relief. Each Party hereto acknowledges that the remedy at law for
breach by any Party of its obligations under this Article 6 is inadequate and that each Party shall
be entitled to equitable remedies, including injunctive relief, in the event of a breach by the
other Party.

          6.6 Acknowledgement. The Parties acknowledge that the members of the Avidia Team were
previously employed by and/or were consultants to Maxygen and that in such capacity each member of
the Avidia Team (a) had access to, and was exposed to, proprietary and valuable Confidential
Information of Maxygen and Third Parties, and (b) was involved in the generation of proprietary and
valuable Confidential Information at Maxygen that has been assigned to Maxygen. All Maxygen
Information shall remain at all times Confidential Information of Maxygen, subject to the terms of
this Article 6, unless assigned by Maxygen to Avidia.

29

 

     7. PATENT PROSECUTION

          7.1 Avidia Rights and Responsibilities.

               7.1.1 Prosecution. Avidia shall have the right, but not the obligation, to (a) file,
prosecute and maintain the Assigned Patent Rights and any Patent Rights claiming the composition,
or method of use or manufacture, of any Veterinary Product (“Vet Product Patents”) and (b) conduct
any interference, reexamination, reissue or opposition proceeding the subject of which is any
Assigned Patent Rights and/or any Vet Product Patent ((a) and (b), collectively, to “Prosecute” or
the “Prosecution” of the Assigned Patent Rights and any Vet Product Patents), in each case using
counsel reasonably acceptable to Maxygen. Avidia shall control the Prosecution and bear the costs
of any such activities undertaken by Avidia or any agent of Avidia. Avidia shall keep Maxygen
fully informed of the status of each patent application and patent within the Assigned Patent
Rights and/or the Vet Product Patents that Avidia Prosecutes, and to that end, Avidia shall, at a
minimum, furnish Maxygen with a copy of each draft submission to a patent authority of any
jurisdiction at least thirty (30) days before the date Avidia proposes to make such submission in
the condition that such draft exists at such time. Avidia shall reasonably and in good faith
consider Maxygen’s comments on each such draft submission, and shall make all reasonable proposed
revisions suggested by Maxygen that may effect the rights of Maxygen or its Licensees in the
Maxygen Field without adversely affecting Avidia’s rights with respect to the Assigned Patent
Rights and/or Vet Product Patents. Maxygen shall reimburse Avidia for any reasonable out-of-pocket
expenses incurred by Avidia as a result of such revisions requested by Maxygen, if such revisions
relate solely to the Maxygen Field. Avidia shall make reasonable efforts to provide Maxygen with
an update to such draft prior to filing to enable Maxygen to monitor progress and further comment
on the draft. Avidia shall provide Maxygen with a copy of each submission to a patent authority of
a jurisdiction within the Territory reasonably promptly after making such filing and copies of any
documents received from any patent office with regard to any of the Assigned Patent Rights and/or
Vet Product Patents reasonably promptly following receipt thereof.

               7.1.2 Election Not to Prosecute. In each country of the Territory, if Avidia elects
not to Prosecute the applicable Assigned Patent Rights and/or Vet Product Patent(s) in such
country, Avidia shall give Maxygen notice of such election promptly, but in any event at least
forty-five (45) days before the next required filing deadline, in order to maintain the
availability of patent protection for the subject matter of such Assigned Patent Rights and/or Vet
Product Patent(s), or payment of fees relating to the Prosecution of such Assigned Patent Rights or
Vet Product Patent(s), if required in such country. If, after receiving any such notice from
Avidia, Maxygen responds with written notice to Avidia that it (or any of its Licensees) wishes to
take responsibility for such Assigned Patent Rights and/or Vet Product Patent(s) in such country
then Avidia shall (i) promptly provide Maxygen with all pertinent files, correspondence, records,
information and other documents relating thereto in Avidia’s possession or control, and (ii) take
all other actions reasonably necessary to transfer to Maxygen (or its designee) the right, power
and authority to Prosecute such Assigned Patent Rights and/or Vet Product Patent(s) in such
country. If Maxygen (or its designee) assumes Prosecution of any patent application or patent
within the Assigned Patent Rights and/or Vet Product Patent(s) in any country pursuant to this
Section 7.1.2 it shall be responsible for all expenses incurred in connection with such activities.

30

 

               7.1.3 Cooperation. Each Party shall reasonably cooperate with the other Party in
the Prosecution of the Assigned Patent Rights and/or Vet Product Patent, and shall execute and
deliver to the Party that is conducting such Prosecution activities (the “Filing Party”) such
documents as may be reasonably necessary in the furtherance of such Prosecution. Patent counsel
for each Party shall cooperate with patent counsel for the other Party in connection with the
filing, prosecution and maintenance of such patent applications and patents. The Party that is not
the Filing Party with respect to a particular patent application or patent subject to this Article
7 will be granted an associate power of attorney (or its equivalent) on such applications solely to
inspect the filings made by the Filing Party and not for any other purpose.

               7.1.4 No Abandonment. During the term of this Agreement, neither Party shall take
actions to abandon any patent application that is within the Assigned Patent Rights and/or Vet
Product Patent without at least thirty (30) days advance written notice of the other Party, but
either Party may discontinue its Prosecution activities with respect to any Assigned Patent Rights
and/or Vet Product Patent without the written consent of the other Party, subject to Section 7.1.2.

               7.1.5 Limits on Patent Filings. In order to facilitate Avidia’s compliance with the
covenant in Section 10.1.6, if after a reasonable inquiry by Avidia, Avidia wishes to obtain advice
from Maxygen whether a particular patent application that would be within the Assigned Patent
Rights and/or Subject Improvements (a) discloses any Maxygen Information, or (b) has claims that
fall within the scope of claims of Patent Rights within the Shuffling Technology, then Avidia may
request such advice from Maxygen. In such case, Maxygen shall review any such patent application
provided hereunder by Avidia and shall, within a reasonable time thereafter, inform Avidia whether
it believes that such patent application discloses any Maxygen Information (and if so, shall
identify such Maxygen Information) and/or falls within the scope of any claims of Patent Rights
within the Shuffling Technology (and, if so, shall identify the relevant Shuffling Technology
claims).

               7.1.6 Notice. Each Party shall inform the other Party of any Patent Rights,
information or proceeding of which it becomes aware that relate to the Assigned Patent Rights and
that may adversely impact the validity, title or enforceability of the Assigned Patent Rights in
the Territory in the other Party’s field.

               7.1.7 Notice of Patent Issue. During the term of this Agreement, promptly following
the issue or grant of any patent owned or Controlled by Maxygen or Avidia, as the case may be, that
may be necessary for the practice of the Authorized Method, Maxygen or Avidia, as the case may be,
shall provide the other Party with a copy of such patent, and at the request of either Party, the
Parties shall discuss the relevance of such patent to the Authorized Method.

          7.2 Necessary Claims.

               7.2.1 Maxygen Necessary Claims. Maxygen shall have the right, but not the obligation,
at its sole discretion, to (a) seek and maintain the Maxygen Necessary Claims and (b) conduct any
interference, reexamination, reissue or opposition proceeding the subject of which is any Maxygen
Necessary Claims ((a) and (b), collectively, to “Prosecute” the Maxygen

31

 

Necessary Claims), in each case using counsel of its choice. Maxygen shall bear the costs of
any such activities undertaken by Maxygen or any agent of Maxygen.

               7.2.2 Avidia Necessary Claims. Avidia shall have the right, but not the obligation,
at its sole discretion, to (a) seek and maintain the Avidia Necessary Claims and (b) conduct any
interference, reexamination, reissue or opposition proceeding the subject of which is any Avidia
Necessary Claims ((a) and (b), collectively, to “Prosecute” the Avidia Necessary Claims), in each
case using counsel of its choice. Avidia shall bear the costs of any such activities undertaken by
Avidia or any agent of Avidia.

          7.3 Common Interest Disclosures. With regard to any information or opinions or advice
of counsel disclosed by one Party to the other Party regarding intellectual property and/or
technology owned by Third Parties, Maxygen and Avidia acknowledge that they have a common legal
interest in determining whether, and to what extent, Third Party intellectual property rights may
affect the Assigned Patent Rights, or the Maxygen Necessary Claims or the Avidia Necessary Claims
and have a further common legal interest in defending against any actual or prospective Third Party
claims based on allegations of misuse or infringement of intellectual property rights relating to
the Assigned Patent Rights, or the Maxygen Necessary Claims or the Avidia Necessary Claims or their
use. Accordingly, [****].

     8. PATENT ENFORCEMENT AND OTHER ACTIONS AGAINST THIRD PARTIES

          8.1 Notice. In the event that Avidia or Maxygen becomes aware of any actual or
threatened infringement of any patents within the Assigned Patent Rights (an “Infringement”), that
Party shall promptly notify the other Party in writing.

          8.2 Enforcement of the Assigned Patent Rights.

               8.2.1 Outside the Maxygen Field. Avidia shall have the first right, but not the
obligation, at its sole expense, to bring or defend, prosecute and control any action, suit or
proceeding with respect to any Infringement outside the Maxygen Field, including any declaratory
judgment action related thereto (each an “Action”) against any Third Party involving the Assigned
Patent Rights outside the Maxygen Field.

               8.2.2 In the Maxygen Field. Maxygen shall have the first right, but not the
obligation, at its sole expense, to bring or defend, prosecute and control any action, suit or
proceeding with respect to such Infringement, including any declaratory judgment action (each an
“Action”) against any Third Party involving any claims in the Assigned Patent Rights covering any
(a) composition of any Maxygen Product, or (b) method of using any such Maxygen Product. Avidia
agrees to join any such Action as a party at Maxygen’s request, if Avidia is an indispensable or
required party under applicable law, and Avidia agrees not to oppose such joinder.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

32

 

               8.2.3 Control; Settlement. The Party conducting an Action under this Section 8.2
shall have full control over its conduct, including settlement thereof; provided, such settlement
shall not be made without the prior written consent of the other Party if it would adversely affect
the rights of such other Party, including without limitation, the licenses granted hereunder.

               8.2.4 Recoveries. The Party bringing an Action pursuant to this Section 8.2 shall
have the right first to reimburse itself out of any sums recovered in such Action or in its
settlement for all reasonable out-of-pocket costs and expenses, including reasonable attorney’s and
expert fees and other direct costs incurred in connection with such Action or settlement. The
remainder is next to be used to reimburse the other Party for its costs and expenses incurred in
providing cooperation requested by the Party controlling such Action pursuant to Section 8.5 below.
Any remaining amounts may be kept by the Party bringing such Action.

          8.3 Enforcement of Maxygen Necessary Claims and Avidia Necessary Claims.

               8.3.1 Maxygen. Maxygen (or its designee) shall have the exclusive right, but not the
obligation, at its sole discretion, to bring or defend, prosecute and control any action, suit or
proceeding with respect to any actual or threatened infringement of any Maxygen Necessary Claims,
including any declaratory judgment action against any Third Party related thereto, at its own
expense and may keep any recovery obtained in any such action, suit or proceeding.

               8.3.2 Avidia. Avidia (or its designee) shall have the exclusive right, but not the
obligation, at its sole discretion, to bring or defend, prosecute and control any action, suit or
proceeding with respect to any actual or threatened infringement of any Avidia Necessary Claims,
including any declaratory judgment action against any Third Party related thereto, at its own
expense and may keep any recovery obtained in any such action, suit or proceeding.

          8.4 Other Actions. With respect to any Patent Rights, Know-How or Software licensed
hereunder not expressly described above in Sections 8.2 or 8.3, as between Maxygen and Avidia, each
Party shall have the exclusive right, at its sole expense, to commence and/or defend any action or
proceeding to enforce or defend any rights it may have to any Patent Rights or Know-How owned
solely by such Party, and to resolve such matters as it deems appropriate, subject to the licenses
granted herein.

          8.5 Cooperation. In any action or proceeding subject to this Article 8, each Party
shall fully cooperate with and assist the other Party as reasonably requested, at the expense of
the requesting Party.

     9. REPRESENTATIONS AND WARRANTIES; DISCLAIMER

          9.1 Mutual Representations and Warranties. Each of Avidia and Maxygen hereby
represents and warrants to the other, as of the Effective Date, as follows:

               9.1.1 it is a corporation duly organized and validity existing under the laws of the state of
its incorporation;

33

 

               9.1.2 the execution, delivery and performance of this Agreement by such Party has been duly
authorized by all requisite corporate action;

               9.1.3 it has the right, power and authority to execute and deliver this Agreement and to
perform its obligations hereunder, including, without limitation, in the case of Maxygen, the
right, power and authority to grant the licenses under Article 2 and, in the case of Avidia, the
right, power and authority to grant the licenses under Article 3; and

               9.1.4 the execution, delivery and performance by such Party of this Agreement and its
compliance with the terms and provisions hereof to such Party’s best knowledge does not conflict
with or result in a breach of any of the terms and provisions of or constitute a default under (a)
a loan agreement, guaranty, financing agreement, agreement affecting any Party or other agreement
or instrument binding or affecting such Party or its property; (b) the provisions of its charter
documents or bylaws; or (c) any order, writ, injunction or decree of any court or governmental
authority entered against it or by which any of its property is bound.

          9.2 Maxygen. Maxygen hereby represents and warrants to Avidia that:

               9.2.1 As of the Effective Date, it owns or Controls the patents listed in Exhibit H and
Exhibit I.

               9.2.2 As of the Effective Date, it owns or Controls the Software and Materials; and

               9.2.3 As of the Effective Date, it is unaware of any claims in any issued patent owned or
licensed by Maxygen (except the Maxygen Necessary Claims listed in Exhibit H) that are necessary
for Avidia to practice the Authorized Method outside the Maxygen Field.

               9.2.4 it is unaware of any claims that are pending as of the Effective Date in any pending
U.S. patent application owned or licensed by Maxygen that, when issued, Maxygen expects will cover
the practice of the Authorized Method such that Avidia would require a license to such claims to
practice the Authorized Method.

               9.2.5 To the best of Maxygen’s knowledge, the practice of the Materials and Software within
the scope of the licenses granted to Avidia in Sections 2.1(e) and (f) respectively, does not
require the practice of the Shuffling Technology.

               9.2.6 As of the Effective Date, the Excluded Technology (as defined in the License Agreement
between Maxygen and Verdia entered into on March 30, 2002) does not include any Maxygen Necessary
Claims.

               9.2.7 As of the Effective Date, the Maxygen Necessary Claims are free and clear of all liens
and any encumbrances that would be inconsistent with the licenses granted to Avidia in Section
2.1(a).

34

 

               9.2.8 As of the Effective Date, neither Maxygen nor its Affiliates has received any written
notice of any claim or allegation that the practice of the Authorized Method infringes any patents
or other intellectual property rights of any Third Party.

          9.3 Disclaimers. Nothing in this Agreement is or shall be construed as:

               9.3.1
Mutual.

                    (a) A warranty or representation that anything developed, made, used, sold or otherwise
disposed of under any license granted in this Agreement is or will be free from infringement of any
patent rights or other intellectual property right of any Third Party; or

                    (b) An obligation to bring or prosecute actions or suits against any Third Parties for
infringement of any of the Patent Rights licensed by Avidia under this Agreement.

               9.3.2 Avidia.

                    (a) A warranty or representation by Avidia as to the validity or scope of any claim or patent
within the Assigned Patent Rights or the Avidia Necessary Claims or the Avidia Useful Claim;

                    (b) An obligation to bring or prosecute actions or suits against Third Parties for
infringement of any of the Patent Rights licensed to Maxygen under this Agreement; or

                    (c) Except as expressly set forth in Sections 3.3 and 3.6, granting by implication, estoppel,
or otherwise indirectly any licenses or rights under patents or other rights owned or Controlled by
Avidia, regardless of whether such patents or other rights are dominant or subordinate to any
patent licensed to Maxygen hereunder.

               9.3.3 Maxygen.

                    (a) A warranty or representation by Maxygen as to the validity or scope of any claim or patent
within the Maxygen Necessary Claims or the Maxygen Useful Claims;

                    (b) An obligation to bring or prosecute actions or suits against Third Parties for
infringement of any of the Patent Rights licensed to Avidia under this Agreement; or

                    (c) Except as expressly set forth in Sections 2.3 and 2.4, granting by implication, estoppel,
or otherwise indirectly any licenses or rights under patents or other rights owned or Controlled by
Maxygen, regardless of whether such patents or other rights are dominant or subordinate to any
patent licensed to Avidia hereunder.

          9.4 Disclaimer of Warranties. ALL PATENT RIGHTS, SUBJECT IMPROVEMENTS, KNOW-HOW,
SOFTWARE AND MATERIALS LICENSED

35

 

HEREUNDER ARE LICENSED “AS IS” AND, EXCEPT AS OTHERWISE EXPRESSLY SET FORTH IN THIS ARTICLE 9,
MAXYGEN AND AVIDIA MAKE NO REPRESENTATIONS OR EXTEND ANY WARRANTIES OF ANY KIND, EXPRESS OR
IMPLIED, STATUTORY OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTY OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE OR OF NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF ANY
THIRD PARTY.

     10. COVENANTS

          10.1 Avidia.

               10.1.1 Avidia hereby covenants to Maxygen that Avidia will not grant during the term of this
Agreement any right, license or interest in or to the Assigned Patent Rights and/or its Subject
Improvements and/or the Avidia Necessary Claims that is in conflict with the rights and licenses
granted to Maxygen under this Agreement.

               10.1.2 Avidia hereby covenants that it shall not enforce, or permit or encourage the
enforcement of, against Maxygen, or its Affiliates, Licensees, successors or assigns (each, a
“Maxygen Protected Entity”), any issued patent owned or Controlled by Avidia that claims any (i)
method of practicing the Assigned Patent Rights and/or Subject Improvements in the Maxygen Field,
or (ii) a composition of matter (including, without limitation, any genus claim) of a Maxygen
Product, or (iii) method of making such Maxygen Product, or using such a Maxygen Product in the
Maxygen Field, if the Maxygen Protected Entity infringes such patent in the course of practicing
the Assigned Patent Rights and/or Subject Improvements for the development, manufacture, use,
importation, offer for sale or sale of such Maxygen Product within the Maxygen Field. Such
covenant shall also apply, solely with respect to such patent, to any person or entity to whom
Avidia assigns such patent or grants a right to enforce such patent.

               10.1.3 Avidia hereby covenants that it and its Affiliates and Licensees shall not, without
Maxygen’s express prior written consent [****], directly or indirectly (a) intentionally develop
for [****], any DBP Therapeutic Conjugate, other than an Approved DBP Therapeutic Conjugate, or (b)
make, have made, use, import, have imported, offer to sell, sell or otherwise commercialize for
[****] any DBP Therapeutic Conjugate, other than an Approved DBP Therapeutic Conjugate.

               10.1.4 Avidia hereby covenants that it and its Affiliates shall not knowingly practice any
Shuffling Technology, without Maxygen’s express prior written consent. Maxygen acknowledges and
agrees that the foregoing covenant shall not be construed as limiting Avidia’s and its Affiliates’
exercise of the licenses granted in Section 2.1(a) and (b).

               10.1.5 Avidia hereby covenants that it shall not enforce, or permit or encourage the
enforcement of, against Maxygen, or its Affiliates, Licensees, successors or assigns (each, a
“Maxygen Protected Entity”) any patent claim owned or Controlled by Avidia that Maxygen identifies
pursuant to Section 3.3.1 as being a potential Avidia Necessary Claim for activities conducted by
such Maxygen Protected Entity with regard to such a claim in connection with the development or
commercialization of Maxygen Products in the Maxygen Field prior to the earliest to occur of (a)
the completion of the process described in Section 3.3

36

 

with regard to the relevant patent claims; (b) the execution of a license between the Parties
for the relevant claims of such patent; or (c) twelve (12) months after the issue of the relevant
patent.

               10.1.6 Avidia covenants that it and its Affiliates and Licensees (excluding Maxygen) and their
respective agents shall not, without Maxygen’s written consent, which Maxygen may withhold in its
sole discretion, file or Prosecute any patent application that would be within the Assigned Patent
Rights and/or Subject Improvements that (a) discloses any Maxygen Information, or (b) has claims
that fall within the scope of claims of Patent Rights within the Shuffling Technology, to the
extent that such claims are known by Avidia, or would have been known to Avidia after a reasonable
inquiry, to fall within the scope of claims of Patent Rights within the Shuffling Technology.

          10.2 Maxygen.

               10.2.1 Maxygen hereby covenants to Avidia that Maxygen will not grant during the term of this
Agreement any right, license or interest in or to the Maxygen Necessary Claims and/or its Subject
Improvements and/or the Software and/or the Materials that is in conflict with the rights and
licenses granted to Avidia under this Agreement.

               10.2.2 Maxygen hereby covenants that it shall not enforce, or permit or encourage the
enforcement of, against Avidia, or its Affiliates, Licensees, successors or assigns (each, an
“Avidia Protected Entity”) any issued patent owned or Controlled by Maxygen that claims any (a)
method of practicing the Assigned Patent Rights and/or Subject Improvements, or (b) a composition
of matter (including, without limitation, any genus claim) of a Product outside the Maxygen Field,
excluding any DBP Therapeutic Proteins other than Approved DBP Therapeutic Proteins (an “Avidia
Product”), or (c) method of making such an Avidia Product outside the Maxygen Field, or using such
an Avidia Product outside the Maxygen Field, if the Avidia Protected Entity infringes such patent
in conjunction with the practice of the Assigned Patent Rights and/or Subject Improvements for the
development, manufacture, use, importation, offer for sale or sale of Products outside the Maxygen
Field. Such covenant shall also apply, solely with respect to such patent, to any person or entity
to whom Maxygen assigns such patent or grants a right to enforce such patent. Notwithstanding the
foregoing, this covenant shall not extend to any patent within the Shuffling Technology; provided,
Avidia shall have the licenses granted in Section 2.1.

               10.2.3 Maxygen hereby covenants that it shall not enforce, or permit or encourage the
enforcement of, against Avidia, or its Affiliates, Licensees, successors or assigns (each, a
“Avidia Protected Entity”) any patent claim owned or Controlled by Maxygen that Avidia identifies
pursuant to Section 2.3.1 as being a potential Maxygen Necessary Claim for activities conducted by
such Avidia Protected Entity with regard to such a claim in connection with the development or
commercialization of Products outside the Maxygen Field prior to the earliest to occur of (a) the
completion of the process described in Section 2.3 with regard to the relevant patent claims, (b)
the execution of a license between the Parties for the relevant claims of such patent; or (c)
twelve (12) months after the issue of the relevant patent.

          10.3 Injunctive Relief. Each Party agrees that in the event of any breach of any of
the foregoing covenants that the non-breaching Party shall be entitled to injunctive relief,

37

 

including specific performance, to allow it to obtain the benefit of such covenant, in
addition to any other remedies available to it at law or in equity.

     11. INDEMNIFICATION

          11.1 Avidia. Avidia agrees to indemnify, defend and hold harmless Maxygen and its
Affiliates and their respective directors, officers, employees and agents (each, an “Indemnitee”)
from and against any and all liabilities, claims, actions, suits, proceedings, costs, demands,
expenses (including, without limitation, attorneys and professional fees and other costs of
litigation), losses, or causes of action (each, a “Liability”) arising out of or relating in any
way to: (a) any breach by Avidia of the representations and warranties in Sections 9.1; (b) the
possession, manufacture, use, importation, sale or other disposition of Products outside the
Maxygen Field by or on behalf of Avidia or its Licensees, whether based on breach of warranty,
negligence, product liability or otherwise; (c) the exercise by Avidia of any right granted it
pursuant to this Agreement, and/or (d) any possession or use of the Materials or the Software or
Software Improvements; except, in each case, to the extent that such Liability is caused by the
negligence or willful misconduct of Maxygen or a Maxygen Indemnitee.

          11.2 Maxygen. Maxygen agrees to indemnify, defend and hold Avidia and its Affiliates
and their respective directors, officers, employees and agents (each, also an “Indemnitee”)
harmless from and against any and all liabilities, claims, actions, suits, proceedings, costs,
demands, expenses (including, without limitation, attorneys and professional fees and other costs
of litigation), losses, or causes of action (each, also a “Liability”) arising out of or relating
in any way to: (a) any breach by Maxygen of any of the representations and warranties in Sections
9.1 or 9.2, (b) the possession, manufacture, use, importation, sale or other disposition of Maxygen
Products in the Maxygen Field by or on behalf of Maxygen or its Licensees, whether based on breach
of warranty, negligence, product liability or otherwise, and/or (c) the exercise by Maxygen of any
right granted it pursuant to this Agreement; except, in each case; to the extent that such
Liability is caused by the negligence or willful misconduct of Avidia or an Avidia Indemnitee.

          11.3 Procedure. Any Indemnitee that intends to claim indemnification from a Party
under this Article 11 (the “Indemnitor”) shall provide notice in writing of any Liability in
respect of which the Indemnitee or its counsel intend to claim such indemnification, and the
Indemnitor shall have the right to participate in, and, to the extent the Indemnitor so desires, to
assume full control of the defense and settlement thereof with counsel mutually satisfactory to the
Parties. The indemnity obligations in this Article 11 shall not apply to amounts paid in any
settlement hereunder if such settlement is made without the prior written consent of the
Indemnitor, which consent shall not be unreasonably withheld or delayed. At the Indemnitor’s
request, the Indemnitee under this Article 11, and its employees and agents, shall cooperate fully
with the Indemnitor and its legal representatives in the investigation and defense of any action,
claim or liability covered by this indemnification and provide full information with respect
thereto. The Indemnitor shall not enter into any settlement or consent to an adverse judgment in
any such claim, demand, action or other proceeding that (a) admits wrongdoing on the part of the
other Party or its Affiliates or their respective officers, directors, employees and agents, or (b)
which imposes additional material obligations on the other Party, without the prior express written
consent of the other Party, which consent shall not be unreasonably withheld or delayed.

38

 

          11.4 Conflict. In the event of any conflict between the indemnification provisions
set forth in this Agreement and the indemnification provisions set forth in a Product License
Agreement, the provisions of this Agreement shall govern.

     12. TERM AND TERMINATION

          12.1 Term. This Agreement shall commence on the Effective Date, and unless earlier
terminated as provided in this Article 12, shall remain in full force and effect in on a
country-by-country basis until the expiration of the earlier to occur of (i) the last to expire of
the Patent Rights licensed hereunder in the applicable country, or (ii) twenty-five (25) years from
the Effective Date of this Agreement (“Expiration”). Following the Expiration of this Agreement,
the licenses granted in Sections 2.1 and 3.1 shall become perpetual on a country-by-country basis.

          12.2 Termination for Cause. A Party shall have the right to terminate this Agreement
in its entirety upon the material breach by the other Party of such other Party’s material
obligations, if such breach is not cured within sixty (60) days after receipt of written notice
from such Party thereof.

          12.3 Termination for Insolvency. If voluntary or involuntary proceedings by or
against a Party are instituted in bankruptcy under any insolvency law, or a receiver or custodian
is appointed for such Party, or proceedings are instituted by or against such Party for corporate
reorganization or the dissolution of such Party, which proceedings, if involuntary, shall not have
been dismissed without prejudice within sixty (60) days after the date of filing, or if such Party
makes an assignment for the benefit of creditors, or substantially all of the assets of such Party
are seized or attached and not released within sixty (60) days thereafter, the other Party may
immediately terminate this Agreement effective upon notice of such termination.

          12.4 Permissive Termination. Either Party may, at any time, terminate any of the
licenses granted to it by the other Party hereunder with written notice of such license termination
to the other Party. Such license shall cease to be perpetual upon such notice.

          12.5 Effect of Termination.

               12.5.1 Accrued Rights and Obligations. Termination of this Agreement for any reason
shall not release any Party hereto from any liability that, at the time of such termination, has
already accrued to the other Party or that is attributable to a period prior to such termination,
nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or
in equity that accrued or are based upon any event occurring prior to such termination.

               12.5.2 Licenses. The licenses granted to Maxygen in Sections 3.1 and 3.3 and any
sublicenses that Maxygen has granted pursuant to Section 3.2, and the licenses granted to Avidia in
Sections 2.1 and 2.3 and any sublicenses that Avidia has granted pursuant to Section 2.2 shall
remain in full force and effect regardless of the Expiration or any termination of this Agreement.
Notwithstanding the foregoing, either Party may terminate such licenses granted by the other Party
to itself voluntarily pursuant to Section 12.4.

39

 

          12.6 Survival. Sections 4.4, 4.5, 4.7, 7.2, 7.3, 9.3, 9.4, 12.5 and Articles 1, 6, 8,
11 (but only to the extent such claim arises from acts or omissions that occurred prior to
termination), 13 and 14 of this Agreement shall survive termination of this Agreement for any
reason.

     13. DISPUTE RESOLUTION

          13.1 Mediation. If a dispute arises out of or relates to this Agreement, or the
performance or any alleged breach hereof, the Parties agree first to try in good faith to settle
the dispute by negotiation and escalation to senior representatives within their respective
organizations.

          13.2 Proceeding. Except as set forth in Section 13.1, any dispute arising out of or
relating to this Agreement, or its performance or any alleged breach (except any dispute relating
to the validity, enforceability or infringement of any patent) that is not settled by agreement of
the Parties shall be finally settled by binding arbitration. Such arbitration shall be conducted
in accordance with the Commercial Arbitration Rules of the American Arbitration Association (except
as specifically provided in this Article 13) and shall be held in Palo Alto, California. Unless
otherwise agreed in writing by the Parties, the arbitration shall be conducted by one neutral
independent arbitrator who shall be a former U.S. district court or California state court judge.

          13.3 Discovery. The arbitrator shall determine what discovery will be permitted,
consistent with the goal of limiting the cost and time that the Parties must expend for discovery;
provided, however, the arbitrator shall permit such discovery as he or she deems necessary to
permit an equitable resolution of the dispute. Any written evidence originally in a language other
than English shall be submitted in English translation accompanied by the original or a true copy
thereof.

          13.4 Costs. The costs of the arbitration, including administrative fees and fees of
the arbitrator, shall be shared equally by the Parties, and each Party shall bear its own costs and
attorneys’ and witness’ fees incurred in connection with the arbitration.

          13.5 Decision. The arbitration proceedings and the decision of the arbitrator shall
not be made public without the joint consent of the Parties and each Party shall maintain the
confidentiality of such proceedings and decision unless otherwise permitted by the other Party;
provided, either Party may make such disclosures as are required to comply with applicable law or
regulation. The Parties agree that the decision of the arbitrator shall be binding as to any and
all disputes, controversies, claims and counterclaims presented to the arbitrator. Any award of
the arbitrator may be entered in a court of competent jurisdiction for a judicial recognition of
the decision and an order of enforcement.

          13.6 Injunctive Relief. Pending the establishment of the arbitral tribunal or pending
the arbitral tribunal’s determination of the merits of the controversy, either Party may seek from
a court of competent jurisdiction any interim or provisional relief that may be necessary to
protect the rights or property of that Party. The Parties further agree that in the event of any
breach of this Agreement for activities conducted outside the scope of the licenses granted in
Sections 2.1 and 3.1 or the violation of any covenant herein, in addition to any other

40

 

remedies available to such Party at law or in equity, the non-breaching Party shall be
entitled to injunctive relief to (a) prevent any continuing breach, and (b) abate any continuing
injury to the non-breaching Party resulting from any such breach.

     14. MISCELLANEOUS

          14.1 Governing Law; Jurisdiction. This Agreement and any dispute arising from the
performance or any breach hereof (except any dispute relating to the validity, enforceability or
infringement of any patent), including any arbitration proceeding subject to Article 13, shall be
governed by and construed in accordance with the laws of the State of California, without reference
to conflicts of laws principles.

          14.2 Assignment.

               14.2.1 Agreement. This Agreement shall not be assignable in whole or in part by
either Party to any Third Party without the written consent of the other Party; except either Party
may assign this Agreement, without such consent, to (a) an Affiliate of such Party; or (b) an
entity that acquires all or substantially all of the business or assets of such Party to which this
Agreement pertains, whether by merger, reorganization, acquisition, sale or otherwise. The terms
and conditions of this Agreement shall be binding on and inure to the benefit of the permitted
successors and assigns of each of the Parties.

               14.2.2 Assignment of Sublicenses. Any sublicenses granted under this Agreement may be
assigned by such sublicensee [****].

          14.3 Notices. Any notice required or permitted under this Agreement shall be
hand-delivered or sent by express delivery service or certified or registered mail, postage
prepaid, or by fax with written confirmation by mail, to the following addresses of the Parties or
such other address as a Party may provide for itself with notice to the other Party. Notice shall
be deemed served when delivered or, if delivery is not accomplished by reason or some fault of the
addressee, when tendered.

	 	 	 
	If to Maxygen

	 	Maxygen, Inc.
	 

	 	515 Galveston Drive
	 

	 	Redwood City, California 94063
	 

	 	Attn: General Counsel
	 
	 	 
	If to Avidia

	 	Avidia Research Institute
	 

	 	515 Galveston Drive
	 

	 	Redwood City, California 94063
	 

	 	Attn: President

          14.4 Further Assurances. At any time or from time to time on and after the Effective
Date of this Agreement, either Party shall, at the request of the other Party, (a) deliver

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

41

 

to the requesting Party such records, data or other documents consistent with the provisions
of this Agreement, (b) execute, and deliver or cause to be delivered, all such consents, documents
or further instruments of assignment, transfer or license, and (c) take or cause to be taken all
such actions, as the requesting Party may reasonably deem necessary or desirable in order for the
requesting Party to obtain the full benefits of this Agreement and the transactions contemplated
hereby.

          14.5 Force Majeure. Neither Party shall be held liable or responsible to the other
Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in
fulfilling or performing any term of this Agreement, other than an obligation to make payments
hereunder, when such failure or delay is caused by or results from fire; flood; earthquake;
tornado; embargo; government regulation; prohibition or intervention; war; act of war (whether war
be declared or not); insurrection; act of terrorism; riot; civil commotion; strike; act of God or
any other cause where failure to perform is beyond the reasonable control and not caused by the
negligence or misconduct of the affected Party (a “Force Majeure Event”) so long as the affected
Party has used reasonable efforts to avoid, mitigate and/or overcome the effects of the Force
Majeure Event.

          14.6 Independent Contractors. The Parties agree that the relationship of Maxygen and
Avidia established by this Agreement is that of independent contractors. Furthermore, the Parties
agree that this Agreement does not, is not intended to, and shall not be construed to, establish a
partnership or joint venture, nor shall this Agreement create or establish an employment, agency or
any other relationship. Neither Party shall have any right, power or authority, nor shall they
represent themselves as having any authority to assume, create or incur any expense, liability or
obligation, express or implied, on behalf of the other Party, or otherwise act as an agent for the
other Party for any purpose.

          14.7 Advice of Counsel. Avidia and Maxygen have each consulted counsel of their
choice regarding this Agreement, and each acknowledges and agrees that this Agreement shall not be
deemed to have been drafted by one Party or the other and will be construed accordingly.

          14.8 Other Obligations. Except as expressly provided in this Agreement or as
separately agreed upon in writing between Avidia and Maxygen, each Party shall bear its own costs
incurred in connection with the implementation of the obligations under this Agreement.

          14.9 Waiver. Neither Party may waive or release any of its rights, remedies or
interests in or arising under this Agreement except in writing signed by the Party to be bound.
The failure or delay of either Party to assert a right or remedy hereunder or to insist upon
compliance with any term or condition of this Agreement shall not constitute a waiver of that right
or excuse a similar subsequent failure to perform any such term or condition.

          14.10 Severability. In the event that any provision(s) of this Agreement are
determined to be invalid or unenforceable, in whole or in part, by a court of competent
jurisdiction, the remainder of the Agreement shall remain in full force and effect without said
provision(s). The Parties shall in good faith negotiate a substitute clause for any provision(s)

42

 

declared invalid or unenforceable, which shall most nearly approximate the intent of the
Parties in entering this Agreement.

          14.11 Limitation of Liability. NEITHER PARTY SHALL BE LIABLE FOR ANY LOST REVENUES OR
PROFITS OF ANY PERSON OR ENTITY OR ANY OTHER INCIDENTAL, SPECIAL, INDIRECT, OR CONSEQUENTIAL
DAMAGES ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF
THE POSSIBILITY OF SUCH DAMAGES.

          14.12 Entire Agreement; Modification. This Agreement, together with the attached
Exhibits, which are hereby incorporated by reference, and the Assignment Agreement of even date
hereof, constitutes the entire agreement between the Parties, with respect to the subject matter
hereof, and supersedes and cancels all prior or contemporaneous understandings or agreements,
whether written or oral, between Maxygen and Avidia with respect to such subject matter. This
Agreement can only be amended or modified with a written document signed by both Parties.

          14.13 Headings. The captions to the several Sections and Articles hereof are not a
part of this Agreement, but are included merely for convenience of reference only and shall not
affect its meaning or interpretation.

          14.14 Counterparts. This Agreement may be executed in two counterparts, each of which
shall be deemed an original and which together shall constitute one instrument.

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed by their
authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 
	MAXYGEN, INC.	 	AVIDIA RESEARCH INSTITUTE
	 
	 	 	 	 	 	 
	By:

	 	/s/ Balkrishan S. Gill
	 	By:
	 	/s/ Victor Perlroth
	 

	 	 
	 	 	 	 
	 

	 	Name: Balkrishan S. Gill
	 	 	 	Name: Victor Perlroth
	 

	 	Title:   President
	 	 	 	Title:   President

43

 

	 	 	 
	Exhibit A:

	 	Agriculture Subfield
	B:

	 	Approved DBP Therapeutic Conjugates
	C:

	 	Assigned Patent Rights
	D:

	 	Avidia Necessary Claims
	E:

	 	Chemicals Subfield
	F:

	 	Invention Disclosures
	G:

	 	Materials
	H:

	 	Maxygen Necessary Claims
	I:

	 	Maxygen Useful Claims
	J:

	 	Form of Product License Agreement

	K:

	 	Reserved Therapeutic Product Criteria
	L:

	 	Software

44

 

EXHIBIT A

Agriculture Subfield

“Agriculture Subfield” shall mean the discovery, development and commercialization of:

     (a) [****];

     (b) [****];

     (c) [****];

     (d) [****];

     (e) [****]; and

     (f) [****].

     Definitions

     1.1 “Bulk Production” shall mean production of commercial Products, including, without
limitation, [****].

     1.2 “Enabling Technology” shall mean patent applications and patents owned or controlled by
Maxygen relating to (i) [****], or the use thereof, and/or (ii) generally applicable [****].

     1.3 “Gene” shall mean a structural gene, including optionally regulatory sequences therefor,
including, without limitation, promoters, enhancers and downstream regulatory elements.

     1.4 “Gene Expression Manipulation” shall mean alteration of one or more Gene(s) (e.g.,
alteration of a sequence of a structural gene or a sequence of a Gene regulatory element, such as a
promoter) to enable and/or facilitate Product development or Bulk Production.

     1.5 “Metabolic Pathway Manipulation” shall mean alteration of one or more single Genes,
multiple Genes, genetic pathways and/or genomes by modification of pathway control mechanisms to
enable and/or facilitate:

          (a) Product development via (i) [****], and/or (ii) [****], and/or (iii) [****], and/or

          (b) Bulk Production.

     1.6 “Microbe” shall mean whole (live or dead) procaryotic organisms (other than Category I
Plants), or extracts thereof.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

     1.7 “Plant(s)” shall mean whole Plants, Plant seeds, Plant parts, Plant cells and/or Plant
cell cultures derived from Category I Plants and/or Category II Plants.

          1.7.1 “Category I Plants” shall mean:

          (a) land plants, including nonseed plants (Bryophytes, Tracheophytes) such as liverworts,
mosses, ferns, and seed plants, such as gymnosperms and angiosperms (monocot and dicots); and/or

          (b) non-land plants, including the Prasinophytes, Chlorophyceae, Trebouxiouphyceae,
Ulvophyceae, Chlorokybales, Streptophyta, Klebsormidiales, Zygnematales, Charales, Coleochaetales
and Embryophytes.

          1.7.2 “Category II Plants” shall mean:

          (a) mushrooms (Basidiomycetes); and/or

          (b) photosynthetic bacteria, including, but not limited to blue green algae (Cyanobacteria);
and/or

          (c) eukaryotic photosynthetic algae and microalgae including, but not limited to green algae
(Chlorophytes and Euglenophytes), yellow algae (Cyanophytes), brown algae (Phaeophytes,
Xanthophytes, Eustigmatophytes and Raphidophytes) and red algae (Rhodophytes); and/or

          (d) microalgae, including but not limited to diatoms (Chrysophytes and Pyrrophytes).

     1.8 “Product” shall mean [****].

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

2

 

EXHIBIT B

Approved DBP Therapeutic Conjugates

As of the Effective Date: [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT C

Assigned Patent Rights

a. [****]

b. [****]

c. [****]

d. [****]

e. [****]

f. [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT D

Avidia Necessary Patents

As of the Effective Date: [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT E

Chemicals Subfield

“Chemicals Subfield” shall mean:

     (a) [****], except for the [****];

     (b) [****]; and

     (c) [****], except for the [****].

Definitions

     1.1 “Agrochemical” shall mean any chemical intended for plant protection or plant growth
applications (e.g., any insecticide, nematicide, insect growth regulator, plant growth regulator,
fertilizer or herbicide).

     1.2 “Biocatalyst” shall mean a whole cell (live or dead) of a Microbe or Category II Plant
that has been [****] that can perform enzymatic catalysis of a particular chemical reaction.

     1.3 “Basic Chemical” shall mean a chemical having a molecular weight of [****]. By way of
illustration and without limitation, a chemical monomer or oligomer suitable for [****], or a
carbohydrate intended for use as a carbon source in fermentation, would each be a Basic Chemical,
if the applicable molecule had a molecular weight of less than [****] Daltons.

     1.4 “Biocatalyst Commercialization” shall mean (i) the preparation, screening and commercial
use of Biocatalysts for the purpose of allowing the selection and commercialization of Biocatalysts
[****], and (ii) the manufacture and commercial sale of Biocatalysts [****].

     1.5 “Building Block” shall mean any [****], that (a) is not a [****] or a [****], and (b) is
intended for addition to one or more [****] to make a [****].

     1.6 “Building Block Development” shall mean the development of one or more Building Blocks for
use in [****].

     1.7 “Bulk Production” shall mean production via enzymatic catalysis (using an Enzyme Product
or a Biocatalyst) or fermentation of:

          (a) any Enzyme Product or Biocatalyst, or

          (b) any Catalysis Product or Fermentation Product, or

          (c) any Scheduled Product.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

     1.8 “Catalysis Product” shall mean a [****].

     1.9 “Codexis” shall mean Codexis, Inc.

     1.10 “Codexis Restricted Field” shall mean:

          (a) [****];

          (b) [****];

          (c) [****]; and

          (d) [****].

     1.11 “Discovery” shall mean the [****].

     1.12 “Enabling Technology” shall mean all patent applications and patents owned or controlled
by Maxygen relating to (i) [****], or the use thereof, and/or (ii) generally applicable [****].

     1.13 “Enzyme Commercialization” shall mean (i) the preparation, screening and commercial use
of Enzyme Libraries for the purpose of allowing the selection and commercialization of one or more
Enzyme Products solely for use for [****], and (ii) the manufacture and commercial sale of Enzyme
Products solely for use for [****].

     1.14 “Enzyme Library” shall mean a set of two or more variant but related enzymes (or genes
encoding such enzymes), in each case, that are made using Enabling Technology.

     1.15 “Enzyme Product” shall mean an enzyme selected from an Enzyme Library.

     1.16 “Fermentation Product” shall mean any [****] that is produced via fermentation of a
Microbe and/or Category II Plant that has been [****].

     1.17 “Functional Compound” shall mean any non-polypeptide, organic chemical produced in
substantially pure form, having a molecular weight of [****] Daltons, that is not a Basic Chemical
and is used (i) as an [****], or (ii) to [****] products, or (iii) to [****] products, or (iv) for
external application to one or more Plants as an [****].

     1.18 “Gene” shall mean a structural gene, including optionally regulatory sequences therefor,
including, without limitation, promoters, enhancers and downstream regulatory elements.

     1.19 “Gene Expression Manipulation” shall mean alteration of one or more Gene(s) (e.g.,
alteration of a sequence of a structural gene or a sequence of a Gene regulatory element, such as a
promoter) to enable and/or facilitate Product development or Bulk Production.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

2

 

     1.20 “Intermediate” shall mean with regard to a particular [****], a [****], chemical produced
in [****]. It is understood and agreed that Intermediate(s) shall not include chemicals having
commercial utility for any purpose other than synthesis of the applicable [****] (e.g., Basic
Chemicals shall not be Intermediates).

     1.21 “Metabolic Pathway Manipulation” shall mean alteration of one or more single Genes,
multiple Genes, genetic pathways and/or genomes by modification of pathway control mechanisms to
enable and/or facilitate:

          (a) Product development via (i) [****], and/or (ii) [****]; and/or

          (b) Bulk Production.

     1.22 “Microbe” shall mean whole (live or dead) procaryotic organisms and/or yeasts and/or
fungi (excluding those which are Category II Plants), or extracts thereof.

     1.23 “Plant(s)” shall mean whole Plants, Plant seeds, Plant parts, Plant cells and/or Plant
cell cultures derived from Category I Plants and/or Category II Plants.

          1.23.1 “Category I Plants” shall mean:

               (a) land plants, including nonseed plants (Bryophytes, Tracheophytes) such as liverworts,
mosses, ferns, and seed plants, such as gymnosperms and angiosperms (monocot and dicots); and/or

               (b) non-land plants, including the Prasinophytes, Chlorophyceae, Trebouxiouphyceae,
Ulvophyceae, Chlorokybales, Streptophyta, Klebsormidiales, Zygnematales, Charales, Coleochaetales
and Embryophytes.

          1.23.2 “Category II Plants” shall mean:

               (a) mushrooms (Basidiomycetes); and/or

               (b) photosynthetic bacteria, including, but not limited to blue green algae (Cyanobacteria);
and/or

               (c) eukaryotic photosynthetic algae and microalgae including, but not limited to green algae
(Chlorophytes and Euglenophytes), yellow algae (Cyanophytes), brown algae (Phaeophytes,
Xanthophytes, Eustigmatophytes and Raphidophytes) and red algae (Rhodophytes); and/or

               (d) microalgae, including but not limited to diatoms (Chrysophytes and Pyrrophytes).

     1.24 “Product” shall mean any [****].

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

3

 

     1.25 “Scheduled Product” shall mean:

          (a) Products for the following [****] applications:

               (1) [****] Applications:

                    (i) [****];

                    (ii) [****]; and/or

                    (iii) [****]

               (2) [****] Applications (for [****]):

                    (i) [****];

                    (ii) [****];

                    (iii) [****];

                    (iv) [****]; and/or

                    (v) [****].

          (b) Products for the following [****] applications:

                    (i) [****];

                    (ii) [****];

                    (iii) [****]; and/or

                    (iv) [****].

          (c) Products for the following [****] applications:

                    (i) [****];

                    (ii) [****];

                    (iii) [****];

                    (iv) [****];

                    (v) [****]; and/or

                    (vi) [****].

          (d) Products that are [****] of a type specified below, for use to make [****]:

               1. [****];

               2. [****];

               3. [****];

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

4

 

               4. [****]; and/or

               5. [****].

          (e) Products that are of a type specified below for use as [****]:

               1. [****];

               2. [****];

               3. [****]; and/or

               4. [****].

          (f) Products of a type specified below for use as [****]:

               1. [****];

               2. [****]; and/or

               3. [****].

          (g) Products of a type specified below, for use in [****]:

               1. [****];

               2. [****]; and/or

               3. [****].

          (h) Products that is/are any of the following [****], to the extent not covered by Section
1.21(d) above:

               1. [****];

               2. [****];

               3. [****];

               4. [****]; and/or

               5. [****].

          (i) Products that are [****] specified below, for use as [****]:

               1. [****];

               2. [****];

               3. [****];

               4. [****];

               5. [****]; and/or

               6. [****].

          (j) Products that is/are any of the [****] specified below, for [****]:

               1. [****];

               2. [****];

               3. [****];

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

5

 

               4. [****]; and/or

               5. [****].

     1.26 “Strain Improvement” shall mean modification of a Microbe or Category II Plant to enhance
its suitability for use in Bulk Production of one or more Fermentation Products.

     1.27 “Template” shall mean the minimally active, non-polypeptide chemical structure (e.g., a
pharmacophore) having a molecular weight of [****] Daltons, that is common to a family of chemical
structures, and (a) is known to possess measurable specific bioactivity (e.g., biostimulatory,
bioinhibitory, receptor binding, enzyme substrate, channel blocking or similar activities) in a
particular in vitro or in vivo disease model system, and (b) is useful as an Intermediate.

     1.28 “Template Decoration” shall mean modification of a Template by a Third Party (other than
an Affiliate of Codexis) by attaching, via one or more chemical and/or enzymatic steps, one or more
Building Blocks to generate an organic chemical product (including, without limitation, a Product
or a Functional Compound) having a molecular weight of [****] Daltons.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

6

 

EXHIBIT F

Invention Disclosures

	1.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	2.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no.: [****]
	 
	3.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	4.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	5.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	6.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	7.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	8.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	9.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	10.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	11.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	12.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]
	 
	13.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no: [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

2

 

	14.	 	Title: [****]
	 
	 	 	Date: [****]
	 
	 	 	Maxygen control no. [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

3

 

EXHIBIT G

Materials

Avidia Maxybody Sequences

[****]

All remaining quantities of the [****] received by Maxygen pursuant to the [****] entered by [****]
and Maxygen, Inc. effective [****].

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT H

Maxygen Necessary Claims

1. [****]

2. [****]

3. [****]

4. [****]

Maxygen Necessary Claims shall also include the claims of non-U.S. counterpart patents that claim
the same subject invention as the foregoing claims.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT I

Maxygen Useful Claims

As of the Effective Date: [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

EXHIBIT J

Form of

PRODUCT LICENSE AGREEMENT

     This
PRODUCT LICENSE AGREEMENT (the “Agreement”), effective as of _______, 200__ (the
“Effective Date”), is made by and between Maxygen, Inc., a Delaware corporation with a principal
place of business at 515 Galveston Drive, Redwood City, California 94063 (“Maxygen”), and Avidia
Research Institute, a
___________ corporation with a principal place of business at
___________ (“Avidia”).

BACKGROUND

	A.	 	Avidia and Maxygen entered into a Cross License Agreement effective July 16, 2003, pursuant
to which Maxygen received certain options from Avidia to acquire exclusive licenses to
Licensed Products (as defined below) to develop and commercialize human pharmaceutical
products.

	B.	 	Maxygen has provided Avidia notice that it wishes to exercise one of its options to acquire
an exclusive license under Patent Rights and Know-How owned or Controlled by Avidia to develop
and commercialize Licensed Products directed to __________, and Avidia is willing to
grant such license, on the terms and conditions herein.

     NOW, THEREFORE, in consideration of the mutual covenants contained herein, and for other good
and valuable consideration, the Parties hereby agree as follows:

ARTICLE 1 — DEFINITIONS

     In this Agreement, the following capitalized terms shall have the meaning ascribed to them
respectively in this Article. In this Agreement, capitalized terms not otherwise expressly defined
herein, if defined in the Cross License Agreement, shall have the meaning ascribed to them
respectively therein.

     1.1 “Affiliate” means any corporation, firm, limited liability company, trust,
partnership or other entity that directly or indirectly controls or is controlled by or is under
common control with a Party to this Agreement. As used in this definition, “controls”, “controlled
by” and “under common control with” means the possession, directly or indirectly, of the power to
direct or cause the direction of the management and policies of an entity, whether through the
ownership of voting securities or partnership interest, by contract or otherwise. In the case of a
corporation, the direct or indirect ownership of fifty percent (50%) or more of its outstanding
voting shares, or in the case of a partnership, status as a general partner, or in the case of any
other type of legal entity, fifty percent (50%) or more of the ownership interests, shall in any
event be deemed to confer control, it being understood that the direct or indirect ownership of a
lesser percentage of such shares or ownership interest shall not necessarily preclude the existence
of control.

 

 

     1.2 “Avidia Know-How” means any Know-How owned or Controlled by Avidia necessary or
useful for the development, manufacture, importation, use or sale of the Licensed Products.

     1.3 “Avidia Materials” means any Materials owned or Controlled by Avidia necessary or
useful for the development, manufacture, importation, use or sale of the Licensed Products.

     1.4 “Avidia Patent Rights” means any Patent Rights owned or Controlled by Avidia
necessary or useful for the development, manufacture, importation, use or sale of the Licensed
Products.

     1.5 “Avidia Technology” means Avidia’s interest in (a) the Avidia Patent Rights, (b)
the Avidia Know-How, and (c) the Avidia Materials.

     1.6 “Biological License Application” or “BLA” means the Biological License
Application, as defined in the U.S. Public Health Service Act, as amended, and the regulations
promulgated thereunder, and any corresponding foreign application, registration or certification in
the Territory.

     1.7 “Combination Licensed Product” shall have the meaning set forth in Section
3.2.3(a).

     1.8 “Commercially Reasonable Efforts” means the level of efforts and resources
reasonably appropriate to diligently develop and/or commercialize (as applicable) Licensed Products
in a sustained manner, consistent with the efforts and resources a similarly situated
biopharmaceutical company would typically devote to a product of similar market potential, profit
potential, and/or proprietary protection.

     1.9 “Confidential Information” means any and all information, whatever its form or
medium (whether written, oral, electronic, graphic or otherwise), including technical information,
results, data and/or designs of experiments, that is disclosed by any Party to the other Party
pursuant to this Agreement that (a) if disclosed in written or other tangible form, is marked or
labeled as “confidential” or “proprietary” or with a similar marking or legend sufficient to notify
the receiving Party that such information is subject to the terms of this Agreement, or (b) if
disclosed orally or in other intangible form, is identified as confidential or proprietary by the
disclosing Party at the time of disclosure, and is confirmed in writing as confidential or
proprietary delivered to the receiving Party within thirty (30) days thereafter.

     1.10 “Control” or “Controlled” means possession of the ability to grant the
licenses or sublicenses as provided for herein without violating the terms of any agreement or
other arrangement with any Third Party.

     1.11 “Cross License Agreement” means that certain Cross License Agreement entered by
Avidia and Maxygen effective July 16, 2003.

     1.12 “Domain-Based Protein” shall have the meaning set forth in the Cross License
Agreement.

     1.13 “FDA” means the U.S. Food and Drug Administration, and any successor entity.

2

 

     1.14 “Field” means treatment and/or prophylaxis of [****] OR [****] [****] disease.

     1.15 “First Commercial Sale” means the first sale of a Licensed Product to a Third
Party in a particular country, following the receipt of all Regulatory Approvals required for the
sale of such Licensed Product in such country.

     1.16 “Investigational New Drug Application” or “IND” means an Investigational
New Drug Application, as defined in the U.S. Public Health Service Act, as amended, and the
regulations promulgated thereunder, and any corresponding foreign application, registration or
certification in the Territory.

     1.17 “Know-How” means any proprietary data, instructions, processes, formulae,
materials, expert opinions and information, including, without limitation, biological, chemical,
pharmacological, toxicological, pharmaceutical, physical and analytical, clinical, safety,
manufacturing and quality control data and information. Know-How does not include any inventions
included in the Patent Rights.

     1.18 “Licensed Product” means a Product for use in the Field, in any formulation or
dosage form.

     1.19 “Major Market Country” means [****].

     1.20 “Materials” means any chemical or biological substances including any: (i)
organic or inorganic chemical or compound; (ii) gene; (iii) vector or construct, whether plasmid,
phage, virus or any other type; (iv) host organism, including bacteria and eukaryotic cells; (v)
eukaryotic or prokaryotic cell line or expression system; (vi) protein, including any peptide or
amino acid sequence, enzyme, antibody or protein conferring targeting properties and any fragment
of a protein or peptide or enzyme; (vii) genetic material, including any genetic control element
(e.g., promoters); (viii) virus; or (ix) assay or reagent.

     1.21 “Net Sales” means the gross revenue received by Maxygen or its Sublicensees for
sales of Licensed Products or Licensed Combination Products by Maxygen and/or its Sublicensees to
bona fide independent Third Parties in arm’s length sales, less: (a) [****]; (b) [****]; (c)
[****], (d) [****], (e) [****], and (f) [****].

     1.22 “Party” means Maxygen or Avidia, and the “Parties” means Maxygen and
Avidia.

     1.23 “Patent Rights” means any and all United States or foreign provisional and/or
utility patent applications (including, without limitation, all divisions, continuations in whole
or in part, substitutions, and patents of addition), and any and all United States or foreign
letters patent and/or registrations (including, without limitation, all reissues, renewals,
extensions, confirmations, re-registrations, re-examinations, re-validations, supplementary
protection certificates and/or other governmental actions that extend the term of any such letters
patent).

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

3

 

     1.24 “Phase I”, “Phase II”, and “Phase III” means Phase I (or Phase
I/II), Phase II (or Phase II/III), and Phase III clinical trials, respectively, in each case as
prescribed by the applicable United States IND regulations, or the corresponding foreign statutes,
rules or regulations in the Territory. For the purposes of this Agreement, a clinical trial shall
be deemed to be initiated upon the first dosing of the first human subject in such trial.

     1.25 “Product” means any product that (a) binds to and is an [agonist] OR [antagonist]
[prior to signing, Maxygen shall select one which corresponds to work performed by Avidia upon the
relevant Avidia Target] of
__________ [prior to signing, Maxygen shall insert the name of the
relevant Avidia Target] and (b) contains a [****]. For purposes of this definition, the term
[****] shall have the meaning set forth in the Cross License Agreement.

     1.26 “Product Patent” means a patent application or patent within the Avidia Patent
Rights that claims a composition of matter that is a Licensed Product, or a method of manufacturing
or using a Licensed Product.

     1.27 “Regulatory Agency” means the FDA, the European Medicines Evaluation Agency, or
any other governmental agency having similar jurisdiction over the development, manufacturing, and
marketing of biopharmaceutical products and any successor agencies thereof.

     1.28 “Regulatory Approval” means, with respect to a country or, where applicable, a
multinational jurisdiction, all such approvals, licenses, registrations or authorizations that are
required to be obtained from any one or more Regulatory Agencies prior to the manufacture,
marketing and/or sale of a Licensed Product in such country or multinational jurisdiction
(including, where applicable, pricing approvals necessary to obtain reimbursement).

     1.29 “Regulatory Filing” means any filing with a Regulatory Agency relating to the
Regulatory Approval of a Licensed Product, including all supporting data. Regulatory Filings
include, without limitation, INDs and BLAs.

     1.30 “Sublicensee” means an Affiliate of Maxygen or a Third Party, in each case, that
Maxygen has granted a license or sublicense to make, use and/or sell one or more Licensed Products.

     1.31 “Territory” means all countries of the world.

     1.32 “Third Party” means any individual, corporation, partnership or other entity or
party other than Maxygen or Avidia or an Affiliate of either of them.

     1.33 “Valid Claim” means a claim contained in (a) an issued and unexpired patent
included within the Avidia Patent Rights that has not been held unenforceable, unpatentable or
invalid by a decision of a court or other governmental agency of competent jurisdiction,
unappealable or unappealed within the time allowed for appeal, and which has not been admitted to
be invalid or unenforceable through abandonment, reissue, disclaimer or otherwise, or (b) a

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

4

 

pending patent application that is included within the Avidia Patent Rights, which application
claims in a first priority date of no more than [****] years prior to the date upon which pendency
is determined. If a claim of a patent application that ceased to be a Valid Claim under subsection
1.33(b) later issues or grants as a patent subject to subsection 1.33(a) then such claim shall
again be considered to be a Valid Claim, effective as of the earlier of the grant, allowance, or
issuance of such patent.

ARTICLE 2 — LICENSE GRANT

     2.1 License to Maxygen. Subject to the terms and conditions of this Agreement, Avidia
hereby grants to Maxygen, and Maxygen hereby accepts, an exclusive, worldwide, royalty-bearing
license under the Avidia Technology, to make, have made, use, import, have imported, offer for sale
and/or sell Licensed Products in the Territory for use in the Field.

     2.2 Sublicenses. Maxygen may grant and authorize sublicenses of the rights granted it
in Section 2.1 to its Affiliates, and Third Parties; provided that, Maxygen shall only have the
right to grant and authorize sublicenses to Third Parties of the rights granted it in Section 2.1,
(a) after such time as it spends at least [****] dollars ($[****]) in the development of a Licensed
Product, or (b) earlier, if the purpose of such sublicense is solely for such Sublicensee to
develop or manufacture the Licensed Product on behalf of Maxygen. Within thirty (30) days of the
grant of any sublicense Maxygen shall provide Avidia with a copy of such sublicense agreement,
which copy may be redacted by Maxygen to avoid disclosure to Avidia of any confidential information
belonging to such Third Party. Maxygen hereto shall remain responsible to Avidia hereto for the
performance of the financial and other obligations of its Sublicensees.

     2.3 No Implied Licenses. Other than those rights and licenses expressly granted
herein, no rights or licenses are granted or shall be deemed granted under this Agreement with
respect to the Avidia Technology and/or other intellectual property owned or Controlled by Avidia.

     2.4 Negative Covenant.

               (a) Maxygen covenants that it shall not, nor shall it cause or authorize any Affiliate or
Sublicensee to, (i) use or practice, directly or indirectly, any Avidia Technology for any other
purpose other than those expressly permitted by this Agreement or except as permitted under the
Cross License Agreement, or (ii) make, have made, use, import, have imported, offer for sale and/or
sell Licensed Products in any manner outside the scope of the license set forth in Section 2.1,
except as may be permitted in another written agreement entered by the Parties.

               (b) If the Field of this Agreement is the treatment and/or prophylaxis of [****], Maxygen
covenants that it shall not, nor shall it cause or authorize any Affiliate or Sublicensee to, (i)
use or practice, directly or indirectly, any Avidia Technology licensed under this Agreement for
the treatment and/or prophylaxis of [****], except as permitted under the Cross License Agreement
or any other written agreement entered by the Parties, or (ii) make,

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

5

 

have made, use, import, have imported, offer for sale and/or sell Licensed Products for
[****], except as may be permitted in another written agreement entered by the Parties.

     2.5 License to Avidia.

          2.5.1 License Grant. Subject to the terms and conditions of this Agreement, Maxygen
hereby grants to Avidia, and Avidia hereby accepts, a non-exclusive, worldwide, royalty-free,
fully-paid license under Maxygen’s interest in any Patent Rights owned or Controlled by Maxygen
that claim generically Products made in the course of practicing the license set forth in Section
2.1, solely to make, have made, use, import, have imported, offer for sale and/or sell (a) [****]
and (b) products that are not Licensed Products but are [****].

          2.5.2 Sublicenses. Subject to Section 2.5.3, Avidia may grant and authorize
sublicenses to any of the rights granted it in Section 2.5.1. Each such sublicense shall be in
writing and consistent with the terms and conditions of this Agreement. Promptly after the grant
of any such sublicense, Avidia shall notify Maxygen in writing of the identity of each such
sublicensee and the specific rights (by field and geographic region) granted to each such Licensee,
provided that Avidia shall have no obligation to reveal any information that is confidential
information of such sublicensee. Avidia hereto shall remain responsible to Maxygen hereto for the
performance of the financial and other obligations of its sublicensees, including any reporting or
other obligations due to the Third Party licensor(s) of such Patent Rights.

          2.5.3 Third Party Payments. With respect to any Patent Rights subject to Section
2.5.1, Avidia hereby agrees it will be responsible for paying any and all amounts due to Third
Parties for the grant to Avidia and/or the practice of any such license by Avidia and its
sublicensees in accordance with a schedule to be agreed in writing by the Parties that will permit
Maxygen to timely meet its obligations to such Third Parties.

          2.5.4 No Implied Licenses. Other than those rights and licenses expressly granted
herein, no rights or licenses are granted or shall be deemed granted under this Agreement with
respect to the Maxygen Technology and/or other intellectual property owned or Controlled by
Maxygen.

ARTICLE
3 — MILESTONE PAYMENTS AND ROYALTIES

     3.1 Milestone Payments.

          3.1.1 Payments to Avidia. Within thirty (30) days following the first occurrence of
each of the events specified below with respect to each different Licensed Product by Maxygen or
its Sublicensees, Maxygen shall pay to Avidia the following nonrefundable, non-creditable (except
as provided for in Section 3.1.2 below) milestone payments:

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

6

 

	 	 	 
	Milestones	 	Amount
	A. [****]

	 	$[****]
	B. [****]

	 	$[****]
	C. [****]

	 	$[****]
	D. [****]

	 	$[****]
	E. [****]

	 	$[****]
	F. [****]

	 	$[****]

               For purposes of this Section 3.1, Licensed Products that contain different Domain-Based
Proteins shall be deemed to be different Licensed Products.

          3.1.2 Backup Licensed Products. The payments due under Section 3.1.1 above shall be
made with respect to the Licensed Products as described above. However, the Parties understand
that Maxygen may cease all development of a particular Licensed Product (a “Discontinued Licensed
Product”), and focus its efforts on another Licensed Product that Maxygen had been developing, or
with respect to which Maxygen commences development, as an alternative to the Discontinued Licensed
Product in the event of its unsuccessful development (the “Backup Licensed Product”). If Maxygen
has made any payment with respect to such Discontinued Licensed Product under Section 3.1.1 in
respect of the achievement of any milestone event described therein, then following the
accomplishment of that same milestone event with respect to its Backup Licensed Product, no
milestone payment shall be due hereunder in respect of such achievement. When milestone events
described in Section 3.1.1 are achieved with respect to such Backup Licensed Product where the
corresponding milestone payment amount was not previously paid with respect to the Discontinued
Licensed Product, then Maxygen shall pay such corresponding milestone payment amount pursuant to
Section 3.1.1.

          3.1.3 No Milestone Skipping. Subject to Section 3.1.2, if an event that triggers a
milestone payment pursuant to Section 3.1.1 occurs, with respect to a particular Licensed Product,
at any time prior to payment of any of the preceding milestone payment amounts set forth in Section
3.1.1, with respect to such Licensed Product, then Maxygen shall pay Avidia within thirty (30) days
of such event both the milestone payment amount triggered by such event and all such unpaid
preceding milestone payment amounts for such Licensed Product.

     3.2 Royalties.

          3.2.1 Royalties on Net Sales. In partial consideration for the rights granted
hereunder, Maxygen shall pay a nonrefundable, non-creditable royalty to Avidia of [****] percent
([****]%) of aggregate Net Sales of Licensed Products by Maxygen and its Sublicensees.

          3.2.2 Non-Royalty Sales; One Royalty. No royalty shall be payable under Section 3.2.1
above with respect to sales of Licensed Products among Maxygen, its Affiliates and Sublicensees for
resale to bona fide independent Third Parties, nor shall such royalty be due on Licensed Products
sold or otherwise distributed for use in clinical trials, or distributed at cost or less for
promotional use or for compassionate use. The royalty rate set forth in Section 3.2.1

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

7

 

shall apply as set forth therein regardless of the number of Valid Claims that cover the
relevant Licensed Product.

          3.2.3 Combination Licensed Products.

               (a) If Maxygen sells any Licensed Product in the form of a combination product containing a
Licensed Product and one or more pharmaceutically active ingredients or a delivery device (whether
combined in a single formulation and/or package, as applicable, or formulated and/or packaged
separately but sold together for a single price) (a “Combination Licensed Product”), Net Sales of
such Combination Licensed Product for the purpose of determining the royalty due to Avidia pursuant
to Section 3.2.1 will be calculated by multiplying actual Net Sales of such Combination Licensed
Product by the fraction A/(A+B) where A is the invoice price of such Licensed Product if sold
separately, and B is the total invoice price of the other active ingredient(s) and/or the delivery
device in the combination if sold separately.

               (b) If, on a country-by-country basis, such other pharmaceutically active ingredient or
ingredients or delivery device in the Combination Licensed Product are not sold separately in such
country, but the Licensed Product component of the Combination Licensed Product is sold separately
in such country, Net Sales for the purpose of determining royalties due to Avidia pursuant to
Section 3.2.1 for the Combination Licensed Product shall be calculated by multiplying actual Net
Sales of such Combination Licensed Product by the fraction A/C where A is the invoice price of such
Licensed Product component if sold separately, and C is the invoice price of the Combination
Licensed Product. If, on a country-by-country basis, such Licensed Product component is not sold
separately in such country, Net Sales for the purposes of determining royalties due to Avidia
pursuant to Section 3.2.1 for the Combination Licensed Product shall be D/(D+E) where D is the fair
market value of the portion of the Combination Licensed Products that contains the Licensed Product
and E is the fair market value of the portion of the Combination Licensed Products containing the
other active ingredient(s) or delivery device included in such Combination Licensed Product, as
such fair market values are determined in good faith by the Parties. If the Parties, after good
faith negotiation, cannot reach agreement on such fair market values under this Section 3.2.3(b),
then either Party may refer the matter for resolution by binding short-form arbitration in
accordance with Section 3.2.3(d).

               (c) If, on a country-by-country basis, such Licensed Product component is not sold separately
in such country, Net Sales for the purposes of determining royalties due to Avidia pursuant to
Section 3.2.1 for the Combination Licensed Product shall be calculated by multiplying actual Net
Sales of such Combination Licensed Product by the fraction D/(D+E) where D is the fair market value
of the portion of the Combination Licensed Product that contains the Licensed Product and E is the
fair market value of the portion of the Combination Licensed Product containing the other active
ingredient(s) or delivery device included in such Combination Licensed Product, as such fair market
values are determined in faith by the Parties; provided, however, that in no event under this
Section 3.2.3(c) shall such fraction be less than 2/3.

               (d) Notwithstanding the foregoing, the Parties agree that adjuvants, excipients, toxins,
PEGylation moieties (or other added generic carbohydrates or polymers),

8

 

and/or half-life extenders, unless any of the foregoing [****], shall not be deemed to be
“pharmaceutically active ingredient(s)”, the presence of which in a Licensed Product would be
deemed to create a Combination Licensed Product; the Parties also agree that peptide domains that
specifically bind a particular molecule shall not constitute a “drug delivery device”, the presence
of which in a Licensed Product would be deemed to create a Combination Licensed Product. If the
Parties, after good faith negotiation, cannot reach agreement under this Section 3.2.3(d), then
either Party may refer the matter for resolution by binding short-form arbitration in accordance
with Section 3.2.3(e).

               (e) If the Parties do not agree upon the fair market value(s) of the Licensed Product and/or
the non-Licensed Product component(s) of any Combination Product at issue pursuant to Section
3.2.3(b), and/or if a dispute arises between the Parties with respect to Section 3.2.3(c), then
such matters shall be finally determined by binding arbitration pursuant to this Section 3.2.3(e)
in accordance with the Commercial Arbitration Rules of the American Arbitration Association by
[****]. For arbitration of disputes subject to this Section 3.2.3, each Party to the arbitration
shall prepare and submit [****]. The arbitrator shall be directed that any arbitration subject to
this Section 3.2.3(e) shall be completed within [****] from the filing of notice of a request for
such arbitration. The arbitration proceedings and the decision shall not be made public without
the joint written consent of the Parties, and each Party shall maintain the confidentiality of such
proceedings and decision, unless each Party otherwise agrees in writing; provided either Party may
make disclosures as are required to comply with applicable law or regulation. The Parties agree
that [****] decision shall be the sole, exclusive and binding remedy between them regarding
determination of the matters subject to arbitration subject to this Section 3.2.3(e).

          3.2.4 Certain Countries. With respect to Net Sales of a particular Licensed Product
in each country of the Territory made during time periods in which there exists no Valid Claim
covering the development, manufacture, importation, offer for sale, sale and/or use of such
Licensed Product in such country by Maxygen or its Sublicensees, then Maxygen’s obligation to pay
to Avidia royalties pursuant to Section 3.2.1 shall be reduced to a royalty rate of [****] percent
([****]%) of aggregate Net Sales of Licensed Products by Maxygen and its Sublicensees with respect
to such country.

          3.2.5 Where Compulsory License have been Granted. If a compulsory license is granted
to a Third Party under the applicable laws of any country in the Territory with regard to any
Licensed Product, then the royalty rate payable by Maxygen pursuant to Section 3.2.1 for sales of
such Licensed Product in such country shall be adjusted to match the royalty rate granted to such
Third Party for such country, if such rate is lower than the rate otherwise payable hereunder, but
only for so long as such compulsory lower royalty rate remains in effect.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

9

 

          3.2.6 Third Party Payments.

               (a) In addition the other payments due to Avidia under Sections 3.1, 3.2 and 5.3, Maxygen
shall be responsible for paying [****] amounts due to Third Parties for activities conducted by
Maxygen and its Sublicensees pursuant to any sublicenses granted by Avidia to Maxygen pursuant to
Section 2.1 in connection with its development or commercialization of the Licensed Products, in
accordance with a schedule to be agreed in writing by the Parties that will permit Avidia to timely
meet its obligations to such Third Parties.

               (b) Maxygen shall be solely responsible for acquiring any other licenses as it deems
appropriate from Third Parties for the development and for paying any amounts due to such Third
Parties for licenses or other rights Maxygen has acquired to develop, make, have made, use, sell,
offer for sale or import or have imported Licensed Products in the Territory.

          3.2.7 Royalty Term. The obligation of Maxygen to pay royalties under this Section 3.2
(except for payments due pursuant to Section 3.2.6) shall commence upon the First Commercial Sale
for each Licensed Product, on a Licensed Product-by-Licensed Product and country-by-country basis,
and continue until the later of (i) such time as there are no Valid Claims covering the
manufacture, sale or use of such Licensed Product in such country, or (ii) [****] years from the
First Commercial Sale of such Licensed Product by Maxygen and/or its Sublicensees in such country.
Notwithstanding the foregoing, if at any time the royalty term with respect to a particular
Licensed Product expires at a time at which there is at least one claim in a pending patent
application that covers the manufacture, sale or use of such Licensed Product but is no longer
deemed to be a Valid Claim due to the priority date of such patent application, then the royalty
term shall restart at such time as such claim becomes a Valid Claim again pursuant to Section 1.33.
Such renewed royalty term shall continue until such time as there are no Valid Claims covering the
manufacture, sale or use of such Licensed Product in such country, and is subject to further
renewal pursuant to this Section 3.2.7.

     3.3 Taxes.

          3.3.1 Payment of Tax. Avidia shall pay any and all taxes levied on payments received
pursuant to Sections 3.1 and/or 3.2. If applicable laws or regulations require that taxes
be deducted and withheld from a payment made pursuant to Sections 3.1 and/or 3.2, Maxygen shall (i)
deduct those taxes from the payment; (ii) pay the taxes to the proper taxing authority; and (iii)
within sixty (60) days following such payment, send to Avidia evidence of the applicable obligation
together with proof of that payment.

          3.3.2 Other Taxes. Any sales taxes (e.g., consumption or value added taxes), use
taxes, transfer taxes, value added, duties and other taxes or governmental charges assessed and
required to be paid in connection with (i) the sale of any Licensed Product by Maxygen or its
Sublicensee to a Third Party, or (ii) the transfer to Maxygen or its Affiliate or Sublicensee of
any Licensed Product manufactured by Avidia or a Third Party, shall be the sole responsibility of
Maxygen or its Sublicensee, as the case may be.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

10

 

          3.3.3 Assessment. Either Party may, at its own expense, protest any assessment,
proposed assessment, or other claim by any governmental authority for any amount of taxes, interest
or penalties or seek a tax credit, refund or other recovery of such amounts paid if permitted to do
so by law. The Parties shall reasonably cooperate with each other in conducting any such protest
or in efforts to receive any such tax credit, refund or other recovery, including without
limitation by providing records and such additional information as may reasonably be necessary for
a Party to pursue such protest, tax credit, refund or other recovery.

ARTICLE
4 — REPORTS; BOOKS AND RECORDS

     4.1 Royalty Reports and Payments. Commencing with the First Commercial Sale of a
Licensed Product by Maxygen or its Sublicensees, Maxygen shall make quarterly written reports to
Avidia within sixty (60) days after the end of each calendar quarter, stating in each such report,
by Licensed Products and by country, the number, description and aggregate Net Sales in U.S.
dollars of Licensed Products sold during the calendar quarter by each of Maxygen and each of its
Sublicensees. The report shall also show (i) the calculation of Net Sales and the royalty payments
due to Avidia on such Net Sales, (ii) the amount of taxes, if any, withheld to comply with
applicable law, and (iii) the exchange rates used in calculating the payments due Avidia, which
exchange rates shall comply with Section 4.3. Simultaneously with the delivery of each such
report, Maxygen shall pay to Avidia the total royalties, if any, due to Avidia for the period of
such report. If no royalties are due, Maxygen shall so report.

     4.2 Payment Method; Late Payments. All amounts due Avidia hereunder shall be paid in
U.S. dollars. Any payments or portions thereof due hereunder which are not paid on the date such
payments are due under this Agreement shall bear interest per annum at a rate equal to the lesser
of: (a) the prime rate as reported by the Chase Manhattan Bank, New York (or its successor) for
the due date of such payment, plus an additional [****] percent ([****]%) per year, or (b) the
maximum rate permitted by law.

     4.3 Currency Conversion. If any currency conversion shall be required in connection
with the calculation of royalties hereunder, such conversion shall be made using the exchange rate
for conversion of the foreign currency into U.S. Dollars, quoted for current transactions for
buying U.S. dollars, as reported in The Wall Street Journal for the last business day of the
calendar quarter to which such payment pertains.

     4.4 Blocked Currency. In each country where the local currency is blocked and cannot
be removed from the country, at the election of Avidia, royalties accrued in that country may be
paid to Avidia in such country in local currency by deposit in a local bank designated by Avidia.

     4.5 Records; Inspection. Maxygen shall keep (and cause its Sublicensees to keep)
complete, true and accurate books of account and records for the purpose of determining the royalty
amounts payable under Section 3.2. Such books and records shall be kept reasonably accessible for
at least [****] years following the end of the calendar quarter to which they pertain. Such
records will be open for inspection during such [****] year period by an

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

11

 

independent accountant reasonably acceptable to Maxygen for the purpose of verifying the
royalty statements. Such inspections may be made no more than once each calendar year, at
reasonable times mutually agreed by Maxygen and Avidia. Avidia’s representative or agent will be
obliged to execute a reasonable confidentiality agreement prior to commencing any such inspection.
Avidia shall bear the costs and expenses of inspections conducted under this Section 4.5 unless a
variation or error producing an underpayment in royalties payable exceeding [****] percent
([****]%) of the amount payable for the period covered by such audit is established in the course
of any such inspection, whereupon all costs relating to the inspection shall be born by Maxygen.
Maxygen shall promptly pay to Avidia any and all unpaid amounts that are discovered in such audits,
together with interest on such unpaid amounts at the rate specified in Section 4.2 above.

ARTICLE 5 — DILIGENCE

     5.1 Reasonable Efforts. Maxygen shall use Commercially Reasonable Efforts to: (i)
[****]. Maxygen may conduct such activities itself or through Third Parties, at its sole
discretion.

     5.2 Voluntary Cessation of Development. If Maxygen makes a decision that it will not
(itself or with a Third Party) conduct further development or commercialization activities with
respect to any Licensed Product, Maxygen shall promptly, and in no event later than thirty (30)
days after such decision, so notify Avidia in writing. If Maxygen decides that it will not
maintain any development or commercialization activities with respect to at least one Licensed
Product for use in the Field, then upon such written notification, this Agreement shall terminate.
At the request of Avidia, the Parties shall then engage in good faith negotiation for an agreement
under which Maxygen would grant to Avidia an exclusive, worldwide, royalty-bearing license, with
the right to grant sublicenses, under all necessary or useful intellectual property rights owned or
Controlled by Maxygen to make, have made, use, import, sell and offer for sale Licensed Products.

     5.3 Sponsored Research. Promptly following the execution of this Agreement, the
Parties agree to use reasonable efforts to negotiate and to endeavor to agree upon the terms of and
enter into a Research Agreement pursuant to which Maxygen would sponsor a minimum of [****] Avidia
FTE (full time equivalent) for [****] year for agreed research on the Licensed Products, at an
annual FTE rate of [****]. The terms of any such agreement, including an agreed research plan,
detailing specific activities to be conducted by Avidia, shall be reflected in a written agreement
executed between the Parties. If within sixty (60) days of the Effective Date such a written
agreement has not been entered by Maxygen and Avidia, then in lieu of such an agreement, Maxygen
shall promptly pay to Avidia $[****] and prior to the first anniversary of the Effective Date,
Maxygen shall spend at least another $[****] on research and/or development with regard to Licensed
Products that may be performed, at Maxygen’s sole election, either internally by Maxygen and/or on
behalf of Maxygen by one or more Third Parties. Commencing on the [****] of the Effective Date and
ending on the earlier of (a) the date that the first IND for a Licensed Product is filed in the
Territory, or (b) Maxygen notifies Avidia

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

12

 

that it is terminating its license hereunder, Maxygen shall make annual expenditures of at
least [****] dollars ($[****]) per year on research and/or development relating to the relevant
Avidia Target and Licensed Products and shall provide Avidia with written evidence that such
expenditures were made. At Maxygen’s sole discretion, such additional expenses may be incurred for
activities (y) conducted by Avidia on behalf of Maxygen, or (z) conducted by Maxygen or by one or
more Third Parties on behalf of Maxygen.

     5.4 Progress Reports. Maxygen shall provide to Avidia, within [****] days after the
end of each of the second calendar quarter and the fourth calendar quarter of each year during the
term of this Agreement, written reports summarizing the activities performed by or on behalf of
Maxygen or its Sublicensees, and the anticipated timelines therefor, for the purpose of updating
Avidia on the anticipated timing and achievement of any of the milestones set forth in Section
3.1.1 relevant to each Licensed Product; except that in no event shall Maxygen be required to
disclose any confidential information of any Third Party. It is understood and agreed that such
stated goals and anticipated timelines may be subject to change by Maxygen or its Sublicensee, as
the case may be, at its sole discretion, subject only to the diligence requirements set forth in
Section 5.1 above. Maxygen shall use reasonable efforts to provide to Avidia all material
additional information that Avidia may reasonably request from time to time regarding the status of
the anticipated timing and achievement of any of the milestones set forth in Section 3.1.1 relevant
to a Licensed Product.

ARTICLE 6 — INTELLECTUAL PROPERTY

     6.1 Patent Prosecution.

          6.1.1 Maxygen Sole Inventions. Maxygen shall be responsible for preparing, filing,
prosecuting and maintaining of any patent applications and patents owned solely by it, worldwide in
such countries as it deems appropriate, and conducting any interferences, reexaminations, reissues,
oppositions or requests for patent term extensions relating thereto, using counsel of its choice,
at its expense.

          6.1.2 Avidia Sole Inventions.

               (a) Avidia shall be responsible for preparing, filing, prosecuting and maintaining of the
patent applications and patents owned solely by it, worldwide in such countries as it deems
appropriate, and conducting any interferences, reexaminations, reissues, oppositions or requests
for patent term extensions relating thereto, using counsel of its choice, at its expense.

               (b) Avidia shall use reasonable efforts to obtain patent coverage with regard to Product
Patents, in at least the [****], and such other countries as Maxygen and Avidia may agree. Avidia
shall notify Maxygen of its intention to file any such patent application, and shall provide
Maxygen with copies of all patent prosecution and maintenance documentation and correspondence so
that Maxygen shall be currently and promptly informed of the continuing

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

13

 

prosecution and maintenance of patent applications and patents within the Product Patents.
Maxygen shall have the right to review and comment upon such documentation and correspondence, as
well as all specifications, claims and responses to office actions prior to their submission to the
relevant government patent office. Avidia shall reasonably consider Maxygen’s reasonable, timely
comments on each such draft submission; provided that Maxygen shall be given a reasonable time, in
view of the relevant filing deadline or goal, within which to provide Avidia with its comments for
Avidia’s consideration. Avidia shall keep Maxygen fully informed of the status of such patent
applications and patents. The Parties acknowledge that in order to obtain an early priority date
for a particular application, in some circumstances Avidia may need to file patent applications
prior to review by Maxygen. Maxygen shall reimburse Avidia for the expenses incurred by Avidia
with respect to the filing, prosecution and maintenance of patents and patent applications within
the Product Patents.

               (c) If at any time Avidia does not wish to file or wishes to discontinue the prosecution or
maintenance of any patent application or patent within the Product Patents filed in any country, on
a country-by-country basis, it shall promptly give notice of such intention to Maxygen. Maxygen
shall have the right, but not the obligation, to assume responsibility for the prosecution of any
such patent applications or maintenance of any such patents in the applicable country, at its own
expense, by giving notice to Avidia of such intention within thirty (30) days.

          6.1.3 Patent Term Extensions. If Maxygen requests that an application be made to
extend the term of a Product Patent covering a Licensed Product, then unless such a filing would
have a material adverse impact on another human pharmaceutical product then being developed or
commercialized by Avidia, the Parties will apply to extend the patent term with respect to such
Product Patent, as provided for in the Patent Term Restoration Act or other similar laws and
regulations affording an extension or restoration of patent term in the United States and similar
laws and regulations in the other countries of the Territory. Avidia will cooperate fully with and
assist Maxygen in making all filings for patent term extensions requested by Maxygen as described
in this Section 6.1.3, at Maxygen’s sole expense.

     6.2 Enforcement.

          6.2.1 Product Patents. If during the Term, either Party believes any Product Patents
are infringed by the activities of any Third Party, then such Party shall notify the other Party in
writing. If such alleged infringement is in the Field, then Avidia shall have the initial right,
but not the obligation, to notify the alleged infringer of the alleged infringement, and to
initiate, prosecute and control any action with respect to such alleged infringement, by counsel of
its own choice, to secure the cessation of the infringement or to bring suit against the alleged or
threatened infringer. If Avidia fails to bring suit as it is permitted to within [****] days after
receiving written notice from Maxygen of the alleged or threatened infringement, then Maxygen shall
have the right, but not the obligation, to bring at Maxygen’s sole expense and in Maxygen’s sole
control, suit against the alleged or threatened infringer; provided that such action is limited
only to [****]. The non-enforcing Party shall participate and/or cooperate, at the request and
expense of the enforcing Party, in any suit brought by the enforcing Party pursuant to this

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

14

 

Section 6.2.1. The non-enforcing Party may participate, in its discretion and at its expense,
in any suit brought by the enforcing Party pursuant to this Section 6.2.1.

          6.2.2 Recoveries. Any damages or other monetary awards recovered in a suit prosecuted
by either Party pursuant to Section 6.2.1 regarding infringement shall be applied first to
reimburse the costs and expenses of the Parties in conducting (or assisting in the conduct of) such
suit (including without limitation the internal costs and expenses specifically attributable to
such suit). Any remaining recovery shall be shared by the Parties as follows: (a) with regard to
any recovery in an action brought by Avidia, [****] percent ([****]%) to Avidia, and [****] percent
([****]%) to Maxygen; and (b) with regard to any recovery in an action brought by Maxygen, or
jointly by Avidia and Maxygen, [****] percent ([****]%) to Avidia, and [****] percent ([****]%) to
Maxygen.

          6.2.3 No Admissions. Neither Party shall admit the unenforceability or invalidity of
any Product Patent in the course of any proceeding that it has the right to conduct pursuant to
this Section 6.2, without the advance written consent of the other Party.

          6.2.4 Cooperation. The Party participating in any such claim, suit or proceeding,
shall keep the other Party hereto reasonably informed of the progress of any such claim, suit or
proceeding. If either Party brings any action or proceeding as permitted under this Section 6.2,
then, if required by applicable law in order to permit the action or proceeding to go forward, the
other Party agrees to be joined as a party to such action and to give the first Party reasonable
assistance and authority to control, file and prosecute the suit as necessary, at the expense of
the first Party.

     6.3 Infringement Claims. If a Third Party asserts that Patent Rights owned by or
licensed to it are infringed by the development, manufacture, use or sale of a Licensed Product by
Maxygen or its Sublicensees during the Term, Maxygen shall have the exclusive right and
responsibility to resolve the problem raised by the asserted infringement, whether by obtaining a
license from such Third Party, by defending against such Third Party’s claims or otherwise and
shall be solely responsible for any liabilities incurred in connection therewith pursuant to
Section 9.2 below. Avidia shall reasonably cooperate with Maxygen at Maxygen’s expense in
conducting the defense of the claim, and Maxygen shall keep Avidia reasonably informed of all
material developments in connection with any such claim, suit or proceeding. Notwithstanding the
above, Maxygen shall not enter into any agreement that makes any admission regarding (i) wrongdoing
on the part of Avidia, or (ii) the invalidity, unenforceability or absence of infringement of any
patent claiming Avidia Technology or, without the prior written consent of Avidia, which consent
shall not be unreasonably withheld.

ARTICLE 7 — CONFIDENTIALITY

     7.1 Confidential Information. Except as expressly provided herein, the parties agree
that, for the term of this Agreement and for five (5) years thereafter, the receiving Party shall
keep completely confidential and shall not publish or otherwise disclose and shall not use for any

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

15

 

purpose except for the purposes contemplated by this Agreement any Confidential Information
furnished to it by the disclosing party hereto pursuant to this Agreement, except that to the
extent that it can be established by the receiving Party by competent proof that such Confidential
Information:

          7.1.1 was already known to the receiving Party, other than under an obligation of
confidentiality, at the time of disclosure;

          7.1.2 was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the receiving Party;

          7.1.3 became generally available to the public or otherwise part of the public domain after
its disclosure and other than through any act or omission of the receiving Party in breach of this
Agreement;

          7.1.4 was independently developed by the receiving Party without reference to any information
or materials disclosed by the disclosing Party; or

          7.1.5 was subsequently disclosed to the receiving Party, other than under an obligation of
confidentiality, by a Third Party without breach of any legal obligation of such Third Party to the
disclosing Party.

     7.2 Permitted Disclosures. Each Party hereto may disclose another’s Confidential
Information to the extent such disclosure is reasonably necessary, in filing or prosecuting patent
applications, prosecuting or defending litigation, complying with applicable laws or regulations or
otherwise submitting information to tax or other governmental authorities, conducting development
of Licensed Products, or making a permitted sublicense or otherwise exercising its rights
hereunder, provided that if a Party is required to make any such disclosure of another Party’s
confidential information, other than pursuant to a confidentiality agreement, it will as far as is
practicable give reasonable advance notice to the latter Party of such disclosure and, save to the
extent inappropriate in the case of patent applications, will use its reasonable efforts to secure
confidential treatment of such information prior to its disclosure (whether through protective
orders or otherwise).

     7.3 Securities and Exchange Commission. If a Party concludes in good faith that it is
required to file or register this Agreement or a notification thereof with any governmental
authority or regulatory agency, including without limitation the U.S. Securities and Exchange
Commission and the Competition Directorate of the Commission of the European Communities, in
accordance with applicable laws and regulations, such Party may do so; provided that, it will as
far as is practicable give reasonable advance notice to the latter Party of such disclosure and
will use its reasonable efforts to secure confidential treatment of such information prior to its
disclosure (whether through protective orders or otherwise). The other Party shall cooperate and
assist such filing/registering Party upon request of such filing/registering Party, in such filing
or notification and shall execute all documents reasonably required in connection therewith, at the
expense of the requesting Party.

     7.4 Non-Disclosure. Except to the extent required by law, each of the Parties hereto
agrees not to disclose to any Third Party the financial terms of this Agreement without the prior

16

 

written consent of each other Party hereto, except (i) [****], in each case under
circumstances that reasonably ensure the confidentiality thereof, or (ii) as may be required by
applicable law, regulation or court order; provided that, it will as far as is practicable give
reasonable advance notice to the latter Party of such required disclosure and, save to the extent
inappropriate in the case of patent applications, will use its reasonable efforts to secure
confidential treatment of such information prior to its disclosure (whether through protective
orders or otherwise).

ARTICLE 8 — REPRESENTATIONS AND WARRANTIES

     8.1 Representations and Warranties.

          8.1.1 Avidia. Avidia represents and warrants to Maxygen as of the Effective Date,
except as set forth in the Schedule of Exceptions attached hereto as Exhibit A, that (i) it has the
full right and authority to enter into this Agreement and, to its knowledge, grant the rights and
licenses granted herein; (ii) [****]; and (iii) it has not previously granted, and will not grant
during the term of this Agreement, any right, license or interest in or to Avidia Technology or the
Licensed Products which is in conflict with the licenses granted under this Agreement.

          8.1.2 Maxygen. Maxygen represents and warrants to Avidia that it has the full right
and authority to enter into this Agreement and to perform its obligations under this Agreement.

     8.2 Disclaimer of Warranties. AVIDIA AND MAXYGEN EACH EXPRESSLY DISCLAIMS ANY
WARRANTIES OR CONDITIONS, EXPRESS, IMPLIED, WRITTEN, ORAL, STATUTORY OR OTHERWISE, WITH RESPECT TO
THE CONFIDENTIAL INFORMATION, LICENSED PRODUCTS AND/OR AVIDIA TECHNOLOGY, INCLUDING, WITHOUT
LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY,
ENFORCEABILITY, OR NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES (EXCEPT
[****]).

ARTICLE 9 — INDEMNIFICATION

     9.1 Avidia. Avidia shall indemnify, defend and hold harmless Maxygen and its
Affiliates and Sublicensees and their respective employees, agents, officers and directors (each a
“Maxygen Indemnitee”) from and against any claims, actions or suits by a Third Party (including,
without limitation, product liability and environmental claims) resulting in any liabilities,
damages, settlements, claims, penalties, fines, and reasonable costs or reasonable expenses
(including, without limitation, reasonable attorneys’ fees and other expenses of litigation)
arising out of or resulting from (i) a breach of any of the representations or warranties of Avidia
in Section 8.1.1, or (ii) the research, manufacture, development, clinical testing, importation,
distribution, marketing, offer for sale, sale or use of any Licensed Products and/or Products
pursuant to Section 2.5 by or on behalf of Avidia or its Affiliates or sublicensees

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

17

 

(including without limitation, product liability claims), except to the extent caused by the
gross negligence or willful misconduct of Maxygen.

     9.2 Maxygen. Maxygen shall indemnify, defend and hold harmless Avidia and its
Affiliates and Sublicensees and their respective employees, agents, officers and directors (each a
“Avidia Indemnitee”) from and against any claims, actions or suits by a Third Party (including,
without limitation, product liability and environmental claims) resulting in any liabilities,
damages, settlements, claims, penalties, fines, and reasonable costs or reasonable expenses
(including, without limitation, reasonable attorneys’ fees and other expenses of litigation)
arising out of or resulting from (i) a breach of Maxygen’s representations and warranties in
Section 8.1.2, or (ii) the research, manufacture, development, clinical testing, importation,
distribution, marketing, offer for sale, sale or use of any Licensed Products by or on behalf of
Maxygen or its Affiliates or Sublicensees (including without limitation, product liability claims),
except to the extent caused by the gross negligence or willful misconduct of Avidia.

     9.3 Procedure. An Indemnitee that intends to claim indemnification from a Party under
this Article 9 shall [****].

ARTICLE 10 — TERM AND TERMINATION

     10.1 Term. This Agreement shall be effective as of the Effective Date and, unless
otherwise terminated earlier pursuant to the other provisions of this Article 10, shall continue in
full force and effect on a Licensed Product-by-Licensed Product and country-by-country basis until
the date Maxygen and its Affiliates and Sublicensees has no remaining royalty obligations hereunder
for such Licensed Products in such country and no possibility of renewed royalty obligations on
account of claims in pending patent applications no longer qualifying as Valid Claims. Thereafter,
the licenses granted by Avidia under Section 2.1 shall be fully paid, non-exclusive and perpetual,
subject to Maxygen’s continued compliance with all provisions that survive expiration of this
Agreement.

     10.2 Termination for Cause. Either Party may terminate this Agreement in the event
the other Party has materially breached or defaulted in the performance of any of its obligations
hereunder, and such default has continued, after written notice thereof (which notice reasonably
describes the events or circumstances related to the alleged breach or default) was received by the
breaching Party from the nonbreaching Party, for [****] days thereof for non-payment by Maxygen or
ninety (90) days thereof for any other breach. The non-breaching Party shall have the right to
terminate this Agreement at the end of such period unless the breaching Party has cured any such
breach or default prior to the expiration of such period.

     10.3 Termination for Insolvency. If voluntary or involuntary proceedings by or
against a Party are instituted, or if a Party otherwise seeks relief, under bankruptcy, insolvency
or similar law, or a receiver or custodian is appointed for such party, or proceedings are
instituted by or against such Party for corporate reorganization or the dissolution of such party,
which proceedings, if involuntary, shall not have been dismissed within [****] days after the date
of

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

18

 

filing, or if such Party makes an assignment for the benefit of creditors, or substantially
all of the assets of such Party are seized or attached and not released within [****] days
thereafter, the other Party may immediately terminate this Agreement effective upon notice of such
termination.

     10.4 Permissive Termination. Maxygen may terminate this Agreement in whole, or in
part on a Licensed-Product-by-Licensed-Product basis, upon at least thirty (30) days written notice
of such termination to Avidia. Termination of this Agreement in whole pursuant to this Section
10.4 shall be subject to the terms of Section 5.2.

     10.5 Effect of Breach or Termination.

          10.5.1 Accrued Rights and Obligations. Termination of this Agreement for any reason
shall not release any Party hereto from any liability which, at the time of such termination, has
already accrued to the other Party or which is attributable to a period prior to such termination,
nor preclude either Party from pursuing any rights and remedies it may have hereunder or at law or
in equity which accrued or are based upon any event occurring prior to such termination.

          10.5.2 Return of Confidential Information. Upon the expiration or termination of this
Agreement, Maxygen and Avidia shall promptly return to the other Party all Confidential Information
received from the other Party except one copy of written and graphic materials (in hard copy or
electronic form) which may be retained for archival purposes.

          10.5.3 Licenses. The licenses granted to Maxygen herein shall terminate in the event
of any termination of this Agreement if either Party properly terminates this Agreement pursuant to
Section 10.2 or 10.3 or if Maxygen terminates this Agreement in its entirety pursuant to 10.4.

          10.5.4 Sublicenses. In the event of any termination of this Agreement, any sublicense
granted by Maxygen shall remain in force and effect and be assigned by Maxygen to Avidia, if and
only if such Sublicensee is not in breach of the its obligations under the sublicense agreement;
provided the financial obligations of any such Sublicensee shall be limited to the amounts Maxygen
is obligated to pay to Avidia for the activities of such Sublicensee under this Agreement.

          10.5.5 Stock on Hand. In the event this Agreement is terminated for any reason other
than Maxygen’s termination pursuant to Section 10.4, until [****] months after the effective date
of such a termination, Maxygen and its Sublicensees shall have the right to sell or otherwise
dispose of the stock of any Licensed Products in the possession of Maxygen or its Sublicensees at
the time of notice of such termination, subject to Articles 3 and 4.

     10.6 Covenant. The covenant in Section 2.4 shall survive in the event of an
expiration of this Agreement following the payment of all royalties due under the Agreement but not
in the

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

19

 

event of any termination of the Agreement pursuant to Sections 10.2, 10.3 or 10.4, solely with
respect to the termination of this Agreement in whole.

     10.7 Survival. Sections 2.5 (subject to any and all ongoing payment obligations to
Third Parties, and if the agreement has not been terminated pursuant to Section 10.2 or 10.3), 3.1
(as to pre-termination events), 3.2 (as to pre-termination sales and sales subject to Section
10.5.5), 3.3, the last sentence of 5.2, 6.1, 6.2 (as to pre-termination enforcement actions only),
6.3, 8.2, 10.4 and 10.5, 10.6 and Articles 1, 4 (as to pre-termination sales and sales subject to
Section 10.5.5), 7, 9, 11 and 12 shall survive the expiration or termination of this Agreement for
any reason.

ARTICLE 11 — DISPUTE RESOLUTION

     11.1 Mediation. If a dispute arises out of or relates to this Agreement, or the
breach thereof, the Parties agree first to try in good faith to settle the dispute by negotiation
and escalation to senior representatives within their respective organizations.

     11.2 Jurisdiction; Venue. Each Party hereby irrevocably consents to the personal
jurisdiction of and exclusive venue before the U.S. district court for the Northern District of the
State of California (and the California Superior Courts for San Mateo and Santa Clara counties),
and hereby waives all defenses such Party may have to the personal jurisdiction of and/or venue
before such courts.

ARTICLE 12 — MISCELLANEOUS

     12.1 Governing Law. This Agreement and any dispute arising from the performance or
any breach hereof, including without limitation any arbitration under Section 3.2.3(d), shall be
governed by and construed in accordance with the laws of the State of California, without reference
to conflicts of laws principles of that State or of any other jurisdiction. Notwithstanding the
foregoing, the interpretation and enforcement of Section 3.2.3(d) shall be governed by the United
States Arbitration Act.

     12.2 Waiver. Neither Party may waive or release any of its rights or interests in
this Agreement except in writing. The failure of either Party to assert a right hereunder or to
insist upon compliance with any term or condition of this Agreement shall not constitute a waiver
of that right or excuse a similar subsequent failure to perform any such term or condition.

     12.3 Assignment. This Agreement shall not be assignable by either Party to any third
party hereto without the written consent of the other Party, which consent shall not be
unreasonably withheld; provided either Party may assign this Agreement, without such consent, to
(i) an Affiliate of such Party; or (ii) an entity that acquires all or substantially all of the
business or assets of such Party to which this Agreement pertains, whether by merger,
reorganization, acquisition, sale or otherwise. The terms and conditions of this Agreement shall
be binding on and inure to the benefit of the permitted successors and assigns of the Parties. Any
assignment not satisfying the foregoing shall be null and void.

     12.4 Notices. Any notices, requests and other communications hereunder shall be in
writing and shall be personally delivered or sent by international express delivery service,

20

 

registered or certified mail, return receipt requested, postage prepaid, in each case to the
respective address specified below, or such other address as may be specified in writing to the
other Party hereto:

	 	 	 	 	 	 	 
	 

	 	Maxygen:
	 	Maxygen, Inc.	 	 
	 

	 	 	 	515 Galveston Drive	 	 
	 

	 	 	 	Redwood City, CA 94063	 	 
	 

	 	 	 	Attn: General Counsel	 	 
	 
	 	 	 	 	 	 
	 

	 	Avidia:
	 	Avidia Research Institute
	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 
	 	 	 	 	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Attn:                                         	 	 

     12.5 Force Majeure. Neither Party shall be liable to the other for failure or delay
in the performance of any of its obligations under this Agreement for the time and to the extent
such failure or delay is caused by earthquake, riot, civil commotion, war, hostilities between
nations, governmental law, order or regulation, embargo, action by the government or any agency
thereof, act of God, storm, fire, accident, labor dispute or strike, sabotage, explosion or other
similar or different contingencies, in each case, beyond the reasonable control of the respective
Party. The party affected by Force Majeure shall provide the other Party with full particulars
thereof as soon as it becomes aware of the same (including its best estimate of the likely extent
and duration of the interference with its activities), and will use reasonable efforts to overcome
the difficulties created thereby and to resume performance of its obligations as soon as
practicable. Notwithstanding the foregoing, the milestone payments and royalty payments hereunder
shall not be delayed by the payer because of a Force Majeure affecting the payer, unless such Force
Majeure specifically precludes the payment process.

     12.6 Independent Contractors. The Parties agree that the relationship of Maxygen and
Avidia established by this Agreement is that of independent contractors. Furthermore, the Parties
agree that this Agreement does not, is not intended to, and shall not be construed to, establish a
partnership or joint venture, and nor shall this Agreement create or establish an employment,
agency or any other relationship. Neither Party shall have any right, power or authority, nor
shall they represent themselves as having any authority to assume, create or incur any expense,
liability or obligation, express or implied, on behalf of the other Party, or otherwise act as an
agent for the other Party for any purpose.

     12.7 Advice of Counsel. Avidia and Maxygen each acknowledges and agrees that this
Agreement shall not be deemed to have been drafted by one Party or another and will be construed
accordingly.

     12.8 Patent Marking. Maxygen agrees to mark and have its Affiliates and Sublicensees
mark all Licensed Products they sell or distribute pursuant to this Agreement in accordance with
the applicable statute or regulations in the country or countries of manufacture and/or sale
thereof.

21

 

     12.9 Other Obligations. Except as expressly provided in this Agreement or as
separately agreed upon in writing between Avidia and Maxygen, each Party shall bear its own costs
incurred in connection with the implementation of the obligations under this Agreement.

     12.10 Severability. In the event that any provisions of this Agreement are determined
to be invalid or unenforceable by a court of competent jurisdiction, the remainder of the Agreement
shall remain in full force and effect without said provision. The Parties shall in good faith
negotiate a substitute clause for any provision declared invalid or unenforceable, which shall most
nearly approximate the intent of the Parties in entering this Agreement; provided, if the Parties
are unable to agree on such a substitute clause and the deletion of the provision held invalid or
unenforceable would produce material adverse financial consequences for one Party, such Party shall
have the right to terminate the Agreement with one hundred eighty (180) days notice.

     12.11 Further Assurances. At any time or from time to time on and after the date of
this Agreement, either Party shall at the request of the other party (i) deliver to the requesting
party such records, data or other documents consistent with the provisions of this Agreement, (ii)
execute, and deliver or cause to be delivered, all such consents, documents or further instruments
of assignment, transfer or license, and (iii) take or cause to be taken all such actions, as the
requesting Party may reasonably deem necessary or desirable in order for the requesting Party to
obtain the full benefits of this Agreement and the transactions contemplated hereby.

     12.12 Export Laws. Notwithstanding anything to the contrary contained herein, all
obligations of Avidia and Maxygen are subject to prior compliance with United States export
regulations and such other United States laws and regulations as may be applicable, and to
obtaining all necessary approvals required by the applicable agencies of the government of the
United States. Avidia and Maxygen, respectively, shall each use its best efforts to obtain such
approvals for its own activities. Each party shall cooperate with the other Party and shall
provide assistance to the other party as reasonably necessary to obtain any required approvals.

     12.13 LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER OR ANY
THIRD PARTY FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL OR INDIRECT DAMAGES (INCLUDING, WITHOUT
LIMITATION, LOST PROFITS) ARISING OUT OF ANY PERFORMANCE OF THIS AGREEMENT, HOWEVER CAUSED, UNDER
ANY THEORY OF LIABILITY, UNLESS SUCH DAMAGES ARISE FROM [****].

     12.14 Entire Agreement; Amendment. This Agreement, together with the attached
Exhibits which are incorporated herein by reference, constitutes the entire agreement between the
Parties with respect to the subject matter hereof, and supersedes and cancels all prior or
contemporaneous understandings or agreements, whether written or oral, between Maxygen and Avidia
with respect to such subject matter, except that certain Cross License Agreement entered by the
Parties dated June 30, 2003, which shall survive according to its terms. This Agreement can only
be amended or modified with a written document signed by both Parties.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

22

 

     12.15 Headings. The captions to the several Sections and Articles hereof are not a
part of this Agreement, but are included merely for convenience of reference only and shall not
affect its meaning or interpretation.

     12.16 Counterparts. This Agreement may be executed in two counterparts, each of which
shall be deemed an original and which together shall constitute one instrument.

     IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed by their
authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 
	MAXYGEN, INC.	 	AVIDIA RESEARCH INSTITUTE
	 
	 	 	 	 	 	 
	By:

	 	 	 	By:	 	 
	 

	 	 
	 	 	 	 
	Name:

	 	 	 	Name:	 	 
	 

	 	 
	 	 	 	 
	Title:

	 	 	 	Title:	 	 
	 

	 	 
	 	 	 	 

23

 

Exhibit A

Schedule of Exceptions

24

 

EXHIBIT K

Reserved Therapeutic Product Criteria

	A.	 	General Principles. Whether a particular Domain-Based Protein is a Reserved
Therapeutic Product will be determined with reference to the criteria in this Exhibit K. It
is the intent of the Parties that such determination will be based on (1) the [****], as
assessed in an assay agreed by the Parties, and (2) the [****], as assessed in an assay agreed
by the Parties. Reserved Therapeutic Products are those that both (1) [****]; and (2) [****].
A single assay may be adequate to demonstrate [****].
	 
	 	 	The assays expressly listed in this Exhibit for a particular Reserved Therapeutic Product
(i.e., in Section B.4 and C below) have been agreed to by the Parties.

	B.	 	[****] Assays. Assays for [****] will measure [****]. Several types of [****]
assays are described below.

	 	1.	 	[****]
	 
	 	2.	 	[****].
	 
	 	3.	 	[****]
	 
	 	4.	 	Assays demonstrating [****] are illustrated below with regard to assays for
assessing the [****].

	 	a.	 	[****]
	 
	 	b.	 	[****]
	 
	 	c.	 	[****]

	C.	 	[****] Assays. Assays for [****] will measure [****]. [****] of an agonist in the
applicable assay that is [****]. [****] of an antagonist in the applicable assay that results
in [****].

	 	1.	 	[****]

	 	a.	 	[****]: [****]1

	 	2.	 	[****]

	 	a.	 	[****]: [****]

 

			
	1	 	By way of example and without illustration, if a
[****].
	 
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

 

 

	 	3.	 	[****]

	 	a.	 	[****]: [****]

	 	4.	 	Agonists of any [****]

	 	a.	 	[****]:

	 	A.	 	[****]; or
	 
	 	B.	 	[****]; or
	 
	 	C.	 	[****].

	 	5.	 	Antagonists of any [****]

	 	a.	 	[****]: [****]
	 
	 	b.	 	Assay:

	 	A.	 	[****]
	 
	 	B.	 	[****]
	 
	 	C.	 	[****]

	 	6.	 	Antagonists of [****]

	 	a.	 	[****]: [****]

	 	7.	 	Agonists or antagonists of [****]

	 	a.	 	Agonist [****]: [****]
	 
	 	b.	 	Antagonist [****]: [****]

	 	8.	 	Agonists or antagonist of a [****]

	 	a.	 	Agonist [****]: [****]
	 
	 	b.	 	Antagonist [****]: [****]

	 	9.	 	Agonists or Antagonists of [****]

	 	a.	 	Agonist [****]: [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

2

 

	 	b.	 	Antagonist [****]: [****]

	 	10.	 	Agonists or Antagonists of [****]

	 	a.	 	Agonist [****]: [****]
	 
	 	b.	 	Antagonist [****]: [****]

	 	11.	 	Agonists or antagonists of [****]

	 	a.	 	Agonist [****]: [****]
	 
	 	b.	 	Antagonist [****]: [****]

	 	12.	 	Agonists or antagonists of [****]

	 	a.	 	Agonist [****]: [****]
	 
	 	b.	 	Antagonist [****]: [****]

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.

3

 

EXHIBIT L

Software

	1.	 	[****]
	 
	2.	 	[****]
	 
	3.	 	[****]
	 
	4.	 	[****]
	 
	5.	 	[****]

All the foregoing are copyrighted by Maxygen.

 

			
	*	 	Certain information on this page has been
omitted and filed separately with the Securities and Exchange Commission.
Confidential treatment has been requested with respect to the omitted portions.exv10w28

 

Exhibit 10.28

CONFIDENTIAL TREATMENT REQUESTED – EDITED COPY

**** Certain confidential information contained in this document has been omitted and filed
separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities
Exchange Act of 1934, as amended. Omissions are designated as [****].

Endwave Procurement Private

MASTER MANUFACTURING SERVICES

AND SUPPORT AGREEMENT

Between

Endwave Corporation and Hana Microelectronics Limited

October 15, 2006

 

 

Table of Contents

	 	 	 	 	 	 	 
	 	 	 	 	Page No.
	Opening and Recitals	 	 	 	 
	 	 	 
	 	 	 	 
	Agreement Terms	 	 	 	 
	Article 1.	 	Effective Term
	 	 	3	 
	Article 2.	 	Scope
	 	 	3	 
	Article 3.	 	Structure
	 	 	4	 
	Article 4.	 	Definitions of Terms
	 	 	4	 
	Article 5.	 	Engagement of Manufacturer
	 	 	4	 
	Article 6.	 	Responsibilities
	 	 	5	 
	Article 7.	 	Order Management Process
	 	 	7	 
	Article 8.	 	Quality
	 	 	7	 
	Article 9.	 	Engineering Change Notices
	 	 	9	 
	Article 10.	 	Factory Returns
	 	 	10	 
	Article 11.	 	New Product Introduction Process
	 	 	10	 
	Article 12.	 	Property Management & Control
	 	 	10	 
	Article 13.	 	Intellectual Property
	 	 	11	 
	Article 14.	 	Contractual Changes
	 	 	11	 
	Article 15.	 	Reporting and Liaison
	 	 	12	 
	Article 16.	 	Reviews
	 	 	12	 
	Article 17.	 	Payment Terms
	 	 	13	 
	Article 18.	 	Product Warranties & Disclaimers
	 	 	13	 
	Article 19.	 	Indemnification
	 	 	14	 
	Article 20.	 	Insurance
	 	 	15	 
	Article 21.	 	Limitation of Liability
	 	 	15	 
	Article 22.	 	Confidentiality
	 	 	16	 
	Article 23.	 	Termination
	 	 	17	 
	Article 24.	 	Disputes
	 	 	17	 
	Article 25.	 	General Provisions
	 	 	17	 

Exhibit 1: Definitions of Terms and Acronyms

Exhibit 2: Service Pricing

Exhibit 3: Hana Provided Manufacturing Material & Supplies

Exhibit 4: Equipment Loan Agreement of January 2005

Appendix A: Logistics Matters

Appendix B: New Product Introduction (“NPI”) Process

Appendix C: Factory Return Process and Procedures

 

 

Endwave Procurement Private

Master Manufacturing Services Support Agreement

          This Master Manufacturing Services & Support Agreement, hereinafter referred to as the
“Agreement” or alternately “MMSSA,” is made by and between Endwave Corporation, With principal
offices at 776 Palomar Avenue, Sunnyvale, California 94085 (“Buyer”) and Hana Microelectronics Ltd.
with principal offices at 10/12 Moo 4, Chiangmai-Lampang Road, T. Baanklang, Lamphun 51000,
Thailand (“Manufacturer”), and is effective on and after October 15,2006.

Recitals

          Whereas, Buyer’s addressable world-wide market has expanded in terms of numbers of customers,
unit volume, and variants of microelectronic transceiver designs since 2002; and

          Whereas, the previous contractual arrangements only address and regulate [****]
products; and

          Whereas, the parties each desire to update their contractual arrangements to more completely
and clearly reflect current and projected business needs for new product introduction,
build-to-forecast procedures, single-piece flow manufacturing, annual cost reduction and continuous
improvement;

          Now Therefore, in exchange for their mutual promises and other good and valuable
consideration, the sufficiency of which is acknowledged, Buyer and Manufacturer do hereby agree to
a revised contractual relationship as more particularly set forth below.

Terms of Agreement

     1. Effective Term. The parties agree to a fixed term of 2 years commencing October 15, 2006
(the “Effective Date”) and concluding, unless earlier terminated or extended by mutual agreement,
on October 14. 2008. Additionally, the parties agree that the contract relationship established
hereunder shall automatically continue without interruption for successive one year terms, on the
same contractual terms and conditions, if neither party gives the other party at least 365 days
advance written notice of its intention not to renew.

     2. Scope. This Agreement is intended by the parties to comprehensively define and document
the business relationship now subsisting between them, and to create a flexible framework for
accommodating unknown future changes in business requirements and prices in a mutually beneficial
way. Accordingly, this Agreement intentionally describes and endorses voluntary commercial
behavioral rules that are aimed at establishing, protecting, and improving a vital commercial
relationship built on trust, respect, and goodwill.

**** Certain confidential information contained in this document has
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

 Endwave Procurement Private

     3. Structure. This Agreement is Structured as a relationship “frame agreement”, with legally and
operationally significant commercial terms and conditions applicable the entire relationship
expressed in the main body of the Agreement. Logistical process and procedure describing the
recurring mainstream planning-forecasting-ordering-build-ship cycle of activity is the subject of
Appendix A to this Agreement. Subsequent Appendices shall be modular in construction, and address
Buyer end-user customer specific requirements, such as Appendix B. New Product Introduction. In
this regard, any Exhibit or Appendix referred to in the main body of this Agreement is considered
to be incorporated by reference into the Agreement, and is regarded as integral to the whole.
Lastly, as the commercial nature and volume of business changes, additional Appendices may be
amended to this Agreement by written amendment in accordance with the Changes clause below.

     4. Definitions of Terms. To the extent that this Agreement uses words, terms or phrases that
have specialized meaning to the parties that are not defined in the body of this MMSSA. they shall
be defined in Exhibit 1 to this Agreement, which Exhibit is incorporated by reference.

     5. Engagement of Manufacturer.

          5.1 Manufacture of Products for Buyer. Buyer hereby engages, hires and retains Manufacturer on
a non-exclusive basis to manufacture, assemble, test, inspect, pack, ship, and repair Buyer
designed Products in accordance with the terms of this Agreement, including applicable exhibits and
appendices, solely for sale to Buyer. Manufacturer acknowledges and agrees that Buyer shall retain
the right, either on its own or through the use of a third party, to obtain the same services as
provided by Manufacturer hereunder. Unless otherwise agreed. Manufacturer is not responsible for
the design of Buyer products.

          5.2 Manufacturing Facility. Manufacturer shall fulfill its obligations under this Agreement
solely at a facility designated and approved in writing by Buyer (the “Manufacturing Facility”).
Initially, it is agreed by the parties that all manufacturing service will be performed by
Manufacturer at its existing facility in the free trade zone at Lamphun, Thailand.

          5.3 Exclusivity of Production. Manufacturer herby undertakes to supply Products to Buyer, and
to allocate sufficient labor, facility, capital equipment, tools, and other resources as may be
required to manage and control manufacturing operations in accordance with delivery schedules and
orders placed under the provisions of Appendix A. Manufacturer will manufacture the Products
exclusively for Buyer and will not sell or otherwise provide covered Products, in sample form or
otherwise, to any other person, firm, company, or government without Buyer’s prior written
approval. Except as provided in Article 19 (Indemnification), nothing in this MMSSA is intended to
grant to Manufacturer a license to the Products or to any Buyer Technology or Intellectual Properly
by virtue of the services to be performed.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

          5.4 Non-Delegable Responsibility. Manufacturer acknowledges that Buyer has elected to contract
with Manufacturer on a preferred basis due to Buyer’s understanding of and belief in Manufacturer’s
unique skill in concurrent manufacturing of high volume products of varying design and complexity.
Therefore, Manufacturer’s rights and obligations under this MMSSA may not be subcontracted or
assigned to any third party or successor entity without the express written consent of Buyer. In
the event that Buyer provides such written consent, Manufacturer shall remain wholly responsible to
Buyer for the acts or omissions of any approved third party or successor entity.

          5.5 Covenant Not To Compete. As an integral part of its engagement, and in consideration of
the service prices to be paid by Buyer under this Agreement, Manufacturer agrees not to compete
with Buyer in the design, manufacture, selling or reselling of micro-electronics devices for the
worldwide telecommunications, defense, national security, or homeland security markets. This
covenant not to compete is expressly limited to the following two situations: (a) where
Manufacturer acts as [****] ; and b) where Manufacturer enters into [****] . This
Agreement does not preclude [****] , provided that Manufacturer does not [****] .

     6. Responsibilities.

          6.1 Manufacturer’s Responsibilities. Throughout the period described by this MMSSA. and any
extensions thereto, the Manufacturer shall be responsible for the following performance
obligations:

               (a) manage the manufacturing process, through the daily planning, organization and supervision
of material flow, personnel assignment and rotation, and machine performance, including the
provision of consumable manufacturing material and supplies as listed in Exhibit 3;

               (b) comply with the operational provisions and procedures described by Appendix A to this
Agreement;

               (c) maintain a Kanban supply of finished goods equal to or less than [****]in
secure storage between 15-30 degrees C, and 25-75% relative humidity;

               (d) monitor and maintain Buyer supplied Exhibit 4 Automated Test Equipment in good working
order, and report ATE defects as discovered or suspected;

               (e) reduce raw component scrap rate to a goal of [****] Buyer supplied raw
material, through an active program including the reporting of results at least weekly in a
mutually agreed format;

               (f) detect, report and follow-up with component vendors on RMI components that are judged by
Manufacturer to require a Return To Vendor (“RTV”) for quality reasons;

               (g) make progress towards a goal of [****]yields on finished goods for products
not in NPI;

               (h) collaborate with Buyer in the development of a plan for Continuous Improvement, including
the commission of Kaizen teams as appropriate;

               (i) report on weekly Quality data as detailed in Article 8 below;

               (j) provide Buyer’s staff, including local RO members, with Facility access as required and
reasonably requested;

               (k) provide Buyers customers with Manufacturing Facility access, as reasonably requested in
advance, and on a not-to-interfere basis;

               (l) to support the conduct of Buyer’s evaluation of manufacturability, provide a small space
near the designated manufacturing line for the

 **** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

 Endwave Procurement Private

conduct of Buyers engineering evaluation of engineering prototype or engineering production
unit testing and evaluation on Buyer supplied test equipment;

               (m) report perceived problems as encountered or suspected to Buyer’s designated
representatives for prompt mutual resolution;

               (n) ensure that all discrepant material and assemblies are identified, placed into Material
Review Board (“MRB”) approved storage, and are visibly identified and linked to a Consigned
Material Disposition Report (“CMDR”), or a NCRB, or a CDR ticket number, or any non-conforming item
report ticket number system;

               (o) when specified by Buyer, ensure that all manufacturing materials provided by Manufacturer
are lead-free and handled compliant with EU Directives addressing RoHS and WEEE- requirements no
later than July 1, 2006, specifically EU RoHS Directive 2002/95/EC and IPC/JEDEC J-STD-033A.

               (p) periodically meet and confer with Buyer in evaluating and revising prices upwards or
downwards based upon changed conditions, performance trends, or market conditions.

          6.2 Buyer’s Responsibilities. Throughout the period described by this MMSSA, and any
extensions thereto, the Buyer shall be responsible for the following performance obligations:

               (a) actively collaborate and support the Manufacturer’s execution of its responsibilities
detailed in Article 6.1 immediately above;

               (b) comply with the operational provisions and procedures of Appendix A;

               (c) provide all manufacturing raw material and components to the Manufacturer, except for
manufacturing solder, solder paste, and epoxy;s

               (d) provide manufacturing technical support as requested or required, including the provision
of replacement ATF, if required;

               (e) exercise effective configuration control over all designs released to Manufacturer;

               (f) train Manufacturer’s personnel in new designs, associated tooling, and software as
necessary to release new products to full Manufacturing after Production Validation testing;

               (g) collaborate with Manufacturer’s designated representatives in continuous improvement
efforts aimed at reducing scrap, attrition, and cost;

               (h) perform on-site lot sampling as required on a not-to-interfere basis in order to validate
Manufacturer’s compliance with the provisions of Article 8 (Quality);

               (i) actively participate in weekly production progress reviews and quarterly management
reviews;

               (j) host Buyer’s customer visits to the Manufacturing Facility on a not-to-interfere basis:

               (k) timely pay Manufacturer for its services;

               (l) ensure timely MRB-directed disposition of discrepant material through written CMDRs and
CDRs:

               (m) be responsible for material scrapped during the NPI process;

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

               (n) [****]meet and confer with Manufacturer in evaluating and revising prices
upwards or downwards based upon changed conditions, performance trends or market conditions,
including the mutual determination of the [****], if any, based upon the most recently
concluded [****], which [****]shall be billed and made payable as a
[****]

     7. Order Management Process. The parties agree that Appendix A shall govern their
respective day-to-day procedures and activities comprising the manufacturing cycle. Accordingly,
Appendix A shall define the parties respective and coordinated actions in staging materials
(Buyer), issuing kit launch orders per updated forecast (Buyer), kitting pre-fabrication bins
(Manufacturer), and manufacturing assembly, test, inspect, pack and ship tasks (Manufacturer)
within the prescribed cycle. The order issuance and management process supporting the described
manufacturing cycle shall also be as stated in Appendix A as of the Effective Date, or as that
Appendix may be updated from time to time in the form of an amendment to this Agreement.

     8. Quality. In fulfilling its obligations under this MMSSA, Manufacturer shall comply at all
times with the quality control provisions of this Article 8, as more specifically addressed herein.

          8.1 Quality Warranty. Manufacturer warrants that it shall manufacture the products strictly
in accordance with the Buyer’s individual product Specifications, Quality requirements and notes,
and utilizing Buyer’s approved Workmanship standards published in manual [****] .

          8.2 Supplier Quality. If applicable, the Manufacturer shall exercise appropriate control and
oversight of any sub-suppliers it may choose to utilize, provided that the Manufacturer shall
[****] provide to Buyer’s Quality Director a list of sub-supplier component and service
vendors it is using to support the Objectives of this Agreement. The Manufacturer may assume that
any vendor material procured by Buyer for use by Manufacturer originates from an approved Buyer
source, and that Manufacturer is authorized to deal direct with Buyer vendors on Return To Vendor
items that are found or judged to be deficient.

          8.3 Facility. Manufacturer shall not transfer the manufacture of Products, in whole or part,
to another facility without the prior written consent of Buyer.

          8.4 New Designs. As part of the New Product Introduction (“NPI”) process discussed elsewhere
in this MMSSA (Article 11 and Appendix B), Manufacturer shall provide [****] finished
goods quality manufacturing samples of new Product designs to Buyer’s Quality Assurance
representative for the purposes of qualifying the manufacturing process with respect to that new
Product. Once the Product and the process are judged to be stable and repeatable by Buyer’s Quality
Assurance Director, or his designee, then Production Validation is complete and that manufacturing
process shall be considered baselined under Manufacturer’s control.

          8.5 Quality System Standard. Manufacturer agrees that at all times during the effective period
of this MMSSA, and any extensions thereto, Manufacturer shall maintain a quality assurance system
that is equal to or superior to ISO 9002. Any formal

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

change in the Manufacturer’s certified ISO status shall be reported to Buyer within thirty
(30) days, whether the change in status was planned or unplanned.

          8.6 Environmental Management System. Manufacturer agrees that at all times during the
effective period of this MMSSA, and any extensions thereto, Manufacturer shall maintain an
environmental management system that is equal to or superior to ISO Standard 14001. Any formal
change in the Manufacturer’s certified ISO status–whether planned or unplanned–shall be reported to
Buyer within [****] .

          8.7 Site Visits and Surveys. Manufacturer shall permit Buyer, its authorized employees and/or
its customers, to enter the Manufacturing Facility at all reasonable times and with advance notice
to the Manufacturer’s supervisory representative, for the purposes of facility and product audits,
or inspecting and testing the Products and their conformance to Specifications. Such site visits or
surveys shall be informal in nature, and shall properly extend to the checking of materials and
methods of manufacture, assembly, labeling, testing, line “traveler” documentation, manufacturing
line inventory control, product traceability, RoHS compliance and packaging of Product. Although
it is not intended that Buyer perform 100% finished goods inspection prior to shipment, all
Products supplied hereunder are subject to on-site inspection and test by Buyer to the extent
specific circumstances warrant doing so.

          8.8 Disaster Planning. The Manufacturer shall propose a disaster recovery plan of its own
composition within [****] of the Effective Date of this MMSSA. Local Buyer
representatives may be consulted at no cost to aid Manufacturer’s construction of such a Plan. The
Plan shall describe in reasonable detail what recovery, or relocation, or work-around steps the
Manufacturer shall take in the event of natural or man-made disasters (such as loss of regional
Internet or other utility service). The Plan shall be finalized with Buyer’s approval, and reviewed
annually thereafter for continued currency.

          8.9 Manufacturing Metrics. Manufacturer shall establish and use a standard set of
manufacturing metrics (“Metrics”) through which Manufacturer will accurately discover data to guide
continuous improvement in [****] . At a minimum, Metrics shall be collected on a weekly
basis concerning: (a) [****] (defined as the sum of [****] ); (b)
[****] (at [****] ); (c) [****] ; (d) [****]
( [****] ); (e) [****] ( [****] ); (f) [****]
( [****] ) along with written improvement plan(s) for any step indicating an out-of-control
or degrading condition.

          8.10 Access to Information and Corrective Action. In order to provide the objective evidence
that Quality requirements under this Agreement are being fully met, Manufacturer shall maintain
records of the quality information required by this Article 8 at its Manufacturing Facility in
Lamphun for a period of not less than [****] years. Manufacturer will provide Buyer with
access to such information, either through secure electronic data interchange, or through on-site
visits during normal working hours with reasonable advance notice. In the event that Buyer
concludes from a review of the available data that Manufacturer is not meeting its quality control
obligations under this MMSSA, Buyer shall promptly inform the Manufacturer’s designated
representative in writing. Thereafter, but in no event longer than [****] days,
Manufacturer shall comment upon Buyer’s conclusions and findings, and within a commercially
reasonable time, take appropriate corrective action.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

     9. Engineering Change Notices (ECNs). The contractual relationship described by this Agreement
can be characterized as a “build-to-print” arrangement whereby Manufacturer produces products
designed by Buyer. Given the number of models and variants that Manufacturer is qualified to
produce, as well as the dynamic market forces characterizing Buyer’s competitive market, it is
expected that the Buyer (as designer) will have many engineering changes to make over the lifetime
of any released product. This section is intended to describe the stable and repeatable
Engineering Change process incumbent upon the parties, from first notice to Manufacturer through
release into mass production.

          9.1 The Engineering Change process affecting Manufacturers obligations under this Agreement
shall be as follows:

                    i. Buyer shall post Buyer-released Engineering Change Notices electronically to Manufacturer’s
ftp website in an agreed upon formal, along with e-mail notice that an ECN has been posted;

                    ii. Buyer’s Document Control Service shall indicate via e-mail whether each ECN is to be
treated by Manufacturer as a “Routine” or “Emergent” ECN, and shall copy each ECN posting
concurrently to the Buyer’s in-country RO staff engineer;

                    iii. Manufacturer shall acknowledge receipt of all ECN’s within [****] of receipt
via e-mail to Buyer’s Document Control Services personnel, including their assessment as to whether
the ECN increases or decreases cost or time of performance;

                    iv. In the event that Manufacturer believes in good faith that the ECN represents an increase
or decrease in scope, they shall notify the local Buyer RO Staff Engineer for consultation,
clarification, and written contractual direction;

                    v. In the expected event that the Manufacturer understands and accepts the ECN and its
technical requirements, the Manufacturer shall commence the incorporation of the change through its
engineering Document Control Service, and publish a revised Bill of Material (‘“BOM”) via
[****] , or equivalent, back to Buyer’s Document Control Services personnel;

                    vi. Manufacturer’s implementation of accepted ECNs shall be on a [****] basis for
“Emergent” changes, and on a [****] basis for Routine changes; exceptional cases shall be
handled on a case by case basis;

                    vii. Upon receipt of the Manufacturer’s revised BOM, the Buyer’s Document Control Service
shall fully and finally release and implement the ECN into production, whereby new units built
after that date must incorporate the newly released ECN;

                    viii. In the event that the Manufacturer cannot implement the ECN, or believes it to be in
error, the Manufacturer shall notify both the local Buyer RO staff engineer and Buyer’s Document
Control Service, whereupon Buyer’s Document Control Service will cause the ECN to be re-examined by
Buyer’s Engineering group;

                    ix. Both Buyer and Manufacturer shall maintain on ECN log record, and use the log to brief the
implementation status of all ECNs at the quarterly review meeting discussed elsewhere in this
Agreement.

          9.2 ECN Process Review. The parties shall from time-to-time also review the adequacy and
effectiveness of the ECN process, and shall revise it as necessary to accomplish the objectives of
this MMSSA.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

     10. Factory Returns. Because of its on-going importance in the conduct of business under this
MMSSA, the subject of Factory Returns, also called and known as “RMA Process and Procedures.” is
made the subject of a separate Appendix to this Agreement (Appendix C), incorporated by reference
as if fully set out herein.

     11. New Product Introduction (“NPI”) Process. Although this Agreement predominantly addresses
itself to the standard manufacture of released products, the parties contemplate that during the
life of this MMSSA, newly designed Buyer products will be introduced for low-rate or high-volume
production. The transition from Production Validation (“PV”) to Pull Production is a crucial
period, so much so that the parties have agreed to make it the subject of a separate Appendix to
this Agreement (Appendix B), incorporated by reference as if fully set out herein.

     12. Property Management & Control. In view of the Buyer’s considerable financial investment
in procuring and providing raw materials to enable “turn-key” manufacturing, Manufacturer shall
implement a Material Control Plan that effectively receives, tracks, and accounts for component
material used, consumed or scrapped in the manufacturing process. Such a Material Control Plan
shall also include provisions for the environmentally protected protection and storage of
work-in-process, finished goods inventory, and kanban buffer stock. The Material Control Plan shall
include provisions for monthly inventory of piece parts recorded in the [****] management
system, and a confirming physical inventory at least [****] , at times and in a manner as
the Manufacturer deems appropriate. The Manufacturer’s Material Control Plan shall be furnished to
Buyer’s local representatives within [****] of the Effective Date of this Agreement.
Lastly, the Manufacturer shall procure adequate insurance against risk of casualty loss for Buyer
furnished materials, work-in-process, finished goods, and property in Manufacturer’s custody as
required under Article 20 (Insurance) of this MMSSA.

     13. Intellectual Property.

          13.1 Buyer’s IP Rights. Product designs, selected microwave monolithic integrated circuit
(“mmic”) designs, design documentation, hardware, software. Buyer designed special tooling,
fixtures, firmware, Automated Test Equipment (ATE), Specifications and Buyer Work Instructions
representing manufacturing know-how constitute Buyer Technology. At all times hereunder, Buyer
shall retain and exclusively enjoy all ownership rights in Buyer Technology. All Buyer Technology
included in the license granted to Manufacturer immediately below in Article 13.2 shall be licensed
without fee or royalty. In consideration of this, Manufacturer shall assign to Buyer all ownership
rights in any improvements and developments funded by Buyer, or co-funded by the parties, in
derivatives of and/or modifications to the Products or the underlying Buyer Technology, including
all related Intellectual Property, that is created by either party during the term of this
Agreement.

          13.2 Manufacturer’s IP Rights. Subject to the terms and conditions of this Agreement,
including but not limited to Manufacturer’s Confidentiality obligations under Article 22, Buyer
hereby grants to Manufacturer a revocable, royalty-free, non-exclusive, fully paid and
non-transferable license in and to the Buyer Technology, solely as necessary to permit Manufacturer
to perform its obligations under this MMSSA.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

          13.3 Limitations on Rights. The following operational considerations constitute limitations
on the Intellectual Property rights exercisable under this Agreement:

               (a) the design of all Products under this Agreement is proprietary to Buyer;

               (b) Manufacturer does not acquire any right to manufacture and/or sell Products passing under
this Agreement to any third parties;

               (c) Buyer retains all copyrights in drawings, specifications, data, software and other
material represented in fixed tangible media;

               (d) Manufacturer shall not mention or present information to unaffiliated third parties
concerning this Agreement or the engagement it controls without the express written consent of
Buyer;

               (e) Buyer acknowledges that the Manufacturer may be required to declare Buyers name for
customs, export, or other governmental purposes;

               (f) Buyer does not assert intellectual property rights over Manufacturer’s pre-existing
Intellectual Property know-how respecting the manufacturing process.

     14. Contractual Changes. Buyer may from time to time issue written changes to this contract as
may be required to account for revised business requirements. Such changes include, but are not
limited to, place of manufacturing, method of shipment, and modification of express
responsibilities delineated in Article 6, above. In the event Buyer issues a written change to this
contract under the authority of this Article 14, Manufacturer shall have [****] to assert
a claim for equitable adjustment in the prices to be paid for Products, or for service fees not
previously within the scope of the contract. A failure to assert a claim for equitable adjustment
within the prescribed [****] period shall be conclusive as to whether the ordered change
is reimbursable or not by Buyer. Moreover, in the event that Buyer’s conduct (including
contractual direction by authorized Buyer representatives) under this MMSSA is deemed to constitute
a material or cardinal change in Manufacturer’s existing obligations, Manufacturer may assert a
unilateral claim for equitable adjustment for the Buyer’s consideration prior to performing the
allegedly changed work. In such a case, the parties shall immediately meet and confer as to whether
the changed requirement shall be the subject of a formal, written contract amendment. A failure to
agree shall be treated as a dispute under the provisions of the Disputes clause (Article 24).

     15. Reporting and Liaison. Regular reporting and close professional liaison on a
[****] basis is considered critical by the parties to maintaining a commercially vibrant
and mutually beneficial relationship. In the service of this objective, Buyer has established an
in-country Representative Office, principally to facilitate regular, rapid and accurate exchange of
information concerning new orders, work in process, engineering, and quality concerns. Both Buyer
and Manufacturer commit to exert best efforts in meeting reporting and liaison objectives as
follows:

                    (a) [****] telephone calls and e-mail correspondence as circumstances require;

                    (b) [****] electronic data exchange (“EDI”);

                    (c) [****] Production Progress reviews at Factory or the RO facility

                    (d) [****] Quality metrics reporting and physical inventory reporting, within 5 days
of the conclusion of the prior month;

                    (e) Quarterly Management Reviews at Factory or the RO facility in accordance with Article 16,
below;

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

 Endwave Procurement Private

                    (f) Periodic Executive Management meetings as requested by either party;

                    (g) Periodic Kaizen Team meetings, as required, to enable mutually selected manufacturing or
business process improvement efforts.

     16. Reviews. The Quarterly Management Review (“QMR”) shall be treated by the parties as the
primary method for clear communications and refreshing of contract objectives. In light of the
volume of supporting communications occurring in a typical week, month or quarter, QMRs shall be
treated by the parties as action-oriented reviews of progress, problems, and plans. The QMR shall
be convened no later than the [****] of a new quarter, and shall be closed to non-Buyer
and non-Manufacturer personnel. The QMR shall nominally be held either at the Manufacturing
Facility, or at Buyer’s RO, or at such other mutually agreeable place as the parties shall select.
The QMR shall be chaired by [****] , or in his absence, the Buyer’s [****] .
Although either party may propose additional topical discussion, the standard QMR agenda shall be
as follows:

	 	(a)	 	[****];
	 
	 	(b)	 	[****];
	 
	 	(c)	 	[****];
	 
	 	(d)	 	[****];
	 
	 	(e)	 	[****];
	 
	 	(f)	 	[****];
	 
	 	(g)	 	[****];
	 
	 	(h)	 	[****];
	 
	 	(i)	 	[****].

Buyer shall be responsible for composing and publishing QMR meeting minutes within [****]
of the conclusion of the meeting for appropriate distribution via electronic means.

     17. Payment Terms.

          17.1 Payments. Provided that Manufacturer is in compliance with the terms and conditions of
this Agreement, Buyer shall pay Manufacturer as full and complete compensation the Product prices
stated in Exhibit 2 Product Pricing, attached hereto and incorporated by reference. Such amount
shall be payable in United States dollars (“USD”) within [****] of receipt of a
conforming Manufacturer’s invoice. If Buyer shall dispute any portion of any invoice, then Buyer
shall promptly pay the undisputed portion according to this Agreement, while concurrently informing
Manufacturer of the nature of the dispute. The parties shall use their best efforts to promptly
resolve the discrepancy. A failure to do so shall be handled under the Disputes clause of this
MMSSA.

          17.2 Payment Conditions. All payments made by Buyer are conditional on the following: (i.)
Manufacturer has delivered the full quantities of the Products ordered, or has received Buyers
written permission to make a partial delivery, and (ii.) the delivered Products conform to the
Product Specifications and Workmanship standards in all material respects. Buyer is entitled to
withhold payment for any unapproved partial deliveries. Lastly, undisputed payments owed by Buyer
to Manufacturer shall be deemed late after [****] from receipt of a proper invoice, and
shall thereafter bear simple interest at a rate of [****] per annum.

          17.3 Taxes and Duties. Except as otherwise provided in this Agreement, all Product prices are
net of any taxes and duties. Buyer agrees that it is responsible for and

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

shall reimburse Manufacturer for any sales, use, import, export, value-added or similar tax or
duty relating to any Product pursuant to the terms of this MMSSA, paid by Manufacturer on Buyer’s
behalf, other than those based on Manufacturer’s net income. If a resale certificate or other
certificate or document of exemption is required in order to exempt manufactured Product from such
liability, Manufacturer agrees to promptly execute and furnish such document or certificate to
Buyer and relevant taxing authorities. In the event that The Manufacturing Facility is relocated
from the Lamphun Free Trade Zone, or otherwise loses its free-trade status, the parties agree to
renegotiate this provision.

     18. Product Warranties & Disclaimers.

          18.1 Product Warranty. Manufacturer warrants to Buyer that (a) upon delivery, each unit of
Product will he free and clear of any lien or encumbrance; (b) each unit of Product will conform in
all material respects to the Specifications and Quality criteria; (c) be made entirely of new or
unused material, and (d) each unit of Product will be free from defects in workmanship and
materials under ordinary and proper use for [****] from the date Manufacturer ships the
Product to Buyer or Buyer’s designated customer (the “Product Warranty”). For the avoidance of
doubt, the following elements are included in this Product Warranty: (i.) all Product tendered for
delivery shall be new, unused, and in good working order; (ii.) be free from defects in materials
and workmanship, excluding design defects or Buyer supplied RMI material; (iii.) strictly conform
to the Specifications and Quality Requirements in all material respects; and (iv.) unless a
particular Manufacturer’s Failure Analysis Report determines beyond reasonable doubt that a
returned product is defective because of customer or Buyer mishandling or abuse, Manufacturer shall
pay for all costs of repair or replacement of defective Product.

          18.2 Warranty Service. If any unit of Product breaches the Product Warranty, Manufacturer
shall promptly either repair or replace, at Manufacturer’s option, or by mutual agreement, credit
Buyer for, Buyer’s sale price of the breaching unit(s). The [****] Product Warranty shall
also apply to all Products supplied by Manufacturer in replacement of defective Products. Whether
Manufacturer elects to repair or replace defective product, the Manufacturer shall comply with the
RMA unit cycle-time requirements delineated in Article 10 (Factory Returns) above.

          18.3 Latent Defects. Notwithstanding any time limitations set forth in this Article 18,
Manufacturer shall repair or replace, at its expense, any unit of Product that contains a defect
that existed at the time of manufacture but without being then active or discernible or evident,
such that the defect could not have been discovered through the exercise of ordinary manufacturing
diligence under acceptance test methods then customary in the industry.

          18.4 Repair/Replacement System. Manufacturer shall be solely responsible for establishing an
effective system for receiving, trouble-shooting, discovering, and repairing previously delivered
Products returned by Buyer or Buyer’s customer within the [****] Product Warranty period,
as described in Article 10. The parties agree that their mutual manufacturing excellence goal is to
keep factory warranty returns [****] of total units delivered.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

          18.5 Non-Warranty Returns. (Reserved).

          18.6 Reporting. Consistent with the provisions of Article 10 and Article 8 (Quality
Requirements), Manufacturer shall provide Buyer with a standard monthly report containing data
relating to all units of Product returned to Manufacturer for repair or replacement. Such unit
specific reporting data shall include: (i.) the serial number(s) of the received unit(s); (ii.) a
description by serial number of the actions taken to repair or replace; (iii.) an indication
whether such repair or replacement action is made under the Product Warranty; (iv.) the price
charged for such repair or replacement if not made under the Product Warranty. Such data, and past
reports containing data, shall be retained by Manufacturer and available for on-site inspection by
authorized Buyer Representatives.

     19. Indemnification.

          19.1 Infringement Indemnification by Manufacturer. Subject to the terms and conditions of this
Agreement, Manufacturer will indemnify, defend and hold Buyer harmless from and against any
damages, liabilities, costs and expenses (including reasonable attorney’s fees) actually paid by
Buyer in settlement of, or held against Buyer arising out of, a claim that (a) the use or sale of
any Product infringes a patent, copyright, trade secret or other proprietary right of a third party
(a “Third Party Proprietary Right”), to the extent such claim is based upon modifications to the
Product, Specifications, or Product Quality Criteria made by Manufacturer, or (b) the manufacturing
process used by Manufacturer to produce the Product infringes any Third Party Proprietary Right.

          19.2 Infringement Indemnification by Buyer. Subject to the terms and conditions of this
Agreement, Buyer will indemnify, defend and hold Manufacturer harmless from and against any
damages, liabilities, costs and expenses (including reasonable attorney’s fees) actually paid by
Manufacturer in settlement of, or held against Manufacturer arising out of, a claim that the
manufacture or use of any Product infringes a Third Party Proprietary Right, to the extent such
claim is based upon the manufacture of a Product made in accordance with the Specifications and/or
Product Quality Criteria.

          19.3 Product Liability. Subject to the terms and conditions of this Agreement, Manufacturer
will indemnify, defend and hold Buyer harmless from and against any damages, liabilities, costs and
expenses (including reasonable attorney’s fees) actually paid by Buyer in settlement of, or held
against Buyer arising out of, a claim by a third party for personal injury or property damage which
arises out of (a) a [****] , or (b) the [****] , provided that the personal
injury or properly damage was not caused by use of products outside of their intended usage. Any
settlement or compromise of claims effecting this indemnification shall be coordinated and mutually
agreed upon between the parties before being finalized with any third party claimants.

          19.4 Indemnification Procedure. A party seeking indemnification under this Agreement (the
“Indemnified Party”) will (a) give the other party (the “Indemnifying Party”) notice of such claim;
(b) cooperate with the Indemnifying Party, at the Indemnifying Party’s expense, in the defense of
such claim; and (c) give the Indemnifying Party the right to control the defense and settlement of
any such claim, except that the Indemnifying Party will not enter into any settlement that affects
the Indemnified Party’s rights or interest without the Indemnified Party’s prior written consent.
The Indemnified

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

Party shall have no right or authority to settle any claim on behalf of the Indemnifying
Party.

     20. Insurance. Manufacturer shall at all times maintain “all risk” or similar insurance
(including coverage for damage caused by earthquake, fire. flooding and construction defects) in an
amount equal to [****] . Within [****] of the Effective Date, Manufacturer
shall provide written proof of commercial casually loss or self insurance coverage in a minimum
amount of [****] with a reputable insurance or re-insurance company of its own choosing,
naming Endwave Corporation as an Additional Insured party.

     21. Limitation of Liability. TO THE EXTENT PERMITTED BY APPLICABLE LAW, IN NO EVENT SHALL
EITHER PARTY BE LIABLE UNDER THIS AGREEMENT FOR ANY INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL
DAMAGES, INCLUDING LOSS OF PROFITS, INCURRED BY THE OTHER PARTY, WHETHER IN AN ACTION IN CONTRACT,
TORT, OR BASED ON WARRANTY, EVEN IF THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
THE FOREGOING LIMITATIONS SHALL NOT APPLY TO MANUFACTURERS LIABILITY UNDER SECTIONS 19
(Indemnification) OR TO A BREACH BY MANUFACTURER OF ITS OBLIGATIONS UNDER SECTION 22
(Confidentiality).

     22. Confidentiality.

          22.1 Restrictions on Use and Disclosure. Recipient agrees to hold the Discloser’s Confidential
Information in strict confidence, and to use such reasonable precautions to protect such
Confidential Information as it employs to protect its own Confidential Information, but in no case
shall such protective actions be less than a reasonable standard of care as practiced in the
competitive microelectronics manufacturing industry. Except as expressly set forth herein,
Recipient may not disclose Discloser’s Confidential Information or any information derived
therefrom to any third party. Recipient agrees not to use Discloser’s Confidential Information for
any purpose other than as necessary to fulfill Recipient’s obligations or exercise its rights under
this MMSSA. Recipient will limit access to Discloser’s Confidential Information to Recipients
employees and authorized directors, agents or representatives who are bound by pre-existing
obligations of confidentiality substantially similar to, and no less restrictive than, those
contained herein. Recipient agrees to take all reasonable steps to ensure that the Discloser’s
Confidential Information is not disclosed or distributed by its employees, directors, agents or
authorized representatives in violation of the terms of this Agreement. Recipient agrees to
promptly advise the Discloser if Recipient is aware or suspects that the security of the
Discloser’s Confidential Information has been or may be compromised in any way.

          22.2 Required Disclosure. The restrictions of Article 22.1 will not operate to prevent
disclosures of Confidential Information required by any law or regulation, or in response to a
valid order by a court of competent jurisdiction or other governmental authority; provided however,
that: (a) Recipient provides the Discloser with prompt written notice of such pending disclosure,
if reasonable under the circumstances, in order to provide the Discloser (at its own expense) to
object to the disclosure, or to seek confidential treatment or other protective measures to
preserve to the extent possible the

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

confidentiality of the Confidential Information and (b) Recipient reasonably cooperates with
Discloser in connection therewith, at Discloser’s expense.

          22.3 Injunctive Relief. The recipient acknowledges that the Discloser’s Confidential
Information constitutes valuable trade secrets of the Discloser. Recipient acknowledges that any
unauthorized use or disclosure of Discloser’s Confidential Information would cause Discloser
irreparable harm, for which Discloser’s remedies at law would be inadequate. Accordingly. Recipient
acknowledges and agrees that if any such unauthorized use or disclosure occurs, the Discloser will
be entitled, in addition to any other remedies available to it at law or in equity, to seek the
issuance of injunctive or equitable relief.

          22.4 No Rights Granted. Except as otherwise provided in this MMSSA, the Recipient acquires no
license or other rights to any Confidential Information of the Discloser, including, without
limitation, any right that has issued or may issue based upon such Confidential Information. All
Confidential Information and materials furnished to the Recipient by the Discloser, and all copies
thereof made by the Recipient, will remain the property of the Discloser.

          22.5 Survival of Rights. Discloser’s rights to the protection of its own Confidential
Information shall survive this Agreement, and are not diminished in any way by the suspension,
termination, assignment, or completion of other executory obligations under the contract.

     23. Termination.

          23.1 Termination for Convenience. Either party may terminate this MMSSA without cause and for
its own convenience upon the giving of at least 365 days written notice to the other party.

          23.2 Termination for Cause. Either party may terminate this Agreement upon written notice to
the other for the breach of any material provision of this Agreement. For a material breach that is
capable of being cured in the reasonable judgment of the non-breaching party, the non-breaching
party shall first serve the breaching party with written notice describing the nature of the breach
and demanding a cure within the next thirty (30) calendar days. If after the passage of such
period the noticed breach has not been cured, the non-breaching party may terminate this contract
and immediately seek all legal and equitable remedies available to it.

          24. Disputes. In the event of a dispute between the parties to this Agreement affecting their
respective rights and obligations, the following four tier process shall be triggered:

               (a) the aggrieved party shall report the existence, nature and scope of the dispute to the
other in writing by the fastest means, and the parties shall locally attempt to settle the dispute
through negotiation and accommodation;

               (b) if after [****] from the commencement of local negotiations the matter is not
mutually resolved, either party may refer the matter for more formal meet-and-confer discussions
and negotiations between their respective senior executive representatives;

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

               (c) if, after [****] from the first commencement of management negotiations the
matter is not mutually resolved, either party may refer the matter to non-binding mediation under
the International Chamber of Commerce (“ICC”) Rules for Commercial Mediation, before a single
mediator in Honolulu, Hawaii, U.S.A.;

               (d) if the parties are unable to reach a settlement with the aid of the ICC mediator, the
parties agree to authorize the mediator to arbitrate the dispute in accordance with ICC Rules, and
to render a binding, non-appealable decision in the form of a written arbitral award. In such an
event, the prevailing party shall be entitled to recover its reasonable costs and fees, including
attorney’s fees, from the non-prevailing party. If the nature of the award is such that a
prevailing party cannot reasonably be identified, the parties agree to bear their own costs of
mediation and arbitration.

     25. General Provisions. The following General Provisions shall govern the parties conduct and
relationship under this MMSSA.

          25.1 Governing Law/Venue. This Agreement shall be governed by and construed in accordance with
the laws of the United States and the State of California as applied to agreements entered into and
to be performed wholly within California between California residents, notwithstanding the actual
residence of the parties, and without resort to those jurisdiction’s rules respecting conflicts of
laws. Any legal action, suit or proceeding arising out of or relating to this Agreement not settled
by the Disputes process described in Article 24 above, shall be instituted exclusively in a court
of competent jurisdiction, state or federal, located in the Stale of California, County of Santa
Clara, and in no other jurisdiction. The parties hereby irrevocably consent to personal
jurisdiction and venue in, and agree to service of process authorized by, such courts. In any such
action, suit or proceeding, the prevailing party (by final and non-appealable order or judgment in
its favor) shall be entitled to recover from the non-prevailing party its reasonable legal fees and
expenses incurred in connection with such action, suit or proceeding. The parties expressly agree
that no part of this MMSSA shall be governed by or interpreted under the United Nations Convention
for the International Sale of Goods (“CISG”).

          25.2 Notices. All notices under this Agreement must be delivered in writing by courier,
electronic facsimile, electronic mail, or by certified or registered mail (postage pre-paid and
return receipt requested) to the other party at its address set forth on the first page above or as
amended by notice pursuant to this Article 25.2. If not received sooner, notice by mail shall be
deemed received five (5) days after deposit in the U.S. or Royal Thai mail system. Notices to Buyer
shall be addressed to Buyers Director of Supply Chain Management at 776 Palomar Avenue, Sunnyvale,
California 94085. Notices to Manufacturer shall be addressed to the address in the introductory
paragraph of this Agreement.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

          25.3 Relationship of the Parties. The parties hereto are independent contractors, acting on
their own account. Nothing in this Agreement shall be deemed to create an agency, employment,
partnership, fiduciary or joint venture relationship between the parties. Neither party (nor any
agent or employee of that party) is the representative of the other party for any purpose, and
neither party has the power or authority to act as agent or employee in order to represent, act
for, bind or otherwise create or assume any obligation on behalf of the other party for any purpose
whatsoever.

          25.4 No Third Party Beneficiaries. No party shall be deemed as a third-party beneficiary to
this Agreement.

          25.5 Assignment. Manufacturer may not assign this MMSSA, nor assign its rights or delegate
its obligations under this Agreement, by operation of law or otherwise. without Buyer’s prior
written consent. Any attempted assignment in violation of this Article 25.5 shall be null and void
and without effect. Subject to the foregoing, this Agreement shall be binding upon and shall inure
to the benefit of the parties and their respective successors and permitted assigns.

          25.6 Force Majeure. Except with respect to payment obligations, any delay in or failure of
performance by either party to this Agreement shall not be considered a breach of this Agreement,
and shall be excused, to the extent such delay or failure is caused by any events in the nature of
earthquakes, famines, epidemics, other natural disasters, acts of God, war, riots, civil unrest, or
other similar causes beyond the reasonable control of such party. A party subject to a force
majeure event shall be obligated to (i) give prompt notice to the other party, (ii) use best
efforts to mitigate the effects of such causes on its performance of obligations, and (iii) resume
full performance with notice to the other party as soon as is practicable under the circumstances.

          25.7 Waiver and Amendments. All waiver requests (and approvals) to the terms and conditions of
this MMSSA must be in writing. Any waiver by either party to enforce a provision of this Agreement
on one occasion shall not be deemed a waiver by that party of any other provision or such provision
on any other occasion, nor shall a single waiver be deemed a continuing waiver of that term or
condition. This Agreement may only be amended by a written document expressly identified as an
amendment and signed by both parties.

          25.8 Construction. The following rule shall govern construction of this Agreement: (a)
article and sub-article headings are for reader convenience only and are not to be used in
interpreting this Agreement: (b) as used in this Agreement, the words “including” means “including
but not limited to”; (c) in constructing the terms of this Agreement, no presumption shall operate
in favor of or against any party as a result of its counsel’s role in drafting the terms and
provisions thereof; (d) all references to Articles or sub-Articles shall be deemed to be references
to those within this Agreement unless otherwise indicated; (e) all capitalized terms defined herein
apply equally to the singular and plural forms of such terms; (f) all monetary amounts refer to
U.S. dollars unless otherwise indicated.

          25.9 Entire Agreement. This MMSSA with associated Exhibits and Appendices constitute the
entire agreement between the parties regarding the subject

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

mailer hereof and supersedes all prior or contemporaneous agreements, understandings and
communications, whether written or oral, regarding the subject matter hereof.

          25.10 Counterparts. This Agreement may be signed in several counterparts, each of which shall
constitute an original.

          In Witness Whereof, the parties hereto have caused this Agreement to he executed by their duly
authorized representatives as of the Effective Date.

	 	 	 	 	 	 	 	 	 	 	 
	BUYER	 	 	 	MANUFACTURER	 	 
	 
	 	 	 	 	 	 	 	 	 	 
	By:

	 	/s/ Steve Layton
Oct. 18, 2006	 	 	 	By:	 	/s/ W.K. Chow Oct. 18,
2006	 	 
	 

	 	 

Steve Layton
	 	 	 	 	 	 

W.K. Chow
	 	 
	Name:

	 	 	 	 	 	Name:	 	 	 	 
	 

	 	 

Vice-President & General Manager
	 	 	 	 	 	 

Vice President, Sales
	 	 
	Title:

	 	 	 	 	 	Title:	 	 	 	 
	 

	 	 

	 	 	 	 	 	 

	 	 

Exhibits:

	 	 	 	1: Definitions of Terms and Acronyms
	 
	 	 	 	2: Service Pricing
	 
	 	 	 	3: Hana Provided Manufacturing Materials & Supplies
	 
	 	 	 	4: Equipment Loan Agreement of January 2005

Appendices

	 	 	 	A: Logistics Matters
	 
	 	 	 	B: New Product Introduction (“NPI”) Process
	 
	 	 	 	C: Factory Return Process and Procedures

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

EXHIBIT 1

Definitions of Terms and Acronyms

“ATE” means Automated Test Equipment, generally furnished by Endwave and maintained by Manufacturer
under this Agreement.

“Buyer” means Endwave Corporation, or any of its authorized subsidiaries and affiliates.

“Buyer Technology” means all physical device designs, drawings, manufacturing process instructions,
test equipment and software, and Bill of Material items used under this MMSSA, whether reduced to a
physical medium form or not, and regardless of whether patented, trademarked, or copyrighted.

“CDR” means Contact Discrepancy Report

“CMDR” means Consigned Material Disposition Report

“ECN” means Engineering Change Notice, whereby an engineering design change is fully disclosed
along with its affected documentation

“EU” means the multi-national confederation of European Union nations, currently numbering 24

“FGI” means Finished Goods Inventory, describing goods that have completed the manufacturing
process, have not shipped, and are still in the physical custody of the Manufacturer

“Intellectual Property” means any and all original works or derivatives of original works that are
lawfully owned or in the possession of the party, whether categorized as patents, copyrights,
trademarks, service marks, trade secrets or general know-how, whether or not represented in a
physical medium, or reduced to actual practice

“Kanban” means the designated holding bin for finished goods that are used as buffer stock in
ensuring post-manufacturing order fulfillment

“Manufacturer” means Hana Microelectronics Ltd. of Bangkok, Thailand, wherever situated, and
including subsidiaries, affiliates, subcontractors and vendors

“Manufacturing Facility” means the Manufacturer’s facility in the Lamphun free-trade zone. Thailand

“MMSSA” means this multi-year Agreement and all exhibits and appendices, known as the Master
Manufacturing Supply & Service Agreement

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

“MRB” means Material Review Board, a Buyer entity that reviews allegedly defective or outdated
material in order to exercise configuration control over physical designs

“NCRB” means Non-Conforming Receipts Board

“NPI” means New Product Introduction, a multi-gate Buyer process for transitioning a new design
into full production; per Appendix B, NPI is complete at the end of Product Validation (“PV” or
“Gate 4”), wherein [****]

“Products” means any and all models or variants of Buyer designed devices manufactured under
this Agreement by Manufacturer

“RMA” means Returned Material Authorization, a Buyer documented and controlled system for accepting
field returns for rework, repair or scrap at the Manufacturers Facility

“RMI” means Raw Material Inventory, usually provided by Buyer, and physically stored at
Manufacturer’s Facility in secure storage

“RTV” means Buyer provided RMI components that are deficient in Manufacturer’s reasonable judgment,
and must be returned to vendor by Manufacturer.

“RoHS” means the European Union legislation regulating, among other things, the permitted lead
content of products intended for use within the EU countries

“STE” means Special Test Equipment, whether automated or not

“WEEE” means the Asian continent equivalent of the EU RoHS rules regarding lead-free manufacturing
processes and products.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Endwave Procurement Private

EXHIBIT 2

Service Pricing

	 	 	 	 	 	 	 
	 	 	 	 	 	 	Hana
	Program	 	Part	 	Description	 	Price
	[****]
	 	[****]
	 	[****]
	 	[****]
	 	 	 	 	 	 	 

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

APPENDIX A

BUSINESS LOGISTICS

     1.0 Introduction. This Appendix A is intended by the parties to the MMSSA to define their
respective roles, responsibilities, and control actions in establishing and maintaining an
efficient manufacturing cycle. The processes described herein and pictured in Figure 1 are
designed to minimize material waste, rework, interruption of work, and late deliveries. The success
of the contractual relationship largely hinges upon each party’s commitment of human and machine
resources to make the described processes effective on a daily basis, and to openly collaborate
when necessary to modify them.

     2.0 Overview. Figure 1 pictorially represents what the parties logistically intend to do to
establish a vibrant, best-in-class manufacturing relationship. The actions depicted are informed by
an Endwave provided, non-binding, periodically updated, [****] forecast of future orders
expected to be issued under the authority of this Agreement. While the forecast is non-binding
more than [****] prior to actual delivery against firm kit launch orders, the forecast is
provided so that the Manufacturer can independently detect trends and engage in longer range
resource planning. In general, the binding order process described by this Appendix A can be
summarized as follows: the parties will act in concert to pre-stage sufficient material to
initiate parts kitting against firm orders a full [****] prior to the required shipment
date, while maintaining sufficient (“Kanban”) stores of finished goods to account for ordinary
failures, fluctuations, or delays in manufacturing.

     3.0 Material Staging. Informed by its own Material Requirements Planning (“MRP”) system,
Endwave will procure required parts, components, and sub-assemblies at its direct expense, and will
cause them to be shipped to Manufacturer for pre-kitting receipt as Raw Material Inventory (“RMI”).
On a regular and recurring basis, Endwave and Manufacturer shall engage in an Electronic Data
Interchange (“EDI”) whereby [****] and what [****]. Initially, the common
system to enable EDI shall be the Buyer’s [****], but the parties are free to choose an
alternative system at a later date. Endwave shall [****] that 100% of all parts required
are physically present in Manufacturer’s stores [****]. For its part, Manufacturer agrees
that it shall [****] commence manufacturing against Orders with less than 100%
pre-positioned parts in hand, provided that it has at least [****] of all parts necessary
to begin kitting.

     4.0 RMI Stores. Manufacturer shall maintain so-called RMI material in secure, weather-proof
storage at its own expense. Manufacturer shall be responsible for ensuring material receipts are
accurately and timely recorded in electronic records on a daily basis, and shall make its material
inventory records supporting Endwave RMI inventory available to designated, approved, and
authorized Endwave personnel. Manufacturer shall conduct a physical inventory of FGI, WIP, and RMI
stores on a monthly basis, and report results to authorized Endwave personnel. In the event that
Manufacturer detects deficiencies in vendor-supplied RMI, Manufacturer shall be authorized direct
liaison with Buyer’s approved vendor in arranging RTV and replacement parts of conforming quality.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

     5.0 Kit Launch Orders (“Orders”). [****], Endwave will issue a Kit Launch Order
against firm requirements needed to be shipped [****]. The Order type and quantity may
not be changed by Endwave by more than [****] up or down once given, although successive
Orders not yet issued may be influenced by mutual assessments of changed needs and work in
progress. However, even successive Orders outside the [****] window that are yet to be
issued by Endwave and accepted by Manufacturer may not be changed up or down by more
[****] of the [****] for the most recently completed [****]. Each
[****] launch Order will contain a specific mix of models by part number and common name,
as well as a firm quantity for each model comprising the Order. In any given calendar quarter,
[****] Orders will be electronically issued, usually on [****] of
[****], addressing the [****] production kit starts.

     6.0 The Manufacturing Sequence and Cycle Time. While Manufacturer shall be solely responsible
for ensuring proper flow and sequencing of individual kits into finished goods, the parties agree
that the following are performance activity targets for any single kit launch Order:

	 	a.	 	[****]: kit assembly from RMI, and launch into production;
	 
	 	b.	 	[****]: fabrication into final assemblies
	 
	 	c.	 	[****]: final assembly test, seal, and documentation
	 
	 	d.	 	[****]: ship from FGI, or from Kanban, or to Kanban, as required.

     7.0. Kanban. The parties agree that Kanban stored finished goods are to approximate no more
[****] of manufacturing activity. In the event that a drawdown of Kanban units is
required to fulfill any [****] shipment order, the Manufacturer will inform Endwave of
such facts by model number and quantity. Thereafter, Endwave may adjust its next consecutive
[****] kit launch orders to reflect the need to replenish Kanban units. The Manufacturer
is expressly NOT authorized to build additional units beyond those in Orders explicitly ordered by
the Endwave Master Scheduler on its own, in order to replenish Kanban unit drawdown. This
operational rule exists and must be strictly observed to avoid ambiguity in Order issuance or
production planning, as well as miscounting of available units for shipment. However, the
Manufacturer shall be entitled. but not obliged, to advise Endwave on how fast Kanban drawdown can
be replenished without work-force disruption.

     8.0 Manufacturer Supplied Items. The special materials that Manufacturer shall procure in
order to support the manufacturing process are agreed to be solder, solder paste, and epoxy. In
addition, Manufacturer shall provide its own tools, machinery, and human resources to fulfill its
Order obligations.

     9.0 Special Test Equipment. Endwave shall provide Special Test Equipment (“STE”) to
Manufacturer in order to support the manufacturing process. STE shall be used, maintained, and
repaired in accordance with the provisions of Exhibit 4, Equipment Loan Agreement (January 2005).

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

     10.0 Periodic; Review. The operational logistics described by this Appendix A are at the
heart of the parties” day-to-day relationship, and will determine the success of the strategic
engagement. In view of this, the continued viability and suitability of the Appendix A process
shall be a mandatory review and discussion item at any monthly or quarterly progress review by the
parties. If, as a result of experiences reported at such reviews, the parties mutually conclude
that changes are required, such changes shall be made the subject of an amendment to this MVISSA.
Additionally, [****] the parties shall review [****] to determine the amount of
the [****], owed by Buyer to Manufacturer for [****]. Any accumulated
difference will be billed and paid [****].

     Figure 1

[****]

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

Figure 1A

[****]

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

APPENDIX B

NEW PRODUCT INTRODUCTION PROCESS

     1.0 Introduction. This Appendix B is intended by the parties to document their respective and
coordinated actions in managing the introduction of newly designed Buyer products into full-scale
production. Hard won experience establishes that Manufacturer cannot reliably integrate new designs
into their fleet of customized Buyer product production without an orderly, phased, controlled
process for learning the new designs. It is foreseeable during the term of this MMSSA that Buyer
will require Manufacturer to commence full-scale production of many new products, and
Manufacturer’s ability to do so will substantially influence Buyer’s actual time to market. As a
consequence, this Appendix is and shall continue to be a vital part of the commercial relationship.

     2.0 Overview. In designing new microelectronic products for commercial use, Buyer executes a
multi-phase, sequential, “gate controlled” product development process, Gate No. 4 is known as
Production Validation (“PV”). As planned, PV entails production team familiarization with the
product design, the creation of precise work instructions, and the build of production prototype
units in small quantities to validate process, documentation, and test equipment prior to
full-scale production. This Appendix describes those required steps in detail, and shall be
rigorously followed by both Buyer and Manufacturer.

     3.0 PV Initialization. Production Validation begins with the Buyer’s delivery of as built
documentation from the end of the Design Validation (“DV”) phase of development. As built
documentation includes, but is not necessarily limited to, drawing packages, parts lists, and test
plans and procedures that are applicable to the new design. To the extent the new product requires
different or altered test software to be properly tested with ATE, as built documentation includes
such test software in source code format, installed by Buyer on the ATE in Manufacturers facility.
As built documentation shall be submitted to Manufacturing in sufficient time to permit
understanding and foreseeable obstacles or limitations. The Manufacturer shall be permitted to
follow-up its initial review of as-built documentation with questions of the Buyer’s technical and
QA staff members, in essence performing a Production Readiness Review (“PRR”). Once the
Manufacturer is satisfied that the documentation is complete and feasible, it shall compose
detailed work instructions for its team in their native language.

     4.0 Pre-Production Units. Upon the creation of detailed work instructions, the Manufacturer
shall commence the kitting and building of the first production line units in limited quantities as
agreed upon by the parties. Concurrently, the Buyer shall install any new or revised ATE software
on the test suite hardware in Manufacturers facility. Once the initial units are produced, they
shall be subjected to the same ATE controlled testing as shall be used during full production in
order to prove conformance with specification. Pre-production units shall also be visually
inspected to assure that workmanship is acceptable, and that form and fit have been maintained.

     5.0 Buyer Validation. Upon successful completion of ATE and visual testing; the Manufacturer
shall tender the pre-production units to the Buyer for engineering and Quality Assurance
validation. If such units pass, the Buyer shall report the result along with formal written
authority to commence full production on a stated date in the future. If the units do not pass
Buyer’s examination, or pass with such small margin as to impair future large-scale production pass
rates, then the Buyer shall return the units with its report on the nature of the failure(s) and
the recommended corrective action. After receiving the units back with the error report,
Manufacturer shall rework the units (or start new pre-production units, if circumstances warrant),
and repeat the process all the way through Buyer acceptance of pre-production units.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

     6.0 Low Rate Initial Production (“LRIP”). Upon successful passage of the pre-production unit
inspection and testing steps, and Manufacturer’s receipt of Buyer’s written order to proceed with
limited quantity production release. Manufacturer shall assemble sufficient kits with Buyer
procured parts as to enable Low Rate Initial Production. LRIP shall be considered the last stage of
Production Validation, and is structured to prove that production process and methods are stable
and repeatable for that new model. Manufacturer and Buyer shall agree in advance as to what number
of units constitutes a statistically significant LRIP run of products. It shall be Manufacturer’s
responsibility to kit, release, build, and test LRIP units in exactly the same way as it intends to
apply to mass production units. Upon the successful conclusion of LRIP unit build. Buyer shall
review test results, and either grant or withhold grant (with reasons stated) of authority to begin
full production per the Appendix A forecast and ordering procedures. From that moment, the new
product is considered released to full production.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

APPENDIX C

FACTORY RETURN PROCESS & PROCEDURES

     1.0 Introduction. This Appendix C is intended by the parties to document their respective and
coordinated actions in dealing with fielded units returning to the factory for repair, rework, or
scrapping. Because the process entails important sequential steps on a time-scale that directly
bears on and influences customer satisfaction, it is important that the process be clearly stated,
executable, and reliably repeatable.

     2.0 Overview. The factory return process, sometimes called the “RMA Process,” is by its
nature an interruption in the normal Manufacturing single-piece flow contemplated by this
Agreement. Under this Agreement, factory returns may be handled by Buyer or Manufacturer, as
further defined below, in Buyer’s reasonable discretion. This Appendix is intended to define the
factory return process in those cases where Manufacturer actions are required to complete repairs.
The factory return process begins with unscheduled notice to Buyer by Buyer’s customer, followed by
physical movement of the returning item(s) to Thailand, followed in rapid succession by noticed
receipt, assessment, Buyer authorization, repair action, and return shipment. In this sequence of
actions, both parties have responsibilities to each other that are described in detail below.

     3.0 Initial Report. The Buyer will be contacted by customers on an unscheduled basis when a
fielded unit problem implicating factory repair is encountered. The Buyer will interact with the
customer as necessary to determine what the problem description is, whether the serialized item(s)
is in or out of warranty, and what the appropriate action should be. If the Buyer concludes that a
return to factory is warranted, the Buyer will give the customer a Returned Material Authorization
(RMA) number with shipment instructions. The authorization shall be documented with the customer
via electronic mail, with a copy to Manufacturer’s factory return coordinator if the item is coming
back to Manufacturer. This will permit work-flow planning to a limited degree. Ordinarily,
[****] will be borne by [****], especially for [****]. However, the
downstream results of [****] may cause the [****].

     4.0 Receipt. For those items returned under Buyer RMA to the Manufacturer, the Manufacturer
will acknowledge receipt to Buyer within [****] of receipt, [****]. Incoming
items shall be recorded in Manufacturer’s factory return log by RMA number and date/time of
receipt.

     5.0 Analysis. Buyer shall be responsible for the official evaluation and analysis of factory
return items, unless Buyer has authorized a field return direct to Manufacturer’s site. Buyer will
conduct themselves in such a way that cause and corrective action (“C&CA”) is promptly determined
by Buyer, with or without outside assistance.

          In the case where C&CA results objectively suggest that the root cause of an in-warranty
return is a failure in Manufacturer’s compliance with workmanship standards, such determination
shall be electronically communicated by Buyer’s factory return representative to Manufacturer,
together with the objective evidence supporting that conclusion. Concurrently, Buyer’s factory
return representative shall cause a debit memorandum to be issued and processed. A failure to agree
on financial responsibility shall be handled as a dispute with the meaning of the Disputes
provisions of this MMSSA. Out-of-warranty factory returns assigned to Manufacturer for repair shall
be compensated by Buyer without regard to root cause responsibility and shall be treated as a
credit billing on the next regularly occurring invoice for services.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

 

 

     6.0 Confirmation. Manufacturer shall confirm physical receipt of all factory return units
within [****] of actual receipt, [****].

     7.0 Repair Action. Immediately upon receipt of a confirming message from Buyer authorizing
repair, Manufacturer shall repair the item in accordance with then current product model
documentation, fully restoring the returned item to operational status. It is contemplated that
repair action will include updating a repair item for approved ECNs that have been released since
the item was first manufactured. If repair without intervening ECN incorporation is
desired, Buyer must affirmatively say so in the confirmation message required by Section 6
immediately above. Manufacturer shall endeavor to complete all repairs of authorized, confirmed
items within [****] of first attempting repair (thus excluding evaluation, recommendation
and repair authorization periods described above). The parties agree that the cycle-time goal for
completed repair from authorization to shipment is [****], in those instances where a) no
new technical issues arise during repair to interrupt or delay work; b) all repair material is
available during the course of the repair work; and c) the corrective action is of the same scope
as the Buyer’s authorization. In those cases where the above three conditions do not exist. Buyer
and Manufacturer will mutually agree on a revised RMA unit completion date that may require greater
than [****] cycle-time.

     8.0 Shipment. Upon completion of repair, the Manufacturer shall report completion in a
standard Repair Action Report (RAR) formal, and electronically inform Buyer’s factory return
coordinator, with a copy to Buyer’s local RO staff engineer. Upon completion of the RAR,
Manufacturer shall be authorized to ship the repaired item at Buyer’s expense, unless otherwise
informed. If the item has been scrapped, or failed to survive the repair process, Manufacturer
shall similarly report that fact to the Buyer. RAR data and C&CA data shall be kept by the
Manufacturer for a period of [****] years.

     9.0 Financial Responsibility. The nature of the reported Held item failure ultimately
determines who is financially responsible for the repair and shipment actions to be made in rapid
succession. In general, the financial responsibility rules to be applied under this Agreement are
as follows:

     a. where the cause of the return is a defect in design within the warranty period or any
extensions, it shall be Buyer’s responsibility to pay for shipment and repair;

     b. where the cause of the return is a defect in manufacturing, serialization, or as-built
documentation, it shall be Manufacturer’s responsibility to pay for shipment and repair;

     c. where the cause of the return is abnormal wear and tear, or product abuse, or a condition
that cannot be duplicated or proven, Buyer’s customer shall be financially responsible for shipment
and repair activity.

**** Certain confidential information contained in this doc
been omitted and filed separately with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Omissions
are designated as [****].

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00119-of-00352.parquet"}]]